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I. ABSTRACT 
Extraocular muscles (EOMs) are among the fastest and most fatigue resistant skeletal muscles; 
they are categorized as a separate group of muscles or ‘allotype’ since they represent a unique 
group of highly specialized muscles anatomically and physiologically different from other skeletal 
muscles. The distinct origin and innervation of EOMs are probably responsible for their different 
gene and protein expression. This also applies for the excitation–contraction coupling (ECC) and 
the calcium handling in EOMs. The main goal of this thesis is to establish methods to study the 
ECC in mouse EOMs and apply these new techniques on different mouse models. 
 Calcium is an ubiquitous second messenger mediating numerous physiological processes, 
including muscle contraction and neuronal excitability. Ca2+ is stored in the ER/SR and is released 
into the cytoplasm via the opening of intracellular inositol trisphosphate receptor and ryanodine 
receptor calcium channels. Whereas in skeletal muscle, isoform 1 of the RYR is the main channel 
mediating calcium release from the SR leading to muscle contraction, the function of ubiquitously 
expressed ryanodine receptor 3 (RyR3) is far from clear. The previous finding of our group, that 
RyR3 is highly expressed in EOMs versus limb muscles (Sekulic-Jablanovic et al., 2015) is the basis 
of the first paper entitled “Extraocular muscle function is impaired in ryr3−/− mice”. By using the 
RyR3 KO mouse we were able to show that RyR3 is an essential factor for normal vision, which is 
the first real functional role of this channel. In detail, the loss of RyR3 reduced the peak force and 
altered the twitch kinetic of isolated EOMs. Additionally, we found altered calcium transient 
kinetic in isolated single EOM fibers. 
Mutations in the RYR1 gene are associated with neuromuscular disorders and patients with 
recessive mutations are severely affected and characteristically display ptosis and/or 
ophthalmoplegia. Previously we constructed a compound heterozygous 
RyR1p.Q1970fsX16+p.A4329D (DKI) mutant mice based on a patient biopsy (Klein et al., 2012) 
and characterized the skeletal muscles (Elbaz et al., 2019b; a). In order to gain insight into the 
mechanism leading to extraocular muscle involvement, we investigated the biochemical, 
structural and physiological properties of EOMs from this mouse model. We also investigated the 
properties of EOMS of heterozygous single mutation carriers as well as mice carrying the 
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homozygous mutation. These studies constitute the second paper entitled “Molecular basis of 
impaired extraocular muscle function in a mouse model of congenital myopathy due to 
compound heterozygous RYR1 mutations”. In this paper we were able to show a significant 
reduction in the ex vivo force of the DKI mouse, while the other lines do not show any changes. 
These findings were constant with a reduction in the peak calcium transients and in several ECC 
involved proteins. Interestingly, we also found a tremendous reduction in the specific MyHC-EO 
isoform. To sum it up, our results shows that the combination of a reduced content of ryanodine 
and dihydropyridine receptors, changes in the calcium release units and reduced MyHC-EO leads 
to impaired vision.  
The methods and findings in this thesis will be the start of further investigation into EOM specific 
disorders or neuromuscular disorders which where EOMs are spared or heavy affected. 
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1 INTRODUCTION 
Muscles can be split into three main types: skeletal, smooth and cardiac muscles (Figure 1.1: 
Muscle types). While the skeletal muscles are mostly under voluntary control, smooth and cardiac 
muscles are only controlled by the autonomic nervous system or pacemaker cells. Skeletal and 
cardiac muscles can be grouped together based on their structural similarities, as striated 
muscles. 
Constituting approximately 40 percent of our body mass, the skeletal muscle represents the 
biggest organ in our body. The main function of skeletal muscle (but not the only one) is 
locomotion and therefore the production of force and the ability to shortening itself. Because of 
the high energy uptake, it is also responsible for a significant amount of heat production and is 
involved in regulation of metabolism. 
Smooth muscles are the contractile tissue present in many hollow organs, blood and lymphatic 
vessels. In comparison to skeletal muscles, they are not striated and cannot be moved voluntarily.  
Cardiac muscle is classified as one muscle and not a group of muscles. Like skeletal muscle, it is 
striated and also shares several basic functional and structural properties. Nevertheless, it has a 
unique protein composition and is constructed and optimized for repeated contractions at a 
frequency of around 60 Hz for our entire life. 
 
Figure 1.1: Muscle types 
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Histological (top), cell shapes (middle) and description (bottom) of the three muscle 
types. From left to right: skeletal, cardiac and smooth. (Marieb et al.) 
1.1 Skeletal Muscle Structure 
The skeletal muscle is a highly hierarchical structure, from the top layer, the muscle itself, down 
to the smallest contractile elements, the myofibrils. Most skeletal muscles are attached to the 
bones via tendons on both sides. The muscle itself is surrounded by a connective tissue called 
fasciae, which separates it from other tissues or organs and helps maintain muscle integrity. 
Directly underneath the fasciae is a sheet of soft connective tissue, called epimysium (Figure 1.2: 
Structural organization of skeletal muscle). Inside the epimysium the muscles are subdivided into 
bundles of muscle fibers called fasciculus. These substructures are again surrounded by a layer of 
connective tissue called perimysium. The bundles of fibers are then subdivided into smaller 
compartments, the individual muscle fibers. Each muscle fiber is surrounded by the last 
connective tissue layer called endomysium.  
The muscle fiber is a highly specialized cell type with unique features. Usually the muscle fibers 
span from tendon-to-tendon which depending on the muscle can be quiet long up to several 
centimeters in Sartorius, the longest muscle in humans. Also, the diameter varies and can be as 
thin as 3 µm in extraocular muscle. To reach these length muscle fiber precursor cells, called 
myoblasts, fuse to form myotubes. These myotubes differentiate later into muscle fibers. This 
differentiation path makes the muscle fibers the only type of multinucleated cell in our body. In 
a healthy muscle the nuclei are located at the outer membrane of the muscle fiber.  
The three above mentioned connective tissue layers in muscle mainly contain collagen (reticular 
fibers) and elastic fibers. Each layer has a transition to the next deeper layer. Through this 
network, nerves and blood supply can reach the individual fibers. The individual hierarchical 
compartments also help for fine adjustment of contraction patterns inside each muscle. So that 
only parts of the muscle contract.  
Each muscle fiber is enveloped by a membrane called sarcolemma. This membrane is not a 
connective tissue as the membranes described above but rather is surrounded by a basement 
membrane (extracellular matrix) which is composed of two layers. The outer one, the reticular 
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lamina and the inner one, the basement lamina. The inner basement lamina can be further 
divided into an outer lamina densa (basal membrane) and an inner lamina lucida, which is 
connected to the sarcolemma via glycoproteins (MacIntosh et al., 2006). 
Each muscle fiber can be further subdivided into substructures, called myofibrils. These mostly 
tube-like structures run along the whole length of the fiber and are surrounded by membranous 
cisternae and a sarcoplasmic reticulum (SR) network.  
 
Figure 1.2: Structural organization of skeletal muscle 
Hierarchical structure of the entire muscle (a) over the fascicle, a bundle of fibers (b) 
to individual fiber (c). Each layer is separated by sheet of connective tissue from the 
epimysium around the muscle over the perimysium surrounding the fascicle to the 
endomysium and the sarcolemma around the single fiber. The smallest structure is 
the myofibril which separate the fiber itself (Powers and Howley, 2018). 
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The myofibrils are made of the smallest contractile compartments, the sarcomeres. Unlike the 
other substructures the sarcomeres are connected in series (chain like). This serial arrangement 
results in repetitive dark and pale bands, which give the skeletal muscle its name of striated 
muscle (Franzini-Armstrong and Peachey, 1981). The reason for the striated appearance is that 
the sarcomere itself is made up of two bands, the pale I-band (isotropic) and the dark A-band 
(anisotropic). (Figure 1.3: Organization of the sarcomere). This pattern appears inverted under 
polarized light.  
The sarcomere has three additional, visible and distinguishable components: Z-disk, M-line and 
H-zone. The H-zone is a paler region inside the A-band. Its width depends on the contraction of 
the sarcomere. It reaches its narrowest width when the sarcomere is fully contracted. The M-line 
is a thin dark line inside the H-zone. All lines, bands and discs reflect the specific protein content 
and protein filaments composing the structures as well as the areas of overlap within the 
filaments. 
There are two major filaments in the sarcomere: the thick myosin filaments (15-18 nm) and the 
thin actin filaments (5-8 nm). The myosin filaments constitute the A-band while the I -band 
contains the actin filaments. Myosin, the motor protein, is a dimer where each monomer has a 
head and a long rod region. The head region has a high affinity for actin filament and the tail 
builds a coil-coil structure which basically forms the filaments. The head region undergoes a 
conformation change when it is connected to actin, whereby the two filaments slide over each 
other to generate force and shortening. The energy necessary for cross-bridge-cycling is provided 
by the hydrolysis of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) at the myosin 
head region. The myosin filaments are attached on either side of the M-line so that the heads can 
extent to both sides. The actin filaments on the other hand are attached to the Z-disk. The cross 
section of a sarcomere reveals a highly regular pattern of thick and thin filaments. The thick 
filaments form lines where each line is shifted by half the distance of two filaments. While the 
actin forms a hexagonal lattice around the thick filaments. Depending where the cross section is 
cut through the sarcomere it is possible to see both or only one of these filaments. (Figure 1.3: 
Organization of the sarcomere)  
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There are 15 classes of myosin heavy chain proteins. In skeletal muscle the most commonly found 
classes are class I and class II, which also define the specificity of the muscle fiber type. Fibers 
which contain class I (MyHC 1) are mostly slow twitch fiber and fibers which contain class II (MyHC 
2) are mostly fast twitch fibers. The myosin isoform composition is just one of the structures 
defining the fiber type. Nevertheless, the expression of a particular myosin heavy chain isoform 
parallels other biochemical and cellular characteristics of the muscle fiber such as proteins 
composition, mitochondrial density and type of metabolism. Fast twitch fibers can be further 
divided into three sub types (in human into two), which are type IIA, type IIB and type IIX.  
 
Figure 1.3: Organization of the sarcomere 
(A) Electron micrograph of cross section of two sarcomeres at the level of I band (1) 
and H line (2) showing the real distribution of filaments in sarcomere. Individual 
sarcomeres are separated by the vesicles of sarcoplasmic reticulum (SR) system (3). 
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(B) Electron micrograph of one sarcomere sliced longitudinally. All bands and lines 
are marked as I, Z, A, H, and M. (C) Schematic representation of the sarcomere. The 
thick filaments, thin filaments, Z- and M-lines are indicated by blue, red, yellow and 
green boxes, respectively. The protein components shown to localize in the 
sarcomere have been directly labelled on the appropriate area of the ultrastructure. 
(D & E) Schematic representations of a myofibril and a sarcomere with bands 
indicated. F - I are cross sections at the levels indicated in D. A-B: (Zoladz, 2018) C: 
(Au, 2004) D-I: (Hall, 2016) 
Of course, this is a simplified view of the proteins present in the sarcomere and many additional 
proteins are essential for a healthy working muscle. To name a few: myosins are also made up of 
four light chains, two essential and two regulatory; titin, which stretches from the Z-disc to the 
M-line where it overlaps with the titin from the other half sarcomere. It acts as a spring which 
holds the sarcomere together; myosin-binding proteins (MyBP), mainly MyBP-C wraps around the 
thick filament; troponin complex, which is located on the actin filaments. The complex binds 
another protein called tropomyosin and regulates the myosin binding to actin. If the Ca2+ 
concentration is low the tropomyosin blocks the myosin interaction with actin. When the Ca2+ 
concentration is high the complex can bind calcium and undergoes a conformational change with 
the tropomyosin and releases the myosin binding side on the actin. (Figure 1.3: Organization of 
the sarcomere) (Craig and Woodhead, 2006; MacIntosh et al., 2006; Hill et al., 2012; Frontera and 
Ochala, 2015; Craig, 2017; Zoladz, 2018)  
 
1.2 Cranialfacial Muscles / EOMs  
The craniofacial muscles are a subtype of skeletal muscles, located on the head and the neck. 
They are an example of skeletal muscles which are not involved in locomotion, but rather involved 
in vision, facial expression, breathing, mastication, swallowing, speech and other functions. 
Rather than grouping them on their function, craniofacial muscles can be grouped based on their 
developmental origin into extraocular muscles (EOM), branchiomeric muscles and hypobranchial 
muscles (Figure 1.4: Human craniofacial muscles) (Ziermann et al., 2018). While their clinical 
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relevance is growing and is based on specific diseases like strabismus, laryngeal dystonias, facial 
paralysis or others (McLoon and Andrade, 2012), they are even more fascinating from a research 
point of view because of their unique role in some neuromuscular disorders. Indeed they are 
selectively spared in some muscular disorders including Duchenne's muscular dystrophy (Andrade 
et al., 2000; Khurana et al., 1995), amyotrophic lateral sclerosis (McLoon et al., 2014) and aging 
(Kallestad et al., 2011). Nevertheless, extraocular muscles remain a niche research topic, on which 
the research publication just doubled in the last 25 years and remains stable at around 200 papers 
per year in the last 4 years (Web of Science: https://apps.webofknowledge.com).  
 
Figure 1.4: Human craniofacial muscles 
Illustration of human craniofacial muscles colored according to their embryonic 
origin, which are either one of the branchial (pharyngeal) arches (1st arch, 2nd arch 
or caudal arches) or lateral mesoderm adjacent to occipital somites for the 
hypobranchial muscles. Extraocular muscles developed separately (Ziermann et al., 
2018) 
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The developmental origin of most muscles in the body is the mesoderm. During embryogenesis 
the mesoderm splits into the lateral plate mesoderm (LPM), intermediate mesoderm (IM) and 
paraxial mesoderm (PM). In the later stages the paraxial mesoderm segments and forms the so 
called somites (Chang and Kioussi, 2018). These somites will subsequently develop into limb and 
trunk skeletal muscles, while the cardiac muscle as well as most craniofacial muscles will develop 
from the unsegmented PM (cranial mesoderm). After further maturation, this will be the origin 
of the 60 muscle groups located at the head and neck. The craniofacial muscles originating from 
the branchial arches can be sub grouped as follows: the muscles mainly responsible for 
mastication and jaw movement, derive from the 1st  branchial arch and are innervated by 
branches of mandibular nerves (cranial nerve (CN) V), the muscles for facial expression derive 
from the 2nd branchial arch and are innervated by CNVII and the muscles derived from the caudal 
arches, also called the 3rd branchial arch, which control the larynx and the pharynx. Hypobranchial 
muscles including the tongue and infrahyoid strap muscles, are the only craniofacial muscle which 
derive from the somites and migrate to the head region during development. The last group of 
craniofacial muscles are the six different extraocular muscles (EOMs) (per eye), which originate 
from the prechordal and unsegmented paraxial mesoderm, independent from the arches (Figure 
1.5: Origins of the craniofacial muscles in avian head muscle primordia) (Noden and Francis-West, 
2006; McLoon and Andrade, 2012; Ziermann et al., 2018). In contrast to limb muscles, the 
development of craniofacial muscle seems to be more under the control of molecular markers 
rather than anatomical factors (Sambasivan et al., 2011). 
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Figure 1.5: Origins of the craniofacial muscles in avian head muscle primordia 
The map is based on labeling experiments by in situ injections or transplantation of 
already labeled precursor. These studies were done in different animals, including  
mice (Nathan et al., 2008; Theis et al., 2010), and developmental patterns appear to 
be conserved among divergent vertebrates. (Ziermann et al., 2018) 
Craniofacial muscles not only have a distinct origin compared to other skeletal muscles, but their 
genetic program and regulatory signals make them unique. One example is that the upstream 
regulators of craniofacial muscle differentiation are unlike those regulating trunk and limb muscle 
differentiation while the myogenic regulatory factors (MRF) are the same across skeletal muscles: 
Tcf21, Msc, Tbx1, Pitx2 and Lhx2 are needed to activate MRF genes for head myogenesis and are 
not required for limb or trunk muscles, while Pax3 is not essential for head muscle development. 
Within the head muscle group, EOMs and muscles originating from the 1st branchial arch have a 
distinct genetic program, and while masticatory muscles rely on several regulators, EOMs rely 
heavily on Pitx2 as shown by the fact that the absence of Pitx2 expression results in the complete 
absence of EOMs (Tzahor, 2009; McLoon and Andrade, 2012; Michailovici et al., 2015). 
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1.2.1 Extraocular Muscles 
As described in the previous sections, within the group of craniofacial muscles EOMs can be 
characterized as an individual sub-class of muscles having a distinct origin, developmental 
pathway and pattern of gene expression (Porter et al., 2001; Fischer et al., 2002). Furthermore, 
EOMs are among the fastest and most fatigue resistant skeletal muscles (Close and Luff, 1974). 
Seven different muscles (per eye) constitute the EOMs. They can be further divided into three 
subgroups according to their function. The levator palpebrae superiosis muscle which is 
responsible for raising the upper eyelid will not be further discussed and characteristics of the 
remaining 6 muscles will be presented. As shown in Figure 1.6 eye movement is controlled by: 
two oblique muscles (the superior oblique (SO) and the inferior oblique (IO) which can apply a 
torque to the globe; four rectus muscles, (superior rectus (SRM), inferior rectus (IR), medial rectus 
(MR) and lateral rectus (LR)). Together these 6 muscles can move the eyeball in a linear fashion 
in all 4 directions (up, down, left and right). Except for the inferior oblique muscle all others share 
the same origin at the apex of the orbit. The 4 rectus muscles arise from the common tendinous 
ring (also called anulus of Zinn), and the optic nerve, ophthalmic artery and some nerves also pass 
through this ring. Both oblique muscles are attached to the orbital walls. The superior oblique 
from the superonasal wall to the annulus of Zinn, while the inferior oblique is attached to the 
orbital floor adjacent to the lacrimal fossa, and posterior to the orbital rim (Figure 1.6 Anatomy 
of human extraocular muscle)(Yanoff and Duker, 2018). 
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Figure 1.6 Anatomy of human extraocular muscle 
Two views (sidewise/lateral: left; frontal/anterior: right) on the 6 EOM with their 
origin, common tendinous ring (also called annulus of Zinn), and their direction of 
movement (red arrows). The optic nerve is colored in orange. By OpenStax College 
[CC BY 3.0 (https://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons 
The movement of one eye is called duction. Remarkably, during duction, opposing muscles such 
as the medial rectus and the lateral rectus, must work together synchronously to enable 
purposeful eye movements. This agonist-antagonist relation is termed Sherrington’s law of 
reciprocal innervation. The synchronized movement of both eyes in one direction is called 
version. For version to occur, the muscles of one eye must operate in reverse order and 
synchronized with the other eye, an event termed Hering's law of equal innervation (King, 2011). 
For example, the lateral rectus from the left globe and medial rectus from the right globe will 
contract simultaneously to allow both eyes to focus on the same object. These pair of agonist-
antagonist muscles are called yoked muscles. There are a few exceptions violating Hering’s law, 
for example when eyes focus on close objects and both eyes move in opposite directions. These 
complex interactions are the basis of our stereo vision and empower us to have a 3-dimensional 
stereo view of our environment, which is essential for humankind and our culture (Yanoff and 
Duker, 2018).  
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1.2.2 Microanatomy of the EOMs 
Extraocular muscles also have a unique microanatomy. Every extraocular muscle consists of two 
different layers. In inner one, called global layer, and an outer one facing the orbital wall, called 
orbital layer. The most obvious difference between these two layers is that the global layer is 
directly connected to the sclera while the orbital layer terminates earlier and inserts directly into 
the connective tissue pulley. At the point where the orbital layer ends the global layer passes 
through the pulley. The pulley is a ring surrounding the globe and consists mainly of collagen, 
elastin and smooth muscle (Figure 1.7: Schematic drawing of the EOMs with their insertion into 
the globe and cross-section micrograph of one EOM with their two layers)  (Spencer and Porter, 
2005; McLoon and Andrade, 2012; Yanoff and Duker, 2018). Not long ago (Demer et al., 2000) 
realized for the first time that passive pulleys cannot explain the normal movements of the eye. 
So, they introduced the active pulley hypothesis. The current dominant theory is that the orbital 
layer moves the pulleys in coordination with the global layer however, this theory only applies to 
the rectus muscles (Ruskell et al., 2005; Miller, 2007). 
But it is not only the terminal portion of the muscle which differs between the two layers. Even 
though both layers have a complex fiber type arrangement, the fibers present in the orbital layer 
have a smaller average diameter and even contain a group of fibers having a diameter of 3-4 µm 
(in human). Such small fibers are not present in the global layer (Figure 1.7: Schematic drawing of 
the EOMs with their insertion into the globe and cross-section micrograph of one EOM with their 
two layers). While there is a consensus in the literature that the average size of the fibers present 
in the orbital layer is small, the absolute size in human EOMs varies. One paper report orbital fiber 
diameter ranging from less than 20 µm to a maximum of 26 µm, a second paper reports average 
cross sections with an average diameter of around 21 µm and a third paper reports fibers of 
approximately 50 µm. Similar size divergences can be found for the global layer with a maximum 
dimeter of 40 µm in two papers, and an average of 70-80 µm in a third report. The latter also 
reports a group of smaller fibers in the global layer. (Stirn Kranjc et al., 2009; Kjellgren et al., 2003; 
Wasicky et al., 2000). Rather than saying one reference is more correct then the others this 
highlights the complexity of EOMs and the fact that EOMs are far from being uniform along their 
contraction axis. Additionally, the diameter depends on where the muscles have been sectioned. 
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There is also evidence showing that unlike limb muscles, EOM fibers do not span from tendon-to-
tendon (Harrison et al., 2007). Finally, EOM fibers can be grouped into six fiber types 
characterized by the expression of specific myosin heavy chain (MyHC) isoforms, innervation and 
enzymatic activity (see below).  
 
 
Figure 1.7: Schematic drawing of the EOMs with their insertion into the globe and 
cross-section micrograph of one EOM with their two layers 
(Left) Anatomy of the EOM. Rectus muscles entering the globe with their global layer 
while the orbital layer terminates in the pulley ring. Virtual cuts through three 
different position perpendicular to the fiber muscle orientation. Connective tissue is 
marked in different colors. IO: inferior oblique; IR: inferior rectus; LPS: levator 
palpebral superioris; LR: lateral rectus; MR: medial rectus; SO: superior oblique; SR: 
superior rectus (Spencer and Porter, 2005). (Right) Micrograph of a monkey lateral 
rectus muscle showing the two layers. The c-shape orbital layer consists of fibers with 
a smaller diameter and surrounds the global layer(Spencer and Porter, 2005). 
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A third external layer in human extraocular muscles has been observed and called marginal zone. 
It is located outside of the orbital layer and stretches almost the full length except for the very 
proximal and distal regions, where the organization becomes unclear. The fibers found in the 
marginal zone are mainly larger than the fibers in the orbital layer or global layer, having a 
diameter of approximately 83 µm (Wasicky et al., 2000). 
1.2.3 Innervation of EOM 
EOMs are innervated by the abducens (CNVI) and the oculomotor (CNIII) except for the superior 
oblique which is innervated by the trochlear (CNIV).   
 
Figure 1.8: Innervation in extraocular muscle 
Schematic representation of the two innervation types: singly innervated fiber (SIF) 
and multiply innervated fiber (MIF). The endplate zone of the SIF is called “en plaque” 
while the endplates of the MIF are located at the proximal (orbital and global layer 
MIFs) and distal end (only global layer) and are called  “en grappe” because they look 
like a bunch of grapes. Palisade endings are only found in the global layer at the distal 
ends (Büttner-Ennever, 2007). 
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In EOM two types of innervations can be found, singly innervated fibers (SIF) and multiply 
innervated fibers (MIF) (Figure 1.8: Innervation in extraocular muscle) (Pachter et al., 1976). In 
contrast skeletal muscles contain almost exclusively SIFs and MIFs are only rarely found (Morgan 
and Proske, 1984). Even though the neuromuscular junctions of EOMs are very similar to those 
of limb skeletal muscles from a biochemical point of view (Khanna et al., 2003), the proportion of 
nerve fibers to muscle fibers is more than 10 times higher (1:3 to 1:5 or 1:12) in extraocular 
muscles compared to (1:50 to 1:125) in skeletal muscles (Tibrewal and Kekunnaya, 2018; Pineles 
et al., 2018; Mühlendyck, 1978; Von Noorden and Campos, 2002). While the SIFs follow the all-
or-none contraction as occurs in limb skeletal muscles, the MIFs only generate a local contraction 
at the endplates and the force does not propagate along the muscle fiber (Büttner-Ennever, 
2007). 
1.2.4 Myosin Heavy Chain and Fiber Type Composition of Extraocular Muscles  
Initially  EOM fibers were characterized almost exclusively  by their innervation and mitochondrial 
density (Mayr, 1971). Subsequently, reports showed that EOMs have a complex myosin heavy 
chain (MyHC) isoform composition and this MyHC composition was overlaid on the already 
existing fiber types. It should be mentioned that limb skeletal muscles can be divided into four 
different groups depending on the MyHC isoform they express. MyHC type 1 (slow, β -cardiac, 
MYH7), MyHC type 2A (fast MYH2), MyHC type 2X (2D, fast MYH1) and MyHC 2B (fast MYH4). The 
presence of a specific MyHC isoform also parallels the oxidative metabolic activity of the 
particular muscle type: slow oxidative, slow twitch, and fatigue resistant  fibers contain mainly 
MyHC type 1; fast-twitch, oxidative, glycolytic and mostly fatigue resistant fibers contain MyHC 
2A; fast-twitch, glycolytic and fast fatigable  fibers mainly contain MyHC 2B (this isoform is not 
present in human muscles), and fast-twitch, intermediate fatigue resistant fibers mainly contain 
MyHC 2X humans (Schiaffino and Reggiani, 2011; Talbot and Maves, 2016). Aside these four 
isoforms, mature EOMs also contain MyHC isoforms which are present during development and 
not in adult skeletal muscles including: embryonic MyHC (MyHCemb, MYH3) and 
neonatal/perinatal MyHC (MyHCneo, MYH8) as well as specialized isoforms: alpha-cardiac MyHC 
(MyHC α -card, MYH6) and the EOM specific MyHC MyHCeom, MYH13). Nevertheless, the 
presence of all MyHC isoforms was not always confirmed by different investigators studying 
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EOMs. Sometimes they weren’t able to identify some isoforms and they termed them as 
unidentified isoforms (Stirn Kranjc et al., 2009; Kranjc et al., 2000; Rushbrook et al., 1994; 
Rubinstein and Hoh, 2000; Bicer and Reiser, 2009; McLoon and Andrade, 2012). Furthermore, 
there are also reports showing that the orbital layer and globular layer expressing different MyHC 
isoforms. The global layer expresses more isoforms then the global one. Additional the MyHC 
isoform composition changing along the muscle axis (Figure 1.9:Longitudinal and cross-section 
staining for different myosins in adult rectus muscle) (Bicer and Reiser, 2009; Zhou et al., 2010; 
Park et al., 2012) and even within a single fiber (Bicer and Reiser, 2009; Zhou et al., 2010; McLoon 
et al., 2011). These “hybrid” fibers also occur in limb skeletal muscles but only under stress or 
injury (Caiozzo et al., 2000). Recently, two reports identified two ancient MyHC isoforms 
(MYH14/7b and MYH15) in mammalian EOMs (Rossi et al., 2010; Lee et al., 2019) as well as the 
non-muscle isoform myosin IIB (nmMyHCIIB, MYH10)(Figure 1.10: Myosin heavy chain genes and 
their phylogenic tree) (Moncman and Andrade, 2010). 
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Figure 1.9:Longitudinal and cross-section staining for different myosins in adult 
rectus muscle 
Cross-section antibody staining for MyHC 2A (red), MyHC 2B (green), and slow-
MyHC/ MyHC type 1 (blue) at different positions along a mouse EOM from proximal 
(A), proximal-mid (B), mid-belly (C), and distal (D). The orbital and global layer can 
also be distinguished by their different MyHC composition: MyHC 2A is mainly in the 
orbital layer as well as at the proximal and distal ends and not present in the belly 
regions. MyHC 2B is only expressed in the global layer throughout the whole muscle 
length. MyHC type 1 can be found scattered across both layers. No co-expression in 
the same fiber of these three isoforms can be found. Arrows in C indicates adjacent 
muscles. Scale bar: 100 µm (Zhou et al., 2010) 
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If this complex MyHC isoform expression pattern is combined with the type of innervation and 
other factors it is possible to classify different fiber types within the EOMs. Initially EOMs were 
grouped by into two groups (Siebeck and Kruger, 1955), later into three groups based on their 
mitochondria density and distribution into coarse, fine and granular EOM muscle fibers (Durston, 
1974). But even before their classification (Mayr, 1971) suggested a classification into six groups, 
two groups in the orbital layer and four in the global layer, which is usually today the accepted 
standard. The six groups are, from orbital to the global layer and from most abundant to the least 
abundant: singly innervated, fast and high fatigue resistant in the orbital layer (1); , multiply 
innervated, fast and slow, and variable fatigue resistant in the orbital layer (2); in the global layer: 
“red”, singly innervated, fast and high fatigue resistant (3); “white”, singly innervated, fast and 
low fatigue resistant (4); “intermediate”, singly innervated, fast and intermediate fatigue 
resistant (5); multiply innervated, slow and high fatigue resistant (6) (Table 1: Extraocular muscle 
fiber types) (Kranjc et al., 2000; Skalicky, 2015). 
 
 Table 1: Extraocular muscle fiber types  
The six major fiber types are sorted by their appearance in the muscle layer. Two fiber 
types are present in the orbital layer and four in the global layer. Type of innervation 
is indicated in the fiber type name. Additionally, contraction mode, speed and fatigue 
resistance are shown. Fiber types are divided according to fatigue resistance and 
innervation (Skalicky, 2015). 
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But the literature is not homogeneous when it comes to EOM classification and other 
classifications can be found in the literature. There are studies which classify only five types, four 
in the global and three in the orbital layer with two types found in both layers (Rashed et al., 
2010); in a more recent study ,the same investigators found six different types, four in each layer 
with two types found in both layers (Rashed and El-Alfy, 2012). Others studies also classified six 
different types but three different ones in each layer (Spencer and Porter, 2005). Human EOMS 
are even more complex; They have not two but three layers in the EOMs. It has been reported 
that they have two fiber types in the orbital layer and three in the global layer. Additionally three 
fiber types were characterized in the third layer, the marginal zone: one singly innervated and 
two multiply innervated types, a high and low oxidative (Wasicky et al., 2000). 
A different hypothesis is that EOMS are a continuum rather than distinct types and that 
continuum is what allows  these complex muscles to function in such a precise way (McLoon et 
al., 2011). The basis of this hypothesis is that the continuum would also take into account 
innervation, metabolism as well as force, shortening velocity as well as MyHC pattern into 
consideration (McLoon et al., 2011). And even the first paper describing EOM fiber types 
described the mitochondria density as a “spectrum” (Mayr, 1971). Beside that this hypothesis 
might be correct the distinct fiber types nevertheless helps tremendously to communicate and 
avoid misunderstanding between investigators. 
 
Figure 1.10: Myosin heavy chain genes and their phylogenic tree 
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Table of human myosin heavy chain genes with their chromosome location (Ch.), 
protein alias (N.S. refers to no specification), and primary muscle tissue of expression. 
The phylogeny on the left indicates the evolutionary relationship between the human 
sarcomeric myosin heavy chain genes (this cladogram does not reflect accurate scale) 
(Lee et al., 2019) 
 
1.2.5 Diseases Affecting the Extraocular Muscles 
One of the most common human diseases in the field of ophthalmology is strabismus, with a 
prevalence of 2% - 5% (Dorr et al., 2019). It is characterized by a misalignment of the eyes, so that 
they point in different directions. This results in one eye being fixed on what the patient intends 
to look at (the fixing eye) and the other eye looking at something else (the deviated eye). There 
are subtypes of strabismus depending on the position towards which the deviated eye is pointing 
to: the eyes can deviate inwards (esotropia or crosseyed), outwards (exotropia or wall eye), 
vertically upwards (hypertropia) or vertically downwards (hypotropia). The brain of the handles 
the double image by blurring the one from the deviated eye. In long-standing strabismus, this 
blurred image is completely suppressed by the brain and the patient only sees a single image. A 
more rarely found strabismus form is when the brain merges the two images so that two objects 
appear at the same place. But in all cases the patient suffers from a reduced depth perception. A 
very early onset of strabismus can also lead to amblyopia or lazy eye. It is a permanent reduced 
vision of the deviated eye and is caused by a reduced visual cortex development.  
The first step of strabismus therapy is to rule out a retinoblastoma. After this is ruled out the 
treatment and management of strabismus can take place. In some case of esotropia due to far-
sighting strabismus can be treated with correction glasses. Prism glasses can be used for any 
strabismus type for the temporary comfort. But the most common treatment is strabismus 
surgery. The surgery can be done on one or both eyes and the surgeons usually has two options 
to correct the eye position. They can shorten the EOM by cutting parts away or they can alter 
their position where they attach onto the sclera. If the patient also suffers from amblyopia and is 
young enough the fixing eye can be patched so that the visual cortex can develop properly, and 
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the strabismus surgery follows later. Usually if the eye alignment is attained and maintained to 
the mid-teens it tends to remain stable. 
(Helveston, 2010) 
Another EOM disease condition is ophthalmoplegia. Ophthalmoplegia is the paralyses or 
weakness of eye muscles. Two types of ophthalmoplegia exist, chronic progressive external 
(CPEO) and internuclear ophthalmoplegia. Internuclear ophthalmoplegia is caused by nerve 
damage on fibers controlling the lateral eye movement which leads to double vision. CPEO is 
characterized by slowly progressive weakness and inability to move the EOM and eyelid muscle, 
levator palpebrae superioris. The drop of the eyelid, called Ptosis, may be a first incident for CPEO. 
The spectrum of disease which causes CPEO is wide but typically a mitochondrial disorder is the 
underlying cause. Indeed, the range of mutations causing CPEO is wide: from large-scale mtDNA 
rearrangements, to point mutations in transfer RNA genes to alterations of genes maintaining 
mtDNA encoded by the nuclear genome. CPEO may be a sufficient phenotype to diagnose a 
mitochondrial disease, nevertheless patients often present other symptoms as well. 
Nevertheless, a differential diagnosis is essential to exclude disease such as Grave’s disease, 
myasthenia gravis or glioma which can also cause CPEO. There is no current treatment known for 
CPEO. (Al Kahtani et al., 2016; McLoon and Andrade, 2012) 
These are by far not the only disease affecting EOMs. The one described in the previous paragraph 
are the more EOM exclusive disorders while section 1.3.5 Congenital Myopathies describes some 
disease which affect EOM as well. Other disease with EOM involvement are for example 
myasthenia gravis, Graves' disease, Miller Fisher syndrome, amyotrophic lateral sclerosis. 
(McLoon and Andrade, 2012) 
1.3 Excitation Contraction Coupling (ECC) 
Beside the sarcomere, the contractile part of the muscle, (Paragraph 1.1: Skeletal Muscle 
Structure) there is also a fine network of SR surrounding the sarcomeres and network of tube- 
like structures or invaginations of the sarcolemma perpendicular to the muscle fiber. This so-
called T-tubule (transverse tubule) system together with parts of the SR forms the triads (skeletal 
muscle) or dyads (cardiac muscle). The T-tubules penetrate deep into the muscle fibers and 
 31 
 
cardiomyocytes. There are also longitudinal tubules connecting the T-tubules. This tube system is 
the basis for rapid contraction propagation in either direction longitudinal along the fiber and 
dominantly transversal into the fiber. (Figure 1.11: T-tubule system and triads) 
 
Figure 1.11: T-tubule system and triads 
(A) Schematic representation of a muscle fiber showing T-tubules and SR network. 
Note that t-tubules go deep into the muscle fibers and are surrounded by SR and 
mitochondria. (B) EM photomicrograph of individual triads. RyRs are marked 
according to their location in yellow (junctional) or purple (prejunctional). (C) EM 
photomicrograph of a muscle fiber cross section from zebrafish, showing multiple 
sarcomeres. Triads are indicated with white circles. A: (Blausen.com staff, 2014); B-
C: modified from (Perni et al., 2015) 
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Excitation contraction coupling (ECC) describes the mechanism linking activation of contraction 
initiated by the action potential (AP), to muscle contraction. From a general point of view ECC in 
skeletal and cardiac muscle are similar, but there are distinct differences which gives them their 
unique properties. These differences will be discussed in sections 1.3.1 and 1.3.2 below. In all 
striated muscles, the starting point of ECC is depolarization of the sarcolemma. The action 
potential propagates along the sarcolemma to reach all sides of the fiber. When the AP reaches 
the T-tubules it propagates along the T-tubules deep inside the muscle fiber. When it reaches the 
triads (or dyad), the signal is transmitted inside the muscle fiber leading to the release of Ca2+ 
from the SR into the myoplasm. As detailed in a previous chapter 1.1 Skeletal Muscle Structure 
the Ca2+ ions will then trigger the uncovering of the myosin binding side on the actin molecule 
leading to sarcomere contraction. T-tubules are surrounded by the terminal cisternae of the SR 
giving rise to triads if they are surrounded by two cisternae or dyads if they are surrounded by 
one cisterna.  
Many proteins are involved in ECC and these will be discussed in detail in section 1.3.4 but the 
two key players involved in electrical signal from the AP into a chemical gradient, a rise in 
myoplasmic [Ca2+] are the dihydropyridine receptor (DHPR; also called L-type Ca2+ channel) and 
the ryanodine receptor (RyR). DHPRs are located within the T-tubules and are integral 
components of the sarcolemma, while the RyRs sit in the terminal cisternae membrane of the SR. 
The Ca2+ released from the SR to the myoplasm leading to contraction is first buffered quickly by 
parvalbumin before it is subsequently pumped back into the SR by the sarco/endoplasmic 
reticulum Ca2+ transport ATPase (SERCA) or transported out of the fibers via Na+/Ca2+ exchanger 
(NCX) and plasma membrane Ca2+ ATPase (PMCA).  
Most of these proteins involved in ECC exist as multiple isoforms composed of more than 1 
subunit depending on the muscle type and these will be discussed in the next two sections. 
 
1.3.1 ECC in Skeletal Muscle 
A healthy skeletal muscle mainly expresses triads containing skeletal muscle specific 
macromolecular complexes of RyR and DHPR isoforms, i.e. the RyR1 and the DHPR complex 
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containing the Cav1.1 skeletal muscle specific α1S subunit. A specific feature of these two 
complexes is that they are mechanically coupled. When the AP moves along the T-tubule and 
reaches the DHPR, it causes the latter to undergo a conformational change which allows it to 
come into contact with the and open the RyR1 present in the junctional region of the SR. The 
open RyR1 allow the Ca2+ to flow into the myoplasm and then bind to troponin-C activating the 
cross-bridge cycle and thus muscle contraction (Figure 1.12: Skeletal ECC and see section 1.1 
Skeletal Muscle Structure). This mechanical coupling between Cav1.1 and RyR1 is exclusive for the 
RyR1 isoform and its absence cannot be compensated by other isoforms such as RyR2 or RyR3. 
The same applies for the α1S isoform subunit of the DHPR.  
 
Figure 1.12: Skeletal ECC 
Representation of skeletal ECC. When the depolarization of sarcolemma reaches the 
T-tubules (1), the voltage sensing DHPRs undergo a conformational change and 
activate RyR1 channels resulting in Ca2+ release from the SR (2). Ca2+ diffuses to the 
sarcomere where it binds to the contractile proteins and initiates muscle contraction 
(3). Muscle relaxation takes place when Ca2+ is pumped back into the SR by SERCAs 
(4) or pumped out of the muscle fiber by membrane ion exchangers or pumps (NCX, 
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PMCA) (5). Myoplasmic Ca2+ can also bind to other high affinity calcium binding 
proteins such as NFAT, S100, CaM etc thereby activating intracellular Ca2+-dependent 
signaling pathways resulting in muscle gene regulation (6). High levels of myoplasmic 
Ca2+ can also be sensed by mitochondria (7), where they stimulate the ATP synthesis 
required for muscle contraction and relaxation. (Lasa-Elgarresta et al., 2019) 
Electron microscopy revealed that the RyR1 are organized in regular checkerboard arrays of two 
rows at the terminal cisternae of the junctional SR, called couplons (Figure 1.13: Couplons and 
DHPR-RyR arrangement). The square profile of the RyR1 (see section 1.3.4 ECC Proteins) is tilted 
by 22° relative to the axis of the tubule. Each RyR1 can bind up to four DHPRs so that it looks like 
the DHPRs sits on the corner of a square forming the so-called tetrads. The coupled RyR1-DHPRs 
complex are called calcium release unit (CRU). It is postulated that tetrads occur in an alternating 
way forming a checkerboard array of coupled and uncoupled RyR1s. 
This leads to the existence of a second calcium release mechanism, namely the calcium induced 
calcium release (CICR). While the DHPR is the physiological activator of the RyR1, RyR1 can also 
be activated by Ca2+ itself. The importance of this mechanism lies in the fact that only half of the 
RyR1 are coupled while the other half are not coupled to a DHPR (Figure 1.13: Couplons and 
DHPR-RyR arrangement). So that Ca2+ from coupled RyR1s can activate uncoupled RyR1 in close 
proximity. The CICR mechanism was largely accepted by the scientific community for decades 
until recently some doubts arose and there are now hypothesis that the uncoupled RyR1 if 
present in mature mammalian fibers, work as spacers between coupled RyR1, necessary to 
maintain the structural integrity of the couplons. Simulation studies as well as biochemical 
evidence also suggest that additional uncoupled RyR1 serve as a channel reserve for the coupled 
RyR1 to prolong the natural cycle of the RyR1 array. 
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Figure 1.13: Couplons and DHPR-RyR arrangement 
(A) Freeze-dried rotary shadowed junctional SR membrane from guinea pig. (B) 
Tetrads of particles (CaV1.1) in a freeze-fractured T tubule membrane from toadfish 
muscle, presented with the same orientation and magnification. (C) Canonical 
couplon, with array notation (side view inside diagram). RYR tetramers (or channels, 
or feet; green) are identified by a row index j (which in T tubule couplons range 
between 0 and 1) and a column index k (0–3 in the case illustrated). In this canonical 
configuration, even channels are fully occupied by CaVs (orange elements). Individual 
protomers are identified by index i (0–3), increasing clockwise within the RYR 
tetramer. The horizontal distance between centers of adjacent RYRs is ∼30 nm. (Ríos 
et al., 2019) 
The skeletal DHPR (an L-type Ca2+ channel) is capable of transporting a calcium current but the 
amount of transported calcium is very small and not essential for skeletal muscle ECC as recently 
reported in a study with a non-conducting DHPR from zebrafish.  
Subsequent to its release from troponin-C in fast twitch muscles Ca2+ is buffered by parvalbumin 
before being pumped back into the SR by SERCA. Two main SERCA isoforms are present in mature 
mammalian muscle fibers and their distribution mainly depends on the fiber type. The slow type 
I fibers usually express SERCA 2 while the fast type II fiber mainly express SERCA 1. Co-expression 
of both isoforms in some human muscles has been reported.  
(Rebbeck et al., 2014; Calderón et al., 2014; Drum et al., 2016; Hernández-Ochoa and Schneider, 
2018; Franzini-Armstrong, 2018; Ríos, 2018; Díaz-Vegas et al., 2019; Ríos et al., 2019) 
 36 
 
1.3.2 ECC in Cardiac Muscle 
Cardiomyocytes, the cardiac counterpart of skeletal muscle fibers, are single nucleated cells and 
are much smaller than skeletal muscle fibers but contain a fully developed T-tubule system which 
helps propagate the AP along and through the whole cell. In comparison of skeletal muscles 
cardiac muscles express RyR2 and the α1C subunit of the DHPR. These cardiac isoforms are not 
mechanically coupled (as are the skeletal isoforms) but the α1C subunit of the DHPR acts as a 
voltage sensor and calcium channel so that heart ECC relies on influx from the extracellular 
environment and ECC occurs through a process of CICR. In other words, the Ca2+ transported by 
the DHPR triggers a large release of Ca2+ from the SR via RyR2 and this leads to cardiac contraction. 
To maintain a stable CICR the cardiac DHPR must be activated by a longer pulse explaining why 
the AP in the heart is longer, lasting around 200 ms (Figure 1.14: ECC in the heart).  
 
Figure 1.14: ECC in the heart 
Schematic representation of ECC in the heart. Note the CICR through the DHPR which 
are not in close proximity to the RyR2. The black box shows the chronology of the ECC 
from the AP to Ca2+ release to cardiac muscle contraction. (Bers, 2002) 
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Because in cardiac cells RyRs and DHPRs are not mechanically coupled, the structure of CRUs 
(calcium release units) and T-tubule pattern look different than those in skeletal muscle. Instead 
of one terminal cisternae being located on each side of the T-tubule, only one terminal cisternae 
is present and the structure is called a dyad. Additionally, structured couplons and tetrades are 
missing from cardiomyocytes. Super-resolution microscopy experiments have recently shown 
that in cardiac cells there are clusters of ~14 RyR2 in peripheral coupling and up to ~100 in the 
intracellular site. It is estimated that for each DHPR opening at a dyad, 4-6 RyR will release Ca2+ 
from the SR. 
(Bers, 2002; Lanner et al., 2010; Greenstein and Winslow, 2011; Gambardella et al., 2017; Eisner 
et al., 2017; Ríos, 2018; Zipes et al., 2018; Hamilton and Terentyev, 2019) 
1.3.3 ECC in EOM 
Only little is known about the ECC in EOMs. One study investigated the Ca2+ homeostasis in EOM 
derived myotubes compare to skeletal ones (from tibialis anterior, TA) in rats. Myotubes from 
EOMs showed an elevated calcium release when stimulated by ionomycin or high K+ levels. This 
can be interpreted as a higher Ca2+ content of EOMs compared to limb muscles. Furthermore, 
transcript levels in myotubes and mature muscles were compared between EOMs and TA. A 
tremendous upregulation of several mRNAs from proteins involved in Ca2+ handling including, 
SERCA2, Na+/Ca2+-exchanger, phopholamban, calsequestrin 2, S100A1 and calmodulin to name a 
few, was found. This up-regulations was more pronounced in mature muscles compared to 
myotubes. The most interesting finding is the mRNA expression of the slow/cardiac isoform of 
calsequestrin (calsequestrin 2) and SERCA (SERCA 2). The presence of calsequestrin 2 was 
confirmed by western blot. The authors concluded their findings in schematic representing the 
difference EOM ECC compare to TA. (Figure 1.15: Model of EOM vs TA muscle Ca2+ homeostasis) 
(Zeiger et al., 2010) 
An older study did not really contribute to the understanding of EOM ECC but showed their 
distinct gene expression compared to leg muscles. They showed that 4.5 % (13 genes) of the 
overall changes (>= 2-fold change) are in genes involved in the ECC. (Porter et al., 2001) 
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Two more recent studies from our lab investigated the ECC in human EOMs in more detail 
(Sekulic-Jablanovic et al., 2015, 2016a). They confirmed the upregulation of the genes of 
calsquestrin 2 (CASQ2) and EOM specific MyHC 13 (MYH13) at the mRNA level as well as found 
new upregulations like RYR3, TRDN, ASPH1, SRL and PVALB and downregulation like MYH1, 
CACNA1S, RYR1, SERCA1, CASQ1, JPH1. They confirmed the RyR1, Cav1.1, calsquestrin, 
sarcalumenin, junctophilin-1 and SERCA1 protein content by western blot. Interestingly they 
found Cav1.2 in the EOM biopsies, which is absent from limb muscles. They confirmed these 
findings through immunohistochemistry and showed the Cav1.2 is located on the sarcolemma of 
myotubes. Additionally, they confirmed the above mentioned higher Ca2+ release triggered by KCl 
and showed that EOM myotubes have higher levels of Ca2+ in their SR but a lower resting Ca2+ 
concentration. 
To summarize, the ECC in EOM is not well understood but multiple evidence shows that there are 
significant differences compared to the limb muscles and that EOMs also show characteristics of 
cardiac ECC. Additionally, EOMs have unique features including the expression of RyR3. 
 
Figure 1.15: Model of EOM vs TA muscle Ca2+ homeostasis 
(A) shows an EOM muscle cell with a larger SR, numerous pumps (Pmca: plasma 
membrane Ca2+-ATPase, Ncx: Na+/Ca2+-exchanger) and transporters in both the 
sarcolemma and the sarcoplasmic membrane and many Ca2+ binding proteins in the 
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cytosol ( S100a, parvalbumin: Parv and Calm: calmodulin) and SR (Casq1 and Casq2), 
as well as numerous mitochondria (Mito). CamkII (Ca2+/calmodulin dependent 
kinase II) phosphorylates Pln (phospholamban) at Thr17 (phosphorylated threonine 
17 residue), which regulates Serca2. Schematic (B) represents a TA muscle cell 
containing a smaller SR, fewer pumps and transporters and less Ca2+ binding proteins 
in the cytosol and SR compared with EOM. (Zeiger et al., 2010) 
1.3.4 ECC Proteins 
1.3.4.1 Ryanodine receptors (RyRs) 
As mentioned above, ryanodine receptors (RyRs) are Ca2+ release channels located in the SR in 
muscle cells or endoplasmic reticulum in non-muscle cells. Their name derives from the fact that 
they bind with high affinity to the plant alkaloid ryanodine. Ryanodine locks the Ca2+channels in 
an open sub conductance state at nanomolar concentrations, while at high concentrations (>100 
µM) it acts as an inhibitor (Fleischer et al., 1985; Meissner, 1986; Lattanzio et al., 1987). Each 
functional RyR Ca2+ channel is a homotetramer, each subunit is >500kDa (~5000 amino acids) 
giving a total of ~2.2 MDa for one complete channel. In mammals three RyR isoform are known 
to be expressed, namely RyR1, RyR2 and RyR3 and these are encoded by three different genes on 
three different chromosomes. The RyR1 is the main isoform expressed in skeletal muscle 
(Takeshima et al., 1989; Zorzato et al., 1990a). RyR2s are primarily found in cardiac muscle (Otsu 
et al., 1990; Nakai et al., 1990a) and RyR3 which was originally referred to as brain isoform 
(Hakamata et al., 1992) was later found to be ubiquitously expressed, especially during 
development (Ogawa et al., 2000; Lanner et al., 2010).  
 
Figure 1.16: RyR domain architecture 
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Linear view of the RyR1 protein sequence. Domains are colored individually and 
labeled with the type of predicted or known fold. Divergent regions (DR1-DR3) are 
colored in gray. TM, transmembrane. Black vertical lines indicate positions of 
suspected disease-causing mutations in RyR1.(Van Petegem, 2015) 
The amino acid sequence similarity of the three isoforms is ~65 % (Hakamata et al., 1992) and 
~11% of the sequence is encompassed by three regions, DR1-DR3 (also called D1-D3 (Lanner et 
al., 2010; Hwang et al., 2012)) with the largest divergence of these regions being found between 
RyR1-RyR3 (Van Petegem, 2015). The first region in the sequence, DR2, is critical for the 
mechanical interaction between RyR1 and Cav1.1 while the other regions appear to be regulatory 
domains (Ca2+ and caffeine (only DR1)) (Figure 1.16: RyR domain architecture & Figure 1.20: 
Protein and ion binding domains of RyR1) (Lanner et al., 2010; Hwang et al., 2012). 
RyR1 
The largest ryanodine receptor isoform is RyR1 with one subunit having a molecular mass of 
~565kDa; the gene encoding RyR1 is located at chromosome 19q13.2, spans 106 exons and 
encodes for alternatively spliced isoforms of 5038 and 5033 amino acids. The highest levels of 
expression of RyR1 are found in the junctional region of the terminal cisternae of the SR of skeletal 
muscle (Franzini-Armstrong and Nunzi, 1983; Hakamata et al., 1992; Zorzato et al., 1990b). 
However, low levels of RyR1 can be found in several other tissues such as vascular smooth muscle 
cells (Neylon et al., 1995; Lopez et al., 2016), stomach, cerebellum, Purkinje cells, adrenal glands, 
antigen presenting cells and B-lymphocytes (Marks et al., 1989; Takeshima et al., 1989; Furuichi 
et al., 1994; Giannini et al., 1995; OTTINI et al., 1996; Vukcevic et al., 2008, 2010) 
Because of their large size and distribution within intracellular membranes, the crystal structure 
of RyR1 was not obtained, but cryo-electron microscopy (cryo-EM) studies have been invaluable 
and have elucidated the RyR1 structure at near atomic resolution. While numerous papers agree 
on the overall mushroom shape of the RyR1 (Samsó et al., 2005; Kimlicka and Van Petegem, 2011), 
only recent progress in single-particle cryo-EM, enabling resolutions up to atomic levels from 
membrane proteins (Liao et al., 2013), resulted in structures of the closed state RyR1 with 
resolution from 3.8 Å to 6.1 Å. These results allowed the construction of atomic-level RyR1 
models and poly-alanine-level RyR1 models from rabbits RyR1 (Zalk et al., 2015; Yan et al., 2015; 
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Efremov et al., 2015). Each monomer of the channel can be split into four main domains, the shell, 
core solenoid, pore domains and C-terminal domain (CTD). While the largest part of the RyR1, the 
cap, is located in the cytosol the rest is mainly distributed across six transmembrane helices (S1-
S6) from the pore domain. But only S5 and S6 form the actual pore (Figure 1.17: Architecture of 
the ryanodine receptor). The cap is ~ 270 Å × 270 Å × 100 Å and contains ~80% of the RyR1 
mass while the trans-membrane domain is ~ 120×120×60Å. The structural models have been the 
bases for further crystal structure studies of smaller recombinant RyR1 domains to understand the 
function of RyR1 and allosteric coupling between shell and pore (Hwang et al., 2012; des Georges 
et al., 2016; Clarke and Hendrickson, 2016; Santulli et al., 2018). 
The ATP binding site shown in Figure 1.17 plays a key role in gating. The positively charged 
residues of the TaF domain of the core solenoid can bind to the triphosphate tail of ATP, which 
acts as link between the CTD and the TaF domain and can trigger the conformational change of 
these two domains, which is essential for the gating. This conformational change sequential to Ca2+ 
and AP/caffeine binding makes the monomer more rigid and activates the RyR1 leading to big 
lateral shift of the monomer resulting in the opening of the RyR1. The exact mechanism of opening 
still remains unknown but there are two possible hypotheses: 1: The more rigid monomer allows 
the shell to bend the S6 helix in the pore region by thermal movement. 2: An unknown locking 
mechanism is released by the conformational change, which leads to bending of the monomer and 
opening of the pore (Santulli et al., 2018). 
Mutations in RYR1 are linked to various disorders ranging from the pharmacogenetic disease 
malignant hyperthermia, to different forms of congenital myopathies including dominant and 
recessive myopathies (Hwang et al., 2012). These will be described in more detail in section 1.3.5 
Congenital Myopathies. 
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Figure 1.17: Architecture of the ryanodine receptor 
(A) Ribbon representation, with the shell (residues 1–3666; light blue), core solenoid 
(residues 3667–4253; green), pore domain (residues 4540–4956; orange), and CTD 
(residues 4957–5037; dark red). (B) Zoom onto the CTD area showing ligands and 
locally aligned difference density map calculated between the EGTA-only map and 
Ca2+, ATP, and caffeine map (green/red mesh), contoured at 5s. (C) Schematic 
representation of RyR1. J-sol, junctional solenoid; B-sol, bridge solenoid; C-sol, core 
solenoid; N-sol, N-terminus solenoid. TMx, putative additional transmembrane 
helices (Van Petegem, 2015; Santulli et al., 2018) 
RyR2 
The second largest ryanodine receptor is RyR2 with one subunit having a molecular mass of 
~564kDa; the gene encoding this isoform is location on chromosome 1q43, spans 102 exons and 
encodes for a protomer of 4967 amino acids. RyR2 was first found in and is the major isoform in 
cardiac tissue (Nakai et al., 1990b; Otsu et al., 1990). But subsequently high levels of expression 
were found in Purkinje cells of the cerebellum and cerebral cortex (Lai et al., 1992), where it is 
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involved in cognitive functions (Liu et al., 2012). It is also highly expressed in vascular smooth 
muscle (Berridge, 2008), as well as in insulin secreting pancreatic beta cells (Santulli et al., 2015). 
and in low levels in adrenal glands, kidney, lungs, ovaries, stomach and thymus (Kuwajima et al., 
1992; Giannini et al., 1995).  
The RyR2 is also composed of four identical subunits and its near-atomic 4.4 and 4.2 Å resolutions 
has given important information regarding its closed and open states (Peng et al., 2016). This 
study superimposed the open and closed states and found almost no change in the conformation 
of the selectivity filter (SF), the pore helices, and the supporting helices on S5 and S6 (residues 
4790 to 4840). Rather a deviation around residue Phe4854 after helix S6 was found, leading to an 
outward tilt of all four S6 and an opening of the gate by ~8 Å (Figure 1.18: Structure of the open 
and closed RyR2) (Peng et al., 2016). 
  
Figure 1.18: Structure of the open and closed RyR2 
(Left) Conformational changes of the S6 helices of the pore domain in the open and 
closed RyR2 structures. They are superimposed relative to the selectivity filter and 
supporting turrets (residues 4790 to 4840). The SR luminal side is placed on top. 
(Right) Cytoplasmic view of the dilation of the intracellular gate in the open RyR2. 
The constriction residues in the closed and open states, Ile4868 and Gln4864, 
respectively, are shown as spheres and colored yellow in the closed and green in the 
open structures (Peng et al., 2016) 
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RyR2 mutations are mainly linked to cardiac diseases such as catecholaminergic polymorphic 
ventricular tachycardia (CPVT) (Priori et al., 2001; Laitinen et al., 2001, 2003; Xiong et al., 2018) 
and arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2) (Tiso et al., 2001) 
RyR3 
The smallest isoform of ryanodine receptors is RyR3 with one subunit having a molecular mass of 
~552kDa; it is encoded by a gene located on chromosome 15q13.3-q14, spans 107 exons and 
encodes for a protein of 4870 amino acids. It has one more splicing variant: isoform 2: ~551kDa 
and 4865 amino acids. RyR3 was first identified in the brain (Hakamata et al., 1992; Nakashima et 
al., 1997) explaining why it sometimes called the brain isoform. But this terminology is misleading 
since RyR3 is widely expressed in many tissues (Lanner et al., 2010; Zhang et al., 2011) including 
hippocampal neurons, thalamus, Purkinje cells, corpus striatum (Hakamata et al., 1992; Lai et al., 
1992; Furuichi et al., 1994); skeletal muscles with the highest expression in the diaphragm (Marks 
et al., 1989; Neylon et al., 1995); smooth muscle cells of the coronary vasculature, lung, kidney, 
ileum, jejunum, spleen, stomach of mouse and aorta, uterus, ureter, urinary bladder, and 
esophagus of rabbit (Giannini et al., 1992; Hakamata et al., 1992; Giannini et al., 1995; OTTINI et 
al., 1996). 
RyR3 is the least studied RyR isoform but a recent study suggests that it plays a role in Alzheimer’s 
disease, specifically RyR3s in cortical neurons are neuroprotective in TgCRND8 mouse model of 
Alzheimer’s disease (Supnet et al., 2010). Though its detailed structure has not been investigated 
its overall structure is similar to that of RyR1 & RyR2 (Sharma et al., 2000; Liu et al., 2001). 
RyR1 and RyR2 knock-out (KO) mouse models are lethal and pups die at birth or during embryonic 
development (Takeshima et al., 1995, 1998), whereas RyR3 KO mice show no obvious 
impairments and have a normal lifespan and no reproductive problems (Takeshima et al., 1996; 
Clancy et al., 1999). Nevertheless RyR3 may play a role in the development of skeletal muscle and 
it was shown that in mice the diaphragm expresses RyR3 from the 18th day of the embryonic 
stage up to 15 days postnatally and subsequently decreases until it is almost undetectable 
(Tarroni et al., 1997). In line, isolated neonatal skeletal muscles fibers from RyR3 KO mice show a 
decrease of force development elicited by either caffeine or electrical stimulation even though 
ECC seemed to be normal (Takeshima et al., 1996; Barone et al., 1998) 
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Interestingly, transfection experiments of adult mouse muscle fibers have shown that RyR3 is 
essential for calcium sparks and CICR amplification. These findings are consistent with the fact 
that mammalian muscles lose the ability to produce sparks postnatally, and in conjunction the 
expression of RyR3 is down-regulated (Pouvreau et al., 2007). In their study Pouvreau et al. show 
that RyR3s are localized on the parajunctional membranes (Figure 1.19: Localization of RyR3), 
immediately adjacent to the junctional region and must be activated by a CICR mechanism since 
they don’t interact structurally (Protasi et al., 2000) or functionally (Fessenden et al., 2000) with 
DHPRs. (Pouvreau et al., 2007). These results are consistent with EM studies made on toadfish 
and frog skeletal muscles (Felder and Franzini-Armstrong, 2002). The amplification of 
spontaneous Ca2+ releases by single couplons of RyR3 was also confirmed in zebrafish (Perni et 
al., 2015). 
 
Figure 1.19: Localization of RyR3 
Model of a triad with two different RyR isofroms (RyR1 and RyR3). RyR1 (blue) are 
placed as parallel double row in the junctional feet while the RyR3 (green) in a zigzag 
double row pattern at the parajunctional feet. T tubule (TT), SR sacs (SR) (Felder and 
Franzini-Armstrong, 2002).  
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Regulators 
The large cap/shell of RyRs with ~500 000 Å2 gives them plenty of space for tens of signaling 
molecules for positive and negative regulation. Even though they share an overall sequence 
homology of ∼65% and their similar structure, different RyR isoforms can show different effects 
by the same regulators. 
The most obvious regulator is Ca2+. Cytosolic Ca2+ acts as activator at low concentrations (~ 1 μM) 
and as an inhibitor at high concentrations (~ 1 mM). This is accomplished by two different Ca2+ 
binding sites, of high and a low affinity (Meissner et al., 1986, 1997). But the Ca2+ -dependent 
activation varies between the three RyR isoforms. RyR2 and RyR3 are activated by Ca2+ to a 
greater extent than RyR1 and require higher Ca2+ concentrations for inactivation (Ogawa et al., 
2000; Lanner et al., 2010). In contrast, at high cytosolic Ca2+ concentrations, Mg2+ is a potent 
inhibitor of RyR1 (Lamb, 2000; Meissner, 2002) but a weak inhibitor of RyR2 and RyR3. 
Additionally, luminal Ca2+ (in the SR) can stimulate the Ca2+ release by RyR1 & RyR2 (Lanner et al., 
2010; Chen et al., 2014).  
Aside Ca2+ and Mg2+ there are many other regulators of RyRs. Some of them contain an EF-hand 
such as calmodulin (CaM) or S100. CaM is a ~ 17-kDa protein containing four EF hands in two 
domains, the N-lobe and C-lobe, that can bind directly to RyRs. CaM can also bind Ca2+ so has two 
states, the Ca2+free state, called ApoCaM, and the Ca2+bound state, Ca2+/CaM. The effect of CaM 
varies on the state and the RyR isoform it binds to (Menegazzi et al., 1994; Guerrini et al., 1995; 
Van Petegem, 2015). Cryo-EM studies have revealed that the two states have different bindings 
sites on the RyR1 (Samsó and Wagenknecht, 2002; Huang et al., 2012). In contrast to this ApoCaM 
binds in the RyR2 roughly the same location as Ca2+/CaM in RyR1 which is coherent with their 
function on the RyRs: At high Ca2+ levels it inhibits both RyR1 and RyR2, at low Ca2+ levels, so as 
ApoCaM, it activates RyR1 but inhibits RyR2 (Ikemoto et al., 1995; Tripathy et al., 1995; Buratti et 
al., 1995; Fuentes et al., 1994). Similarly, the small calcium binding protein S100 was found to 
bind to and regulate the activity of RyR1 (Susan  Treves et al., 1997). 
FK506-binding proteins (FKBPs) 12 and 12.6, also called calstabin1 and calstabin2, are two small 
proteins, of 12 and 12.6 kDa, that act as regulators of RyR channel activity. Co-purification studies 
showed that one FKBP binds to one RyR subunit, that is 4 molecules of FKBP per functional 
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channel tetramer (Jayaraman et al., 1992; Kushnir and Marks, 2010). While FKBP12 preferably 
binds to RyR1, FKBP12.6 prefers RyR2. FKBPs have a low affinity for RyR in the open state but a 
high affinity for RyRs in the closed state, even though the exact affinity of the two proteins has 
not been precisely determined (Wagenknecht et al., 1996; Van Petegem, 2015). They play a 
critical role for preventing RyRs from leaking Ca2+ and for coupled gating between RyRs. The effect 
of FKBP12 on RyR1 is that it can make it harder for the RyR1 to open by decreasing the appearance 
of sub conductance states (Brillantes et al., 1994; Venturi et al., 2014; Van Petegem, 2015). While 
it has the opposite effect on the RyR2 and act as an antagonist of FKBP12.6 (Galfré et al., 2012). 
There are more regulatory proteins which act directly or indirectly on RyRs (Figure 1.20: Protein 
and ion binding domains of RyR1 & Figure 1.21: Regulators of RyRs), including: calsequestrin, 
histidine-rich Ca2+ binding protein, homer, junction, S100A1, sorcin, triadin (Hwang et al., 2012). 
But RyR is also regulated by post-translational modifications, including phosphorylation, oxidation 
and nitrosylation (Bellinger et al., 2008). These modification occur mainly on the cytosolic shell 
and alter the shell’s dynamics (Santulli et al., 2017b, 2018). 
 
Figure 1.20: Protein and ion binding domains of RyR1 
Protein and ion binding domains across the RyR1 protein sequence colored 
individually. (Hwang et al., 2012) 
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Figure 1.21: Regulators of RyRs 
An overview of some proteins and molecules regulating RyRs. They can either be 
stimulators (+) or inhibitors (-) of RyR Ca2+ release. Some can even have both effect 
depending on their concentration (Van Petegem, 2015) 
1.3.4.2  Voltage-gated Calcium Channels / Cav1.1 & Cav1.2 
The voltage-gated calcium channels present in skeletal and cardiac muscles (Cav1.1 and Cav1.2) 
belong to a superfamily of transmembrane ion channels, including voltage gated sodium and 
potassium channels (Catterall, 1995). Within the voltage-gated calcium channel family there are 
many sub-families. The group consist of ten channels grouped into five sub-types: L-type (Cav1.1- 
Cav1.4), P/Q-type (Cav2.1), N-type (Cav2.2), R-type (Cav2.3) and T-type (Cav3.1- Cav3.3). L-type 
calcium channels (L for long lasting) are also known as dihydropiridine receptors (DHPR) because 
of the blocking effect of 1,4-dihydropyridines. Phenylalkylamines and benzothiazepines also block 
the activities of these channels. DHPRs are large macromolecular structures composed of several 
subunits including α1, α2δ, β1, and γ. The largest subunit is the pore- forming α1 subunit which 
also serveS as voltage sensor. The core subunit is the specific protein underlying the different 
characteristics of the ten voltage-gated calcium channels, whereby each channel has a different 
α1 subunit, Cav1.1 the α1S and Cav1.2 the α1C. These two α1 subunits are encoded by distinct 
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genes, namely CACNA1S and CACNA1C. The other 8 α1 subunits and the genes encoding them 
have similar names differentiated by a different last letter (A-I). Each α1 subunit within the same 
sub-group shares more than 70% identical amino acid sequence while across the different sub-
groups (ex. Cav2, Cav3 etc.) the sequence similarity falls below 40%.  
α1 subunits contain ~2000 amino acids and have a molecular mass of 190-250 KDa. They contain 
four highly homologous but non-identical intramembrane domains (I–IV). Every domain consists 
out of six transmembrane alpha helical segments (S1-S6) while the amino- and caboxy- terminal 
ends are located in the cytosolic space. The S1-S4 alpha helical segments of each domain is 
responsible for the voltage sensing feature of the α1 subunit and is called voltage-sensing domain 
(VSD). The voltage-sensing ability is thought to be given by the presence of alternating positively 
charged arginine or lysine residues at every third or fourth position in S4 separated by two 
hydrophobic residues. Studies have shown that during depolarization the S4 moves outwards, 
across the plane of the T-Tubule membrane thereby establishing the determinants for voltage 
sensitivity. S5 and S6 on the other hand, form the pore domain while the pore loop between S5 
and S6 is responsible for the ion selectivity of the channel. Only three mutations in the poor loop 
of domain I, III and IV can change the ion selectivity from Ca2+ to Na+. (Figure 1.22: Structure and 
membrane topology of of Cav1.1 the α1S) (Catterall et al., 2003; Hernández-Ochoa and Schneider, 
2018; Zipes et al., 2018) 
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Figure 1.22: Structure and membrane topology of of Cav1.1 the α1S of the DHPR 
(a) Cryo-EM reconstruction of the DHPR showing the different subunits that compose 
it. Side view at 3,6 Å. The α1 subunit is highlighted in blue. Auxiliary β-, α2δ-, and γ-
subunits are colored in green, red, and yellow, respectively. The asterisk represents 
the missing II-III loop in the cryo-EM structure. (b) Cav1.1 membrane topology with 
its four domains (I-IV), transmembrane domains (S1-S6) and its intracellular loops 
which interact with other proteins involved in ECC. (Hernández-Ochoa and Schneider, 
2018) 
One main difference between Cav1.1 and Cav1.2 is the loop between domain II and III. In skeletal 
muscles, the Cav1.1 is mechanically coupled to the RyR1 through the II-III loop. While also other 
regions, for example the I- II loop, may interact with the RyR1, the loop II-III is essential for this 
interaction. Cav1.2 on the other hand, does not interact directly with the RyR2 and activates the 
RyR2 through a mechanism of CICR. The result of this is that Cav1.1 forms tetrads with up to four 
Cav1.1 connected to one RyR1 tetramer (Figure 1.23: Structure of the Cav1.1 (α1S subunit of the 
DHPR) and its interactions with RyR1). 
The auxiliary β-, α2δ-, and γ-subunits contribute to trafficking, anchorage, and regulatory 
functions. The intracellular β-subunits have a molecular mass of 55 kDa and can be expressed as 
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four isoforms encoded by four different genes (CACNB1-4). The 4-TM γ-subunits consist of eight 
isoforms encoded by eight different genes (CACNG1-8). The extracellular α2δ-subunits are 
actually two subunits from one gene, the α2 and the δ, linked via a disulfide bond and have a 
combined size of 170 kDa. The δ- subunit has one TM region while the α2 is completely 
extracellular. There are four different isoforms encoded by four different genes (CACNA2D1-4). 
(Zipes et al., 2018) 
 
 
Figure 1.23: Structure of the Cav1.1 (α1S subunit of the DHPR) and its interactions 
with RyR1 
(a) cryo-EM reconstruction of the Cav1.1 subunit from two views: top=side view, 
bottom=upper view. The auxiliary subunits, the cytoplasmic tails, and loops are not 
shown. Its four domains are colored differently. Positively charged residues are 
indicated in red, negatively charged residues are shown in blue. The voltage sensing 
domains (S1-S4) is not in close proximity to the pore forming domain (S5-S6) as 
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indicated by the dashed ellipse for S1-S4 and the dashed circle for S5-S6. (b) Side (top) 
and upper (bottom) views of cryo-EM reconstruction of the RyR1 and four Cav1.1 
forming a tetrad. (Hernández-Ochoa and Schneider, 2018) 
1.3.4.3 Sarco/endoplasmic Reticulum Ca2+-ATPase 
The sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) is a 110 kDa, type P pump, with one 
cytosolic “headpiece” region and one transmembrane region, located in ER and SR. The cytosolic 
region can be split into three domains named according to their function: the nucleotide binding 
domain (N) which binds ATP, the phosphorylation domain (P) that drives ATP hydrolysis leading 
to the phosphorylation of the catalytic Asp residue, and the actuator domain (A) that catalyzes 
dephosphorylation of the P-domain and is involved in the transmission of the conformational 
change. The transmembrane domain consists of ten hydrophobic membrane spanning helices 
with two binding sites for Ca2+. SERCA is the most abundant protein in the terminal cisternae and 
the longitudinal SR, where it can make up to 80-85 % of the total protein content (Meissner, 1975; 
Costello et al., 1986; Zorzato et al., 1986). SERCAs transport two Ca2+ into the SR/ER per ATP 
hydrolysed (MOLLER et al., 2005; Toyoshima, 2009; Brini and Carafoli, 2009; Zipes et al., 2018) .  
There are three main isoforms, SERCA1-3, encoded by three different genes, ATP2A1-3. 
Additional alternative splicing variants of the main SERCAs extend the number of isoforms to 
twelve: SERCA1a-b, SERCA2a–d, SERCA3a–f. SERCA1 is exclusively expressed in adult (SERCA1a) 
and fetal (SERCA1b) fast-twitch skeletal muscles. SERCA2a is expressed in slower muscles, in 
particular in slow-twitch skeletal muscles and cardiac muscles. SERCA2c and SERCA2d can be also 
found in low amounts in the heart, while SERCA2b can be found in all tissues. The SERCA3 isoforms 
are usually found in non-muscle tissues (Periasamy and Kalyanasundaram, 2007). 
SERCAs can be inhibited by orthovanadate as well as with specific inhibitors such as thapsigargin, 
cyclopiazonicacid, and 2.5-di(t-butyl) hydroquinone. SERCAs are physiologically regulated by 
phospholamban, sarcolipin and myoregulin. Depending on its degree of phosphorylation, 
phospholamban can acts as an inhibitor for SERCA2a in the heart and slow twitch muscles, 
(MacLennan and Kranias, 2003); sarcolipin regulates SERCA1 activity in a Ca2+ concentration-
dependent way in fast-twitch skeletal muscles (Odermatt et al., 1998); myoregulin is a 
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micropeptide encoded within a long non-coding RNA sharing similarities with phospholamban 
and sarcolipin which is present in all skeletal muscles (Anderson et al., 2015). 
1.3.4.4 Calsequestrin 
Calsequestrin (CSQ) is an abundant low affinity high capacity Ca2+ binding protein localized in the 
SR. It is mainly present in the lumen of the terminal cisternae (Saito et al., 1984; Costello et al., 
1986; Franzini-Armstrong, 1987; Wagenknecht et al., 2002). It exists as two isoforms, CSQ1 
(apparent molecular mass of 63 KDa) and CSQ2 (apparent molecular mass of 55 KDa), encoded 
by two genes, CASQ1 and CASQ2. CSQ1 is the only isoform expressed in fast-twitch skeletal 
muscle while slow-twitch muscle express CSQ1 and CSQ2, even though CSQ1 remains the 
dominant isoform. In the heart only CSQ2 can be found. Both isoforms can be present as 
monomers or polymers; calsequestrin polymerizes when the Ca2+ concentration in the lumen of 
the SR is high (~1mM). One mole of CSQ1 can bind up to 50 moles of Ca2+. Beside buffering and 
storing Ca2+, CSQ1 is thought to regulate the activity of RyRs indirectly, mainly by binding to 
junctin and triadin. It is postulated that RyR1, CSQ1, traidin and junctin from a large protein 
complex (Yáñez et al., 2012; Barone et al., 2015; Elíes et al., 2020). 
1.3.4.5 Parvalbumin 
Parvalbumin is also a Ca2+ binding protein but unlike CSQ, it is present predominantly in fast twitch 
muscles and is a cytosolic protein. It has two Ca2+ binding sites. During contraction Ca2+ binds with 
high affinity to troponin-C before getting buffered by parvalbumin and subsequently being 
pumped back into the SR via SERCA. Under resting conditions, parvalbumin binds Mg2+ which is 
later replaced by Ca2+. It has been suggested that this buffering helps speed up muscle relaxation 
explaining why parvalbumin is only expressed in fast-twitch muscles but almost absent in slow-
twitch muscles. (Baylor and Hollingworth, 2003; Yáñez et al., 2012) 
1.3.4.6 JP-45 
As the name suggests JP-45 has a molecular mass of 45 kDa and is located on the junctional face 
membrane of the SR. It has one transmembrane domain with the C-terminus in the lumen of the 
SR and the N-terminus in the cytosol. It binds to the I-II loop of the skeletal α1S subunit of the 
DHPR and interacts with calsequestrin (1 and 2) via its luminal carboxy-terminal domain. Through 
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this interaction, the JP-45/CSQ complex is a negative regulator of Ca2+ entry through the DHPR 
during EC‐coupling. (Zorzato et al., 2000; Anderson et al., 2003; Mosca et al., 2013) 
1.3.4.7 STAC3 
SH3 and cysteine-rich domain-containing protein 3 (STAC3), the third isoform of the adaptor STAC 
protein family, is a relatively newly discovered protein involved in ECC. The gene encoding STAC3 
is mutated in patients with the congenital myopathy, Native American myopathy (Horstick et al., 
2013) (Horstick et al., 2013; Zaharieva et al., 2018). Recently it was shown that STAC3 binds to 
both Cav1.1 and RyR1, that it is essential for the transport of Cav1.1 to the plasma membrane and 
may be the missing link mediating the mechanical coupling between Cav1.1 and RyR1. STAC3 can 
also bind to Cav1.2, but this has a different effect as it greatly slows the rate of current inactivation 
(Polster et al., 2015). STAC3 was also shown to be essential for voltage dependent Ca2+ release 
(Nelson et al., 2013). 
1.3.4.8 Others 
Beside the proteins described many additional ones are present in the SR and triads and are 
involved in ECC (Figure 1.24:Protein components of the skeletal SR involved in the ECC). To name 
some: junctate, junctin, junctophilin, triadin, SRP-35, sarcalumenin and mitsugumin-23. (Treves 
et al., 2009)  
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Figure 1.24:Protein components of the skeletal SR involved in the ECC 
(Left) Schematic representation of proteins involved in ECC showing their location in 
the SR and TT-system. (Right) Coomassie Brilliant Blue stained gradient (5–15%) SDS-
PAGE of proteins involved in the ECC from the longitudinal sarcoplasmic reticulum 
(LSR), the terminal cisternae (TC) and the junctional face membrane (JFM) obtained 
from rabbit SR. (Treves et al., 2009) 
1.3.5 Congenital Myopathies 
Congenital myopathies are a group of non-dystrophic neuromuscular diseases caused by 
mutations in over 20 genes. Their clinical and histopathological features are heterogenous but 
usually they have an early onset, are diagnosed by neurologists based on the characteristics of 
the muscle biopsy. Disease progression can be variable, ranging from sever prenatal forms to a 
slowly progressing form of the disease. Typical weakness in axial and proximal muscles can be 
found in patients with diverse subsets of congenital myopathies while extraocular, cardiac or 
respiratory muscle involvement are specific for diseases caused by mutations in specific genes 
and constitute a smaller subgroup. The most commonly mutated gene in human congenital 
myopathies is RYR1, the gene encoding the skeletal isoform RyR1, but mutations in other genes 
such as myotubularin 1 (MTM1), selenoprotein N (SEPN1), Cav1.1 (CACNA1S), STAC3, BIN1 and 
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DNM2 are also frequently (Table 2: Genes implicated in congenital myopathies and related 
conditions) (Jungbluth et al., 2018). 
 
Table 2: Genes implicated in congenital myopathies and related conditions 
AD, autosomal dominant; AR, autosomal recessive; CCD, central core disease; CFTD, 
congenital fiber type disproportion; CNM, centronuclear myopathy; EOM, 
extraocular muscle involvement; KDS, King–Denborough syndrome; MmD, multi-
minicore disease; MSM, myosin storage myopathy; NAM, North American myopathy; 
TAM, tubular aggregate myopathy; XLMTM, X-linked myotubular myopathy. a=Genes 
most commonly implicated in the classic structural congenital myopathies, and the 
corresponding conditions.(Jungbluth et al., 2018) 
Over 300 mutations in RYR1 have been identified in patients affected by different diseases plus 
200 additional mutation which does not modify the channel function and so does not result in a 
disease. There are three hotspots where most of the disease causing mutations are located: N-
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terminal (~1–600), the central (~2000–2600) and the C-terminal (~4000–5000) region (Santulli 
et al., 2017a). Another hotspot is the phosphorylation domain (Yuchi et al., 2012).  
1.3.5.1 Central Core Disease 
Central core disease (CCD) was first described 1956 (Shy and Magee, 1956), occurs in 1:100 000 
live births and comprises 16-30% of all congenital myopathies, thus it is the most common 
congenital myopathy (Santulli et al., 2017a; Jungbluth et al., 2018). Patients present clinically with 
hypotonia, delayed motor milestones, predominantly proximal weakness and skeletal 
abnormalities such as scoliosis. Also, a positive in vitro contracture test (IVCT) for malignant 
hyperthermia susceptibility (MHS) is a frequent symptom. Histologically CCD is characterized by 
the presence of centrally located cores with reduced oxidative activity, mainly in type 1 fibers; 
the cores run along the fiber axis for a substantial distance on longitudinal sections (Figure 1.25: 
Histopathology of central cores in CCDs). The histopathological findings gave the disease its name 
and serve as a diagnostic criterium together with the clinical symptoms. Another typical finding is 
the reduction or absence of mitochondria, myofibrillar disorganization and accumulation of 
abnormal Z band material, as seen in EM pictures (Jungbluth, 2007b). 
CCD is mostly caused by dominant RYR1 mutations, often missense, and are located at disease 
causing hotspots (Figure 1.26: Distribution of CCD and MmD causing mutations across the RYR1 
gene). Disease progression is mostly slow or even static and most patients have mild to moderate 
symptoms (Jungbluth et al., 2018). Aside the most severe cases, almost all patients achieve the 
ability to walk. Often patients classified as having a recessive form of CCD are more severely 
affected and have a prenatal onset. Some also exhibit respiratory impairment which may affect 
their life span (Jungbluth, 2007b). All patients diagnosed as having CCD share the common 
phenotype that their extraocular muscles are spared and that they do not have an associated 
cardiomyopathy (Jungbluth et al., 2011). 
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Figure 1.25: Histopathology of central cores in CCDs 
Transverse section from the rectus femoris stained with NADH-TR. Dark staining 
indicates high oxidative type 1 fibers with cores in almost all fibers. Arrows show the 
typical cores located in the center of the muscle fiber but occasionally multiple cores 
and eccentrically located cores can appear. (Jungbluth, 2007b) 
1.3.5.2 Multi-Minicore Disease 
Another type of core myopathy is multi-minicore disease (MmD). The distinct separation of CCD, 
MmD and malignant hyperthermia is sometimes not possible due to their pathological and 
genetic overlap and are often discussed together by reviews. Unlike CCD, MmD is mostly caused 
by recessive RYR1 mutations or also by mutations in SEPN1 (SELENON) and in some cases in MYH7 
as well as a few other genes (Jungbluth et al., 2018). It has an estimated prevalence of 3.5 – 
5.0:100 000 (Jungbluth, 2007a) and unlike CCD, MmD is predominantly caused by recessive RYR1 
mutations which are evenly distributed across the RYR1 gene and do not cluster within particular 
hotspots (Figure 1.26: Distribution of CCD and MmD causing mutations across the RYR1 gene) 
(Treves et al., 2008b; Hwang et al., 2012; Santulli et al., 2017a). 
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Figure 1.26: Distribution of CCD and MmD causing mutations across the RYR1 
gene.  
Schematic representation of the RYR1 gene with the distribution of dominant and 
recessive (*) mutations associated with central core disease (CCD, in black) and multi-
minicore disease (MmD, in red). Notable the “hotspots” CCD causing mutations, 
highlighted in grey. (Figure courtesy of Dr Haiyan Zhou) (Jungbluth, 2007a) 
The clinical symptoms of MmD can vary highly depending on the genetic background. In general, 
MmD usually has an early childhood or infancy onset with hypotonia and proximal weakness up 
to reduced prenatal fetal movements and polyhydramnios. Rare cases with an adult onset are 
reported which results occasionally in respiratory or cardiac failure. The classical clinical feature 
of MmD are spinal rigidity, scoliosis and respiratory impairment. Also, axial muscle weakness and 
muscle wasting is prominent and the proximal muscle groups are generally more affected then 
distal muscles, particular those of the shoulder girdle. Aside the classic MmD, MmD can be further 
divided into three additional groups based on the clinical symptoms: a severe prenatal form with 
arthrogryposis multiplex congenita; a moderate form with hand involvement and an MmD form 
with eye muscle involvement, specifically with ophthalmoplegia. The classic MmD is mostly due 
 60 
 
to recessive mutations in the SEPN1 gene while the MmD with ophthalmoplegia is caused by 
recessive RYR1 mutations and not a feature of SEPN1 mutations. Also, respiratory impairment is 
usually milder than in the classic form. Another unique feature of MmD caused by RYR1 mutations 
is the potential risk of MHS (see next paragraph) which is not the case for SEPN1 mutations. 
(Jungbluth, 2007a; Jungbluth et al., 2011, 2018).  
The histopathology of MmD can be as heterogenous as the clinical symptoms and reflects the 
heterogenous gene involvement. In general, MmD muscle biopsies show multifocal, well-
circumscribed areas with reduction of oxidative staining and low myofibrillar ATPase. In 
comparison to CCD, the cores only extend a short distance along the fiber axis, can affect type 1 
and type 2 fibers and are typically unstructured. SEPN1 related MmD shows numerous small 
lesions (“minicores”), sometimes less defined so that they appear as uneven stains. RYR1 related 
MmD on the other hand typically shows multiple larger lesions (“multicores”). (Figure 1.27: 
Histopathology of multi-minicore disease) (Jungbluth, 2007a; Jungbluth et al., 2011) 
Currently there is no curative treatment available for core myopathies, CCD and MmD and patient 
management is mainly supportive (Jungbluth et al., 2011). 
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Figure 1.27: Histopathology of multi-minicore disease 
NADH-TR (a–c) and cytochrome oxidase (COX) (d) stains, horizontal (a,c) and 
transverse (b,d) sections of muscles from a 3-year-old (a–b) and a 9-year-old girl (c–
d) from different families. Numerous small lesions (“minicores”) of limited extent can 
be seen in a and b. Larger lesions (“multicores”) throughout the entire fiber diameter 
are found in c (arrows) and d, which can occasionally affect the same area in adjacent 
fibers (arrows in d). (Jungbluth, 2007a) 
1.3.5.3 Malignant Hyperthermia 
Unlike the above-mentioned diseases, malignant hyperthermia susceptibility (MHS) is a 
pharmacogenetic disorder inherited in an autosomal dominant way. It is triggered by volatile 
halogenated anesthetic (e.g., halothane) and muscle relaxants (e.g., succinylcholine). The so 
caused episodes of MHS are typically rapid and life-threatening if left untreated. An MH crisis is 
characterized by a rapid increase in body temperature, muscle contractures, leading to organ 
failure and death. The physiological reason is a Ca2+ leak from the SR through the mutated RyR1 
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causing the muscles to contract resulting in a hypermetabolic state and leading to metabolic 
acidosis. An acute episode can be stopped and treated by dantrolene which inhibits the Ca2+ leak 
from the RyR1. More than 150 RYR1 point mutations have been identified in humans. An MH 
reaction occurs 1:50 000–100 000 anesthetized adults and 1:15 000 anesthetized children. MH 
susceptibility (MHS) was originally tested using the in-vitro contraction test (IVCT) (Lanner et al., 
2010; Rosenberg et al., 2015; Santulli et al., 2017a, 2018) but now this is often replaced by genetic 
testing. 
1.3.5.4 Centronuclear Myopathy 
Centronuclear myopathy (CNM), as the name suggest, is characterized histologically by numerous 
centrally and multiple located nuclei. Genetically it is more diverse then the other congenital 
myopathies. The most severe form of CNM is the X-linked recessive form with patients carrying 
mutations in the myotubularin gene MTM1 (X-linked myotubular myopathy, XLMTM). Other 
more mild forms of CNM are associated with autosomal dominant mutations in dynamin 2 
(DNM2) and amphiphysin II (BIN1), and autosomal recessive mutations in RYR1, BIN1 and TTN 
(Jungbluth et al., 2018). 
While the central and multiple nuclei are predominant histopathological characteristics, other 
changes can appear over time (Figure 1.28: Histopathology of CNM). These include central zones 
with either accumulation or absence of oxidative enzyme activity (visualized by NADH staining), 
radial strands surrounding the central zone in many fibers, and type 1 fiber predominance and 
hypotrophy (Treves et al., 2008a). Histopathological differences can be found depending on the 
mutated gene (Jungbluth et al., 2018). 
The clinical symptoms of CNM can be as diverse as their mutations but one clinical feature that 
almost all CNM patients have in common (except patients with TTN mutations) is that they show 
extraocular muscles involvement.  
XLMTM, the most severe form, manifests at birth and typically affect males, due to the fact that 
it is X- linked. Affected children are severely hypotonic, show weak and contractured muscles. 
Respiratory involvement is prominent, and patients often require supportive ventilation.  
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CNM caused by dominant mutations in DNM2 or BIN1 are usually milder. Recessive RYR1 CNM 
has a substantial clinical overlap with MmD (Jungbluth et al., 2018). 
  
Figure 1.28: Histopathology of CNM 
Hematoxylin and eosin staining of muscle biopsies from a male neonate with X-linked 
recessive myotubular myopathy (Left) and an adult with DNM2-related CNM (Right). 
The CNM typical centrally placed nuclei can be seen in both biopsies. The DNM2-
related CNM shows additional perimysial fatty infiltration. (Jungbluth et al., 2018) 
1.3.5.5 Other Congenital Myopathies 
There are many more congenital myopathies besides those described in this section. Thus, the 
purpose of this sub-section is to mention additional congenital myopathies without going into 
details. 
Nemaline myopathy (NEM) is named because of the characteristic inclusion bodies, nemaline 
bodies (greek nema is thread) in the muscles. NEM patients suffer from muscle weakness and 
hypotonia from the neonatal period on but also late onset cases have been reported. While more 
than ten genes are mutated in patients with NEM, the most common mutations are dominant 
mutations in ACTN1. 
Congenital fiber type disproportion (CFTD) is a more rare disease. Patients also show muscle 
weakness and hypotonia and the histopathological characteristic is that type 1 fibers are 
substantially smaller than type 2. Genes which are associated with CFTD are TPM3, RYR1, ACTA1, 
SEPN1 and MYH7. (Jungbluth et al., 2018) 
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2 RESULTS 
2.1 Introduction 
Extraocular muscles are a highly specialized muscle group and their clinical relevance becomes 
apparent in the context of diseases like strabismus, laryngeal dystonias and facial paralysis where 
they play a key role. But maybe even more interesting is that EOMs are spared in some 
neuromuscular disease and congenital myopathies while heavily affected in others (Jungbluth et 
al., 2011). Even though most papers in the literature focus on EOM corrective surgery or of EOM 
histopathology, little is known about function at the molecular level. Recently our group 
investigated Ca2+ homeostasis at different points of maturation of human extraocular muscles 
(Sekulic-Jablanovic et al., 2015, 2016b). While these studies brought light to the expression of 
transcripts and proteins involved in muscle ECC, they only investigated the regulation of Ca2+ 
homeostasis at the level of myotubes, precursor cells of muscle fibers and biochemical studies 
were limited to small human muscle biopsies.  
This novel study was therefore undertaken to overcome these limitations and study Ca2+ 
homeostasis of EOMs in isolated single muscle fibers from mice. Even though human samples are 
scarce but more interesting than samples from mice, when it comes to EOM this is not the full 
truth. In fact, since human samples come from corrective surgery most of the fibers are cut and/or 
broken due to the surgical procedure and to the priority given to the patient ‘s well- being rather 
than the condition of the biopsy for research. Therefore, such biopsies cannot be used for 
functional force measurements or single fiber studies. The same holds true for muscle biopsy 
from an organ donor. But muscle biopsies are a good source of satellite cells which can be 
differentiated in vitro into myotubes and thus they were used in the first studies of our research 
group to start characterizing the biochemical and physiological characteristics of human EOMs.  
On the other hand, EOMs from mice are more easily available then human samples and it is 
possible to use the available or new disease models to study the impact of specific mutations or 
gene ablation on EOM function.  
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One should keep in mind however, that EOMs from mice are quite small, ca. 4-5 mm in length 
and a fraction of a millimeter thick (from my own observation), compared to human samples or 
even to the commonly studied mouse muscles EDL and soleus. Murine EOMs are located in and 
surrounded by the orbit, a bone cavity in the skull (Figure 1.6 Anatomy of human extraocular 
muscle). This makes it difficult to isolate intact EOMs from mice. If someone wants to measure 
force on EOMs, they are facing another problem, they do not have a classical tendon. On one side 
the six EOMs merge into a tendinous ring, annulus of Zinn, and on the other side they enter more 
less directly the sclera. This makes classical ligation on the tendon as with EDL or soleus not 
possible. 
Beside the general challenges encountered when assessing EOM force, I also faced great 
difficulties when isolating single fibers from the EOMs, a step which is necessary in order to carry 
out calcium measurements. Regular collagenase digestion mixes like the ones used for FDB or EDL 
fiber isolation do not work for EOMs. Compared to FDBs, EDLs or soleus muscles EOMs have a 
higher relative amount of connective tissue which has a different biological composition. For 
example: the pulley ring contains high levels of elastase as well as smooth muscle cells. So the 
digestion mix und isolation method needed to be adjusted accordingly. 
Therefore, in the beginning my effort focused on overcoming the above-mentioned challenges 
and develop and optimize methods to measure force on EOMs and isolate single EOM fibers to 
study Ca2+ kinetic in individual fibers as well as to perform immunohistochemistry. The goal was 
to use these techniques to investigate the physiological properties of EOMs and understand how 
and why they are affected in some diseases. 
In the first paper we used the new established methods to tie in with our paper “Characterization 
of excitation–contraction coupling components in human extraocular muscles” (Sekulic-
Jablanovic et al., 2015). In fact, in the paper by Sekulic-Jablanovic et al we showed that RyR3 
transcripts are highly upregulated in human EOMs compared to leg muscles. We confirmed this 
interesting upregulation in mouse EOMs and this constituted the starting point of our study of 
the physiological role of RyR3 in EOM. To conduct this, we used the RyR3 KO mouse that was 
created by Prof. Hiroshi Takeshima’s group. Their studies had shown that RyR3 KO mice show no 
alteration in muscle development and no muscle impairment. Except for some cognitive 
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impairment and decreased social contact these mice have normal growth and reproductive 
capacities (Takeshima et al., 1996; Matsuo et al., 2009). This mirrors the idea that RyR3 is not 
directly involved in the EC coupling process. Since no one had ever investigated RyR3 in the 
context of EOMs the RyR3 KO mouse was a useful model and constitutes the basis of our paper 
“Extraocular muscle is impaired in ryr3-/- mice” (Eckhardt et al., 2019) . In this paper we were able 
to show an EOM impairment in the RyR3 KO mouse; this is the only muscle which shows a 
functional impairment in the absence RyR3. 
In our second manuscript, which is currently under review, we moved from the more basic 
research of EOMs to disease models. It is well known that EOM involvement in congenital 
myopathies is predominantly associated with recessive RYR1 mutations. We recently created the 
RyR1p.Q1970fsX16+p.A4329D double knock in (referable as DKI mice) based on the genotype of 
a severely affected child (Klein et al., 2012) . We were able to show that the general phenotype 
of the DKI mouse recapitulates the clinical picture of the patient: showing muscle cores, reduced 
force in EDL and soleus muscles, reduced RyR1 protein content, decreased electrically evoked 
Ca2+ transients (Elbaz et al., 2019a). Therefore, in this second paper we used this mouse model to 
study the effect of recessive RYR1 mutations on the function of EOMs. We were able to show that 
muscles from this DKI mouse exhibit a tremendous force reduction and reduced electrically 
evoked Ca2+ transients. Another unique finding in the DKI mouse is the reduction, or better the 
almost absence, of MyH13, the EOM specific myosin heavy chain. Remarkably, these changes are 
specific to the DKI and not present in single heterogeneous RYR1 mutant carriers nor in the mouse 
carrying the RYR1A4329D mutation at the homozygous state. In conclusion we unraveled the 
molecular basis of the functional defect of EOM in congenital myopathies carrying recessive RYR1 
mutations. 
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Abstract 
Mutations in the RYR1 gene are the most common cause of human congenital myopathies 
and patients with recessive mutations are severely affected and characteristically display ptosis 
and/or ophthalmoplegia. In order to gain insight into the mechanism leading to extraocular 
muscle involvement, we investigated the biochemical, structural and physiological properties of 
eye muscles from mouse models we created knocked-in for RYR1 mutations. Ex vivo force 
production in extraocular muscles from compound heterozygous RyR1p.Q1970fsX16+p.A4329D 
mutant mice was significantly reduced compared to that observed in WT, single heterozygous 
mutant carriers or homozygous RyR1p.A4329D. The decrease in muscle force was also 
accompanied by approximately a 40% reduction in RyR1 protein content, a decrease in electrically 
evoked calcium transients, disorganization of the muscle ultrastructure and a decrease in the 
number of calcium release units. Unexpectedly, the superfast and ocular-muscle specific myosin 
heavy chain-EO isoform was almost undetectable in RyR1p.Q1970fsX16+p.A4329D mutant mice.  
The results of this study show for the first time that the extraocular muscle phenotype 
caused by the RyR1p.Q1970fsX16+p.A4329D compound heterozygous RYR1 mutations is complex 
and due to a combination of modifications including a direct effect on the macromolecular 
complex involved in calcium release and indirect effects on the expression of myosin heavy chain 
isoforms.  
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Introduction 
In skeletal muscle, calcium is a key second messenger regulating contraction and the 
sarcoplasmic reticulum (SR) is the intracellular organelle involved in its regulation (1, 2). The 
ryanodine receptor Ca2+ channel (RyR1) present on the terminal cisternae of the SR, is closely 
apposed to and is directly activated by, the dihydropyridine receptor (DHPR) an L-type Ca2+ 
channel which functions as voltage sensor (3). Upon depolarization, the voltage sensor undergoes 
a conformational change which causes the opening of the RyR1, leading to the release of Ca2+ 
from the lumen of the SR; this elevation of the myoplasmic [Ca2+] is necessary for, and leads to, 
muscle contraction and this process is called excitation-contraction coupling (ECC) (1-4).  
Mutations in RYR1, the gene encoding the RyR1, are the most common cause of 
neuromuscular diseases having a calculated incidence of approximately 1:3000 (5-7). Patients can 
present a variety of symptoms and phenotypes ranging from Malignant Hyperthermia 
Susceptibility (MHS; MIM#145600), exertional rhabdomyolysis, central core disease (CCD; 
MIM#11700), King-Denborough Syndrome, some forms of Multi-minicore Disease (MmD, MIM 
#255320), Centronuclear myopathy (CNM, MIM #255320) and Congenital Fiber Type 
Disproportion (CFTD). The disease phenotype resulting from RYR1 mutations largely depends on 
their location within the RYR1 coding sequence and whether the mutations are dominant or 
recessive (5, 6). Dominant mutations are more commonly associated with the MHS/exertional 
rhabdomyolysis and CCD phenotypes, while most cases of MmD, CNM and CFTD are associated 
with recessive mutations. Importantly, the phenotypic characteristics of patients carrying 
dominant and recessive RYR1 mutations are quite distinct. Patients carrying dominant mutations 
display involvement of proximal and axial muscles (5, 8) whereas patients with recessive 
mutations are typically more severely affected, often requiring nocturnal ventilation and 
characteristically displaying involvement of extraocular muscles (EOM), leading to 
ophthalmoplegia and or ptosis (5, 7, 9). From a biochemical point of view patients with recessive 
(but not dominant) mutations show a significant reduction of RyR1 protein content in their 
muscles (10, 11) leading us to hypothesize that the pathomechanism of dominant and recessive 
RYR1 mutations is different.  
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In order to gain deeper insight into the mechanism leading to severe muscle involvement 
in patients with recessive ryanodinopathies, we recently created the 
RyR1p.Q1970fsX16+p.A4329D double knock in (referable as DKI mice) mutant mouse model, 
knocked in for RYR1 mutations identified in a severely affected patient (12). Extensive biochemical 
and physiological characterization of EDL and soleus muscles from the DKI mice revealed that 
their muscles contained reduced amounts of RyR1 protein, had cores and areas of myofibrillar 
disorganization and exhibited decreased electrically evoked Ca2+ transients. The DKI mice also ran 
significantly less and showed a decrease in body weight (13). Thus, the skeletal muscle phenotype 
of the mouse model recapitulates the clinical picture of patients. The result of this first study, 
however, shed little light into the molecular mechanism through which EOMs are selectively 
affected in patients with recessive RYR1 mutations.  
EOMs constitute a separate muscle allotype compared to limb or respiratory muscles: 
they have a different embryonic origin, are innervated from the cranial nerves, are highly 
vascularized, have almost no glycogen stores and contain a large number of mitochondria (14-
17). Additionally, they are super-fast, fatigue resistant and express a specific myosin heavy chain 
isoform called MyHC-EO encoded by the MYH13 gene (18, 19). EOMs are specifically spared in 
patients with Duchenne muscular dystrophy but affected in patients with myasthenia gravis and 
mitochondrial myopathies (20-22). Mutations in several genes important for the maintenance of 
mitochondrial DNA (mtDNA) have been identified in patients with progressive ophthalmoplegia 
(22). Additionally, mutations in MYF5, MYH2 and RYR1 have been identified in patients with 
myopathies and ophthalmoplegia (7, 23, 24) but little is known about the molecular basis of EOM 
involvement. We therefore used the mouse models we created (13, 25) to investigate the 
physiological and biochemical properties of EOMs from mice carrying recessive RYR1 mutations. 
Our results show that the eye muscle phenotype is the result of a combination of changes, 
including defects in ECC, changes in the ultrastructural organization of the EOM and decreased 
mitochondria and the almost complete absence of MyHC-EO.  
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Results 
EOM force is significantly diminished in RyR1p.Q1970fsX16+p.A4329D mutant mice. 
Patients with recessive RYR1 mutations frequently, show involvement of EOMs (5, 7, 9). 
We therefore investigated whether such muscles are also affected in a RYR1 mutant mouse 
models. In order to answer this question directly we investigated the mechanical properties of 
isolated EOMs from single heterozygous RYR1 mutant carriers (heterozygous RyR1p.Q1970fsX16, 
referable as Ex36; heterozygous RyR1p.A4329D, referable as Ex91), homozygous RyR1p.A4329D 
(referable as HO91) and DKI mice (RyR1p.Q1970fsX16+p.A4329D) compared to WT. Using a force 
transducer, we measured the force generated by electrical stimulation of medial rectal muscles 
from which oblique muscles had been removed, as previously reported (26). The mean force 
generated in response to a single pulse of 1.0 msec and of 24.6 V was not significantly different 
between WT compared to single heterozygous RYR1 and HO91 mutant mice; however, EOMs 
from the DKI mice developed almost no force (Fig. 1 and Supplementary Table 1). The mean 
absolute force (±SEM) developed by WT, Ex36, Ex91 and HO91 EOMs was 656±140 (n=10), 
529±63 (n=8), 633±53 (n=4) and 817±239 (n=4) µNewtons, respectively while that developed by 
the DKI mice was 50±21 (n=6) or more than 10 times lower resulting in a significant decrease in 
the specific force (Supplementary Table 1). Additionally, the presence of the Ex36 and DKI RYR1 
mutations significantly decreased the overall length, weight and cross section of EOMs, whereas 
the presence of the HO91 mutation increased the weight and cross section of the EOMs. 
(Supplementary Table 1). Kinetic analysis of the twitches showed that the half time to peak and 
half relaxation times were significantly increased in EOMs from the DKI mice while the time to 
peak was only affected in the HO91 EOMs (Supplementary Table 2).  
These results demonstrate that the presence of compound heterozygous RYR1 mutations, 
but not of single RYR1 mutations nor of the homozygous Ex91 RYR1 mutation, significantly affect 
force generated in response to electrical stimulation. This effect was independent of neuronal 
RyR1 expression since isolated muscles were directly investigated by inducing action potentials 
via supramaximal field stimulation.  
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The presence of the RyR1p.Q1970fsX16+p.A4329D compound heterozygous mutation affects 
ECC. 
The changes in the mechanical properties of EOMs from the DKI mice could be due to 
alterations in the content of proteins involved in ECC. Indeed, the RyR1 protein content in 
extensor digitorum longus (EDL) and soleus muscles from the same transgenic DKI mouse line was 
significantly decreased (13). We thus investigated by western blot analysis the relative expression 
of the major protein components of the ECC machinery. RyR1 protein content was approximately 
40% lower compared to that in EOMs from WT littermates (Fig. 2A and B) as was the content of 
Cav1.1 and ß1. The content of the other SR proteins investigated was similar in WT and DKI mice 
(Fig. 2A and B). Similar results were obtained when ECC protein content was analyzed by Mass 
Spectrometry analysis (Supplementary Fig. 1), though in the latter case, calsequestrin 1 and 2, 
SERCA2 and calreticulin content was significantly increased whereas sarcalumenin content was 
decreased. We also investigated the expression levels of the transcripts encoding RYR1 and RYR3 
(Fig. 2C); qPCR results confirm that the transcript encoding RYR1 was significantly decreased (from 
1.0±0.13 to 0.60±0.06 in WT vs DKI mice, respectively; P<0.05 Student’s t test) while that 
encoding RYR3 was increased from 1.0±0.2 to 1.90±0.24 (in WT vs DKI mice, respectively; P<0.01 
Student’s t test). Interestingly, in EOMs from single heterozygous and HO91 RYR1 mutant mice 
the relative expression of the RYR1 transcript was either increased (Ex36 and Ex91) or unchanged 
(HO91) while the RyR1 protein content did not change, as assessed by quantitative western blot 
analysis. RYR3 transcript levels were similar in EOMs from WT, single heterozygous and HO91 
RYR1 mutant mice (Supplementary Fig.2A and B).  
 Since enzymes involved in epigenetic modifications are altered in limb muscles from 
patients with recessive RYR1 myopathies (27, 28), we also investigated their expression levels in 
DKI EOMs. No changes in the expression levels of the DNA methylating enzymes DNMT1 and 
TRDMT1 were apparent, however transcripts encoding class II histone de-acetylases HDAC4 and 
HDAC9 were increased and there was a small but significant increase in HDAC1 in EOMs from the 
DKI mice (Figure 2C).  As far as the HDAC1, -4 and -9 expression in HO91 EOMs, their levels were 
similar to those of EOMs from WT mice (values were 1.0± 0.11 and 0.867±0.05 for HDAC1; 
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1.0±0.12 and 0.93±0.15 for HDAC4 and 1.0±0.23 and 0.91±0.18 for HDAC9 in WT and HO91, 
respectively. N= 5).  
The presence of the compound heterozygous RYR1 mutations affects the content of the 
two main macromolecular complexes involved in ECC, namely the RyR1 and the DHPR. The 
decrease in these two calcium channels is likely to impact Ca2+ release, leading to a decrease in 
force development. In order to verify this directly, we studied the properties of electrically evoked 
Ca2+ transients in single isolated EOM fibers. Fibers were loaded with the calcium indicator Mag-
Fluo-4 (Fig. 3A) and stimulated with a 0.5 msec bipolar pulse by means of a computer-controlled 
stimulator. The electrically evoked peak Ca2+ transient (∆F/F) was reduced by approximately 50% 
from 0.4±0.1 to 0.21± 0.1 in fibers from WT and the DKI mice, respectively (Fig. 3B and C), whereas 
the kinetics including half time to peak (HTTP), time to peak (TTP) and half relaxation times (HRT) 
were similar in WT and DKI EOM fibers (Fig. 3D). 
 
EM analysis reveals myofibrillar disorganization and a decrease in the number of CRU in EOMs 
from RyR1p.Q1970fsX16+p.A4329D mutant mice. 
Muscles of patients with RYR1 mutations exhibit areas of myofibrillar disorganization and 
the presence of cores, a finding that was also made while examining EDL muscles from the DKI 
mouse (13). EM analysis of EOMs from DKI mice confirmed that the latter muscles exhibit 
alterations of the muscle architecture, myofibrillar disorganization and a decrease in the number 
of calcium release units (CRU) (Fig.4). Quantitative analysis showed that mis-alignment of the Z-
discs occurred in 80% of the fibers from the DKI mice versus 0% in WT littermates (Supplementary 
Table 3). Quantitative analysis of CRU in 12 fibers from 3 WT and 15 fibers from 3 DKI mice, 
confirmed the visual observations, namely that EOMs from the DKI mice contain significantly 
fewer CRU/100 µm2 (70.7±6.0 vs 40.8±3.7 in WT and DKI, respectively; P<0.001). Muscles from 
the DKI mice also showed a significant reduction in the number of mitochondria adjacent to CRU 
(30.0 ±3.3 vs 16.3 ±1.5 in WT and DKI, respectively; P<0.001, Student’s t test) and an increase in 
the percentage of dyads (1.3±0.8 vs 6.1±2.7 in WT and DKI, respectively)( Supplementary Table 
3).  
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DKI EOMs have reduced levels of MyHC-EO and altered content of many other skeletal muscle 
proteins.   
EOMs are complex muscles, made up of different fiber types and expressing a mixture of 
MyHC isoforms including the EOM-specific isoform MyHC-EO (17, 18, 29). Quantitative PCR 
revealed differences between WT and DKI mice, namely a small increase in the MYH2 transcripts 
encoding the MyHC2A as well as the embryonic/fetal isoform MYH8 (MyHC-neo), MyHC6 (-
cardiac isoform) and of the slow MYH7 isoform. Surprisingly this was accompanied by a dramatic 
reduction in the EOM-specific MYH13 (Fig. 5A). High resolution gel electrophoresis, western blot 
and Mass Spectrometry analysis confirmed that changes were occurring at the protein level as 
well (Fig. 5B, C and D, respectively). Importantly, the immunoreactive band corresponding to 
MyHC-EO was almost completely absent in EOMs form the DKI mice (Fig. 5C). Analysis of MYH 
transcript expression in the single heterozygous and HO91 RYR1 mutant mice showed that there 
was an increase in MYH7 expression in EOMs from heterozygous RyR1p.Q1970fsX16 mice 
(Supplementary Fig. 2C); no changes in the MyHC-EO protein content in the EOMs from single 
RYR1 mutant mice (Supplementary Fig. 2D). The transcript encoding MYH13 as well as MyHC-EO 
protein were decreased in HO91 EOMs, however not to the same extent as in the DKI mice 
(transcript values were 0.80±0.03 p<0.0001 and % MyHC-EO protein content was 46.07±12.13% 
p<0.01 N=5 in HO91 vs WT, respectively) (Supplementary Figure 2C and 2D). 
To assess in-depth changes occurring as a consequence of the compound heterozygous 
RYR1 mutations we performed extensive Mass Spectrometry analysis. Significant (q<0.05) 
changes in the content of >1200 protein occurred between WT and DKI EOMs (Fig. 6A and B). The 
proteins showing the greatest decrease in content being MyHC-EO (MYH13), phosducin-like 
protein, myosin binding protein H-like (MYBPHL), RyR1, protein FAM171A2 and protein PBDC1 
(Fig. 6 and Supplementary Table 4). On the other hand, the skeletal muscle carbonic anhydrase 3 
isoform was the most up-regulated protein, showing an increase of approximately 17 times, 
followed by Myosin regulatory light chain 2 ventricular/ cardiac muscle isoform,  Homeodomain-
only protein, Secretory carrier-associated membrane protein 2, MyHC7, Major urinary protein 1 
and TnnC1 (Fig. 6B and Supplementary Table 5). Cellular component pathway analysis indicated 
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that most mitochondrial proteins (including those of the mitochondrial envelope, inner 
membrane, matrix, respiratory chain and cytochrome complexes) are down-regulated, 
confirming the EM observations that EOMs from the DKI contain fewer mitochondria. 
Additionally, myosin content was severely altered. KEGG pathway enrichment analysis revealed 
that the most affected pathways are those involved in oxidative phosphorylation and the TCA 
cycle, as well as muscle contraction (Fig. 6C).  
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Discussion 
 In the present study we investigated EOMs from a compound heterozygous mouse model 
carrying two RYR1 mutations identified in a child severely affected by MmD. Our results provide 
mechanistic insight into the molecular basis of impaired extraocular muscle function and indicate 
that the phenotype of our mouse model faithfully recapitulates the clinical picture of MmD 
patients with compound heterozygous RYR1 mutations.  
The striated muscle phenotype of congenital myopathies linked to recessive RYR1 mutations 
is influenced by the genetic status of the patients, that is whether they carry dominant or 
recessive mutations. In particular, in the presence of dominant mutations EOMs are usually 
spared whereas they are often compromised in the presence of recessive mutations which 
present either as homozygous mutations or as two distinct mutations at the heterozygous state 
(5-9). Since RYR1 encodes the RyR1 SR Ca2+ release channel playing a fundamental role in ECC, 
our first aim was to assess the impact of mutations on the mechanical, biochemical and 
physiological properties of isolated EOMs. Upon ex vivo electrical stimulation the force developed 
by EOMs from the DKI mice was close to zero. Such a result was not completely unexpected since 
the mechanical properties of isolated EDL and soleus muscles from the same transgenic DKI 
mouse line were also severely reduced, albeit to a lower extent compared to EOMs (13). The 
presence of single heterozygous (RyR1p.Q1970fsX16 or RyR1p.A4329D) or homozygous 
(RyR1p.A4329D) mutations cause different phenotypes depending on muscle type and mutation. 
Indeed, the missense RyR1p.A4329D mutation at the heterozygous and homozygous state does 
not significantly impact force production in EOMs (this manuscript), nor in EDL muscles 
(manuscript in preparation) whereas the expression of the RyR1p.Q1970fsX16 frame shift 
mutation (leading to a premature stop codon), affects limb muscles (25), but spares EOMs (this 
manuscript). In fact, both the proband and mouse model carrying the Ex36 frameshift mutation 
at the heterozygous state had a skeletal muscle phenotype characterized by generalized muscle 
weakness and fatigability. This was accompanied by fibre size variability, a predominance of slow 
twitch fibres, fewer calcium release units, a decrease in the electrically evoked peak calcium 
transient as well as a decrease of RyR1 protein in their skeletal muscles (25). Thus the presence 
of Ex36 frameshift mutation at the heterozygous state is not associated with central core disease, 
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though it is associated with a myopathic phenotype sparing EOMs. Although we have no clear 
explanation for why EOMs are spared in the presence of the single heterozygous (dominant Ex36 
or Ex91) and homozygous HO91 RYR1 mutations, but not in the presence of the compound 
heterozygous (Ex36+Ex91 DKI) RYR1 mutations, we cannot exclude the possibility that this is also 
linked to the content of RyR1 in EOMs.  In fact, contrary to our findings in EDL and soleus muscles 
from the Ex36 heterozygous RYR1 mutant mice (25), the presence of the WT allele plus the 
RyR1p.Q1970fsX16 frameshift mutation does not affect RyR1 content in EOMs (present study). 
Similarly, the presence of the HO91 mutation does not impact RyR1 content. Quantitative mass 
spectrometry analysis shows that the default RyR1 protein content in WT EOMs is approximately 
50% lower than that of WT EDL (the unadjusted RyR1 protein ratio content in mouse EDL vs EOM 
is 0.596, q value=2.91x10-7).  Thus, we hypothesize that the reduction of the default RyR1 protein 
content in EOMs from WT mice may be due to differences in transcriptional regulation between 
EOMs and limb muscles (16, 17, 30, 31).  We speculate that the difference of transcriptional 
regulation may blunt the effect of the monallelic expression of the WT RYR1 allele in EOMs from 
the heterozygous RyR1p.Q1970fsX16 mice. In the presence of the compound heterozygous 
p.Q1970fsX16+p.A4329D RyR1 mutations however, EOMs express 50% less RyR1 protein leading 
to fewer CRU resulting in a decrease of calcium release and poor muscle contraction.  
Striated skeletal muscles are highly dependent upon their finely defined architecture as the 
Ca2+ released from the SR by structures referred to as CRU binds to the neighboring contractile 
proteins to initiate muscle contraction. Mitochondria are often associated with or appear in close 
proximity to the CRU (32, 33). In EOMs from the DKI mice there is a 43% reduction in the number 
of CRU, myofibrillar disorganization and sarcomeric disruption. The effect was so severe that Z-
disc mis-alignment was evident in 80% of the examined electron micrographs of EOMs from the 
DKI mice but none from WT littermates; muscles from the mutant mice also contained dyads and 
importantly, showed a reduced number of mitochondria associated with the CRU. The decrease 
in the number of mitochondria observed in EM micrographs was supported by the Mass 
Spectrometry/proteomic analysis data which confirmed that mitochondrial proteins as well as 
metabolic pathways are significantly downregulated in EOMs from DKI mice. Involvement of EOM 
leading to progressive external ophthalmoplegia and ptosis are common in patients with 
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mitochondrial diseases caused by mutations in mtDNA (reviewed in 22). This is linked to the 
functional demands of EOMs which are different from those of other muscles, since they must 
remain active for extended periods of time, even during sleep. To cope with their constant 
activity, EOMs contain a large number of mitochondria, express higher levels of mitochondrial 
enzymes and rely on blood glucose oxidized via the Krebs cycle as a constant energy source (16, 
17). Thus, a decrease in the number of mitochondria would compromise EOM activity leading to 
ophthalmoplegia, as seen in patients with recessive RYR1 mutations. Nevertheless, it should be 
pointed out that the pathomechanism of EOM involvement in patients with recessive RYR1 
mutation and chronic progressive ophthalmoplegia is different. Mouse models created to study 
mitochondrial myopathies as well as affected patients show (i) a progressive course, which is not 
the case in recessive RYR1-myopathies, (ii) muscles show an increase (not a decrease) in the 
number of mitochondria and (iii) the contractile properties (force generated) of muscles from 
mice mutated in mitochondrial genes are only slightly decreased (33, 35).  
The results of the present study demonstrate that additional factors contribute to the weak 
eye muscle phenotype in the DKI mice (and patients). An important finding relates to the altered 
expression of MyHC isoforms in the RyRp.Q1970fsX16+p.A4329D, but not in the single 
heterozygous mutant mice. In the former mouse line, there is an almost total absence of the 
MYH13 transcript and barely detectable levels of MyHC-EO, the isoform responsible for the 
superfast characteristic of EOM (18, 19, 29). Concomitantly, there is an increase of cardiac atrial 
-myosin (MYH6) and of slow muscle myosin MYH7. The absence of MyHC-EO is puzzling but 
parallels the decrease in RyR1 protein content and does not occur in single heterozygous RYR1 
mutant mice (though its level is decreased in the HO91 RYR1 mutant mouse but not to the same 
extent). Under normal conditions MyHC-EO expression in mice has a late onset, occurring at the 
end of the first postnatal week (18, 36) and, importantly, muscle activity is important for initiating 
and maintaining its expression (37). Thus, its very low expression levels may be caused by the 
decrease of ECC, calcium release and muscle activity during eye muscle development. Decreased 
EOM activity also leads to additional changes as confirmed by the altered expression of many 
enzymes identified by Mass Spectrometry, including carbonic anhydrase 3, CaM kinase and 
creatine kinase.  
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In conclusion the results of this study show for the first time the molecular basis of EOM 
dysfunction linked to compound heterozygous RYR1 mutations causing a congenital myopathy. 
The altered calcium homeostasis and reduced calcium released by muscle fibres during ECC, leads 
to reduced activity of the eye muscles during development causing mis-expression of MyHC 
isoforms, lack of MyHC-EO, myofibrillar disorganization, displacement and decreased number of 
mitochondria.  
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Materials and Methods 
Animal Model and ethical permits: The RyR1p.Q1970fsX16+p.A4329D mouse model was 
generated in our laboratory using CRISPR/Cas9 as previously described (13, 25). Experiments were 
carried out on 8-12 weeks old mice. All experimental procedures were approved by the Cantonal 
Veterinary Authorities (BS Kantonales Veterinäramt Permit numbers 1728 and 2115). All 
experiments were performed in accordance with relevant guidelines and regulations. 
Isometric force measurements: Electrically evoked force was measured in isolated EOMs as 
previously described (26). Briefly, EOMs were mounted intact on a MyoStation-intact (Myotronic, 
Heidelberg, Germany). The force transducer was equipped with small hooks. The medial rectus 
muscle was tied with a prolene suture (Ethicon, EP8703H) by stitching through the eyeball close 
to the entry point of the muscle. The other side was ligated with a surgical suture on the leftover 
orbital socket bone (Look, SP102). After ligation, the remaining EOMs, the optic nerve and the 
retractor bulbi muscle were surgically removed. For force measurements, EOMs were stimulated 
with a single pulse of 1 msec and of 24.6 V. Experiments were performed at 30° C. Muscle force 
was digitized at 4 kHz using an AD Instrument (Powerlab 2/25) or MyoDat (Myotronic, 
Heidelberg, Germany) including its interface and computer-controlled stimulator.  
Quantitative Real-time PCR: Total RNA was extracted from the EOMs using Trizol (Invitrogen, 
15596-018) following the manufacturer’s protocol. 1000 ng were reverse transcribed using the high 
capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814). cDNA was amplified 
by quantitative real-time PCR (qPCR) using Power-UpTM SybrTM Green Master Mix (Applied 
Biosystems, A25742) as previously described (26, 28). The sequence of the primers used for qPCR 
is given in Supplementary Table 6. Quantitative PCR (qPCR) was performed on a 7500 Fast Real-
Time PCR machine from Applied Biosystems using the 7500 software v2.3. Gene expression was 
normalized to ACTN2 expression as a muscle-specific gene, using the ∆∆Ct method. Results are 
expressed as fold change of gene expression in DKI mice compared to expression in WT mice. 
Electrophoresis and Immunoblotting: Total muscle homogenates were prepared form flash frozen 
EOM samples in 10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA and anti-protease (Roche, 
11873580001) as previously described (25). Protein concentration was determined using a Protein 
Assay Kit II (Bio-Rad Laboratories, 500-0002) and BSA was used as a standard. SDS-PAGE, 
protein transfer on to nitrocellulose membranes and immunostaining were performed as previously 
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described (25), except for parvalbumin and MyHC. For parvalbumin, proteins were separated on a 
10% Tris-Tricine gel (38) and subsequently transferred onto nitrocellulose. For separation of 
MyHC isoforms, high resolution gel electrophoresis was performed (39). The following primary 
antibodies were used for Western Blotting: anti-RyR1 (Cell Signaling, 8153S), anti-Cav1.1 (Santa 
Cruz sc-8160), anti-Cav1.2 (Santa Cruz, sc-25686), anti- DHPR β1a (Santa Cruz, sc-32079), anti-
calreticulin (Abcam, ab-92516), anti-sarcalumenin (Thermo Fischer Scientific, MA3–932), anti-
calsequestrin-1 (Sigma, C-0743) and calsequestrin-2 (Abcam, ab-3516), anti-SERCA1 (Santa 
Cruz, sc-8093), anti-SERCA2 (Santa Cruz, sc-8095), anti-JP-45 (40), anti-parvalbumin (Swant, 
PV25), anti-MyHC (Millipore, 05-716) and anti-MyHC13 (DSHB Iowa, 4A6). Secondary 
peroxidase conjugates were Protein G-peroxidase (Life Technologies, P21041) and peroxidase-
conjugated goat anti-mouse IgG (Sigma, A2304). The immunopositive bands were visualized by 
chemiluminescence using the WesternBright ECL-HRP Substrate (Advansta, K-12045-D50) or the 
Chemiluminescence kit from Roche (Roche, 11500694001). Representative immunoblots are 
shown in Supplementary Figure 3. Analysis of the intensity of the immunopositive bands was 
performed using ImageJ/FIJI as previously described (13, 25, 26)(Schindelin et al., 
2012)(Schindelin et al., 2012)(Schindelin et al., 2012)(Schindelin et al., 2012). The intensity values 
were normalized to the intensity of MyHC all (Millipore) antibody. 
Proteomics analysis using tandem mass tags.  
Peptide samples were prepared, including TMT labeling, HpH-fractionation and LC-MS and data 
analysis from mouse muscle tissues as recently described (41). In brief, 1µg of TMT labeled 
peptides were LC-MS/MS analyzed on Q-Exactive HF mass spectrometer coupled to an EASY nano-
LC 1000 system (both Thermo Fisher Scientific) using a linear 90 minute LC gradient and a top10 
MS approach at a MS2 resolution of 30k (FWHM at 200 m/z). The data were analyzed by searching 
against a protein database containing sequences of the predicted SwissProt entries of mus 
musculus (www.ebi.ac.uk, release date 2019/03/27), Myh2 and Myh13 from Trembl, the six 
calibration mix proteins and commonly observed contaminants (in total 17,414 sequences) using 
the SpectroMine software (Biognosys, version 1.0.20235.13.16424). Protein quantification and 
statically analysis was carried out using our in-house developed SafeQuant R script as recently 
described (v2.3) (42). P-values were calculated using empirical Bayes moderated t-statistics and 
were corrected for multiple testing using the Benjamini−Hochberg method into q-values. The 
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errors were calculated according to the propagation of uncertainty. 
EM analysis: Data were collected from EOMs isolated from three months-old WT (n=3 mice) and 
RyR1p.Q1970fsX16+p.A4329D (n=3 mice). In each sample, 12-15 fibers were analyzed. In each 
fiber 2-3 micrographs (all at the same magnification, 14K, and of non-overlapping regions) were 
randomly collected from longitudinal sections. CRUs and mitochondria were marked and counted 
in each micrograph. The number of CRUs/area, mitochondria/area and mitochondria-CRUs 
pairs/area is reported as an average number/100 μm2 (13, 25). For mitochondrial quantification 
14 fibers from 3 WT mice and 15 fibers from 3 DKI mice were analyzed. In each EM image we also 
determined the number of dyads i.e. incomplete triads expressed as percentages over the total 
number of CRUs.  
Single fiber calcium measurements: Ca2+ measurements were performed on single EOM fibers, 
isolated as previously described (26). Briefly, isolated EOM fibers were plated on a chamber with 
a glass coverslip bottom, previously coated with 2 μl of laminin 1 mg/ml (Sigma, Darmstadt, 
Germany) and incubated for 20 min at 20 °C in Ringer solution containing 10 μM of the low affinity 
calcium indicator Mag-Fluo-4 AM (Invitrogen, M14206). Fibers were stimulated by means of a 
0.5 msec bipolar pulse using a computer-controlled stimulator (Myotronic, Heidelberg, Germany, 
MyoDat + Stimulator Amplifier). A Nikon A1R laser-scanning confocal microscope (Nikon 
Instruments Inc.) with a 60× oil immersion Plan Apo VC Nikon objective (numerical aperture, 1.4) 
in resonant mode at super high temporal resolution (7918 lines per second) was used to record the 
linescans. These were saved as stacked images using the microscope software (NIS-Elements, 
version 4.60). All measurements were performed at room temperature.  
Analysis of calcium transient: A detailed description of the method was recently published (26). 
Briefly, for analysis of the Ca2+ transient, the baseline was calculated as the average of the first 5 
msec of the profile. Once the maximum height of the transient was reached, the ΔF/F was 
calculated. The beginning of the peak was defined as the time where the transient increased by 5% 
of the maximum height, with respect to the baseline, for the first time. Time To Peak (TTP) is the 
time from the beginning of the peak to the maximum height. Half Time To Peak (HTTP) is the 
time from the beginning of the peak to the time where the transient increases by 50% of the 
maximum height with respect to the baseline, for the first time. Half Relaxation Time (HRT) is the 
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time from the maximum height until the time where the transient is higher than 50% of the 
maximum height, for the last time.  
Statistical analysis and graphical software: Statistical analysis was performed using the unpaired 
two-tailed Student's t test or the ANOVA test followed by the Bonferroni post hoc test for multiple 
group comparisons. Means were considered statistically significant when the P value was <0.05. 
Data was processed, analyzed and plotted using the software OriginPro 2019 (OriginLab 
Corporation, Northampton, MA, USA) or GraphPad Prism 4.00 (GraphPad Software Inc., San 
Diego, CA, USA). Images were assembled using Adobe Photoshop CS (version 8.0). 
 
  
 103 
 
Acknowledgements 
This work was supported by a grant from the Swiss National Science Foundation (SNF N° 31003A-
169316), a grant from the Swiss muscle foundation (FSRMM), a grant from NeRAB, a grant from 
the OPO Stiftung (N°2013/14-0038), Botnar Stiftung (N° OOG-19-001) and PRIN 2015 to FZ. The 
support of the Department of Anesthesia Basel University Hospital and the technical support of 
Anne-Sylvie Monnet and of Cinzia Tiberi Schmidt of the BioEM C-CINA are gratefully 
acknowledged. We also thank Dr. Alexander Schmidt and the group of the proteomics core 
facility, Biozentrum, Basel University, for performing and analysing the mass spectrometry 
experiments. 
 
 
Conflict of interests: The authors declare that no conflict of interests exists. 
 
 
  
 104 
 
References 
1. Rios, E., and Pizarro, G. (1991) Voltage sensor of excitation-contraction coupling in 
skeletal muscle. Physiol. Rev., 71, 849-908. 
2. Endo, M. (1977) Calcium release from the sarcoplasmic reticulum. Physiol. Rev., 57, 71-
108.  
3. Fleischer, S., and Inui, M. (1989) Biochemistry and biophysics of excitation-contraction 
coupling. Annu. Rev. Biophys. Biophys. Chem., 18, 333-364.  
4. Franzini-Armstrong, C., and Jorgensen, A. (1994) Structure and development of E-C 
coupling units in skeletal muscle Annu. Rev. Physiol. 56, 509-534.  
5. Jungbluth, H., Treves, S., Zorzato, F., Sarkozy, A., Ochala, J., Sewry, C., Phadke, R., 
Gautel, M., and Muntoni, F. (2018) Congenital myopathies: disorders of excitation-
contraction coupling and muscle contraction. Nat. Rev. Neurol., 14, 151-167. 
6. Treves, S., Jungbluth, H., Muntoni, F., and Zorzato, F. (2008) Congenital muscle disorders 
with cores: the ryanodine receptor calcium channel paradigm. Curr. Opin. Pharmacol., 8, 
319-326.  
7. Treves, S., Jungbluth, H., Voermans, N., Muntoni, F., and Zorzato, F. (2017) Ca2+ handling 
abnormalities in early onset muscle diseases: novel concepts and perspectives. Stem. Cell 
Develop. Biol., 64, 201-212. 
8. Jungbluth, H. (2007) Central core disease. Orphanet. J. Rare Dis., 2, 25 DOI: 
10.1186/1750-1172-2-2-25. 
9. Jungbluth, H. (2007) Multi-minicore disease. Orphanet. J. Rare Dis., 2, 31 DOI: 
10.1186/1750-1172-2-31. 
10. Monnier, N., Marty, I., Faure, J., Castiglioni, C., Desnuelle, C., Sacconi, S., Estournet, B., 
Ferreiro, A., Romero, N., Laquerriere, A., Lazaro, L., Martin, J. J., Morava, E., Rossi, A., 
Van der Kooi, A., de Visser, M., Verschuuren, C., and Lunardi, J. (2008). Null mutations 
causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with 
recessive structural congenital myopathies. Hum. Mutat., 29, 670-678.  
11. Zhou, H., Jungbluth, H., Sewry, C. A., Feng, L., Bertini, E., Bushby, K., Straub, V., Roper, 
H., Rose, M.R., Brockington, M., Kinali, M., Manzur, A., Robb, S., Appleton, R., Messina, 
S., D'Amico, A., Quinlivan, R., Swash, M., Müller, C. R., Brown, S., Treves, S., and 
 105 
 
Muntoni, F. (2007) Molecular mechanisms and phenotypic variation in RYR1-related 
congenital myopathies. Brain, 130, 2024-2036. 
12. Klein, A., Lillis, S., Munteanu, I., Scoto, M., Zhou, H., Quinlivan, R., Straub, V., Manzur, 
A.Y., Roper, H., Jeannet, P.Y., Rakowicz, W., Jones, D.H., Jensen, U.B., Wraige, E., 
Trump, N., Schara, U., Lochmuller, H., Sarkozy, A., Kingston, H., Norwood, F., Damian, 
M., Kirschner, J., Longman, C., Roberts, M., Auer-Grumbach, M., Hughes, I., Bushby, K., 
Sewry, C., Robb, S., Abbs, S., Jungbluth, H., and Muntoni. F (2012) Clinical and genetic 
findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. 
Hum. Mutat., 33, 981-988.  
13. Elbaz, M., Ruiz, A., Bachmann, C., Eckhardt, J., Pelczar, P., Venturi, E., Lindsay, C., 
Wilson, A. D., Alhussni, A., Humberstone, T., Pietrangelo, L., Boncompagni, S., 
Sitsapesan, R., Treves, S., and Zorzato, F. (2019) Quantitative RyR1 reduction and loss of 
calcium sensitivity of RyR1Q1970fsX16+A4329D cause cores and loss of muscle strength. 
Hum. Mol. Genet., 28, 2987-2999. 
14. Hoh, J. F. Y., Hughes, S., Hugh, G., and Pozgaj, I. (1989) Three hierarchies in skeletal 
muscle fibre classification: allotype, isotype and phenotype. In UCLA Symposia on 
Molecular and Cellular Biology (Stockdale, F. and Kedes, L., eds), pp. 15–26, Alan R. Liss, 
New York. 
15. Hauschka, S. D. (1994) The embryonic origin of muscle. In Myology (Engel, A.G. and 
Franzini-Armstrong, C., eds), pp. 3–73, McGraw Hill, New York.  
16. Porter, J. D., Khanna, S., Kaminski, H. J., Rao, J. S., Merriam, A. P., Richmonds, C. R., 
Leahy, P., Li, J., and Andrade, F. H. (2001) Extraocular muscle is defined by a 
fundamentally distinct gene expression profile. Proc. Natl. Acad. Sci. U.S.A., 98, 12062-
12067. 
17. Fischer, M. D., Gorospe, J. R., Felder, E., Bogdanovich, S., Pedrosa-Domellöf, F., Ahima, 
N. A., Rubinstein, N. A., Hoffman, E. P., and Khurana, T. S. (2002) Expression profiling 
reveals metabolic and structural components of extraocular muscles. Physiol. Genomics, 9, 
71-84. 
18. Wieczorek, D. F., Periasamy, M., Butler-Browne, G. S., Whalen, R. G, and Nadal- Ginard, 
B. (1985) Co-expression of multiple myosin heavy chain genes, in addition to a tissue-
specific one, in extraocular musculature. J. Cell Biol., 101, 618–629. 
 106 
 
19. Schiaffino, S., Rossi, A. C., Smerdu, V., Leinwand, L. A., and Reggiani, C. (2015) 
Developmental myosins: expression patterns and functional significance. Skeletal Muscle, 
5, 22 DOI 10.1186/s13395-015-0046-6. 
20. Porter, J. D., Merriam, A. P., Khanna, S., Andrade, F. H., Richmonds, C. R., Leahy, P., 
Cheng, G., Karathanasis, P., Zhou, X., Kusner, L. L., Adams, M. E., Willem, M., Mayer, 
U., and Kaminski, H. J. (2003) Constitutive properties, not molecular adaptations, mediate 
extraocular muscle sparing in dystrophic mdx mice. FASEB. J., 17, 893-895.  
21. Kaminski, H. J., and Ruff, R. L. (1997) Ocular muscle involvement by myasthenia gravis. 
Ann. Neurol., 41, 419–420. 
22. Schrier, S. A., and Falk, M. J. (2011) Mitochondrial disorders and the eye. Curr. Opin. 
Ophthalmol., 22, 325-331. 
23. Lossos, A., Oldfors, A., Fellig, Y., Meiner,V., Argov, Z., and Tajsharghi, H. (2013) MYH2 
mutation in recessive myopathy with external ophthalmoplegia linked to chromosome 
17p13.1-p12. Brain, 136:,  e238 doi. 1093/brain/aw365. 
24. Di Gioia, S.A., Shaaban, S., Tüysüz, B., Elcioglu, N.H., Chan, W.M., Robson, C.D., 
Ecklund, K., Gilette, N.M., Hamzaoglu, A., Tayfun, G.A., Traboulsi, E.I., and Engle, E.C. 
(2018) Recessive MYF5 Mutations Cause External Ophthalmoplegia, Rib, and Vertebral 
Anomalies. Am. J. Hum. Genet., 103, 115-124. 
25. Elbaz, M., Ruiz, A., Eckhardt, J., Pelczar, P., Muntoni, F., Boncompagni, S., Treves, S., 
and Zorzato, F. (2019) Quantitative reduction of RyR1 protein caused by a single-allele 
frameshift mutation in RYR1 ex36 impairs the strength of adult skeletal muscle fibres. 
Hum. Mol. Genet., 28, 1872-1884. 
26. Eckhardt, J., Bachmann, C., Sekulic-Jablanovic, M., Enzmann, V., Park, K.H., Ma, J., 
Takeshima, H., Zorzato, F., and Treves, S. (2019) Extraocular muscle function is impaired 
in ryr3-/- mice. J. Gen. Physiol., 151, 929-943. 
27. Rokach, O., Sekulic-Jablanovic, M., Voermans, N., Wilmshurst, J., Pillay, K., Heytens, L., 
Zhou, H., Muntoni, F., Gautel, M., Nevo, Y., Mitrani-Rosenbaum, S., Attali, R., Finotti, 
A., Gambari, R., Mosca, B., Jungbluth, H., Zorzato, F. and Treves, S. (2015) Epigenetic 
changes as a common trigger of muscle weakness in congenital myopathies. Hum. Mol. 
Genet., 24, 4636-4647. 
28. Bachmann, C., Noreen, F., Voermans, N.C., Schär, P.L., Vissing, J., Fock, J.M., Bulk, S., 
Kusters, B., Moore, S.A., Beggs, A.H., Mathews, K.D., Meye,r M., Genetti, C.A., Meola, 
 107 
 
G., Cardani, R., Mathews, E., Jungbluth, H., Muntoni, F., Zorzato, F., and Treves, S. (2019) 
Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with 
selenoprotein N-related myopathies. Hum. Mutat. 40: 962-974. 
29. Briggs, M. M., and Schachat, F. (2002) The superfast extraocular myosin (MYH13) is 
localized in the innervation zone in both the global and orbital layers of rabbit extraocular 
muscles. J. Exp. Biol., 205, 3133-3142. 
30. Kish, P. E., Bohnsack, B. L., Gallina, D., Kasprick, D. S., and Kahana, D (2011) The eye 
as an organizer of craniofacial development. Genesis, 49, 222-230. 
31. Verma, M., Fitzpatrick, K., and McLoon, L. K. (2017) Extraocular muscle repair and 
regeneration. Curr. Ophthalmol. Rep., 5, 207-215 DOI 10.1007/s40135-017-0141-4. 
32. Boncompagni, S., Rossi, A.E., Micaroni, M., Beznoussenko, G.V., Polishchuk, R.S., 
Dirksen, R.T., and Protasi, F. (2009) Mitochondria are linked to calcium stores in striated 
muscle by developmentally regulated tethering structures. Mol. Biol. Cell., 20, 1058-1067. 
33. Franzini-Armstrong, C., and Boncompagni, S. (2011) The evolution of the mitochondria -
to-calcium release units relationship in vertebrate skeletal muscles. J. Biomed. Biotechnol., 
2011, 830573 DOI 10.1155/2011/830573. 
34. Wredenberg, A., Wibom, R., Wilhelmsson, H., Graff, C., Wiener, H. H., Burden, S. J., 
Oldfors, A., Westerblad, H., and Larsson, N. G. (2002) Increased mitochondrial mass in 
mitochondrial myopathy mice. Proc. Natl. Acad. Sci. U.S.A., 99, 15066-15071. 
35. Yin, H., Stahl, J. S., Andrade, F. H., McMullen, C. A., Webb-Wood, S., Newman, N. J., 
Biousse, V., Wallace, D. C., and Pardue, M. T. (2005) Eliminating the Ant1 isoform 
produces a mouse with CPEO pathology but normal ocular motility. Invest. Ophthalmol. 
Vis. Sci., 46, 4555-4562. 
36. Brueckner,J. K., Itkis, O., and Porter, J. D. (1996) Spatial and temporal patterns of myosin 
heavy chain expression in developing rat extraocular muscle. J. Muscle Res. Cell Motil., 
17, 297-312. 
37. Brueckner, J. K., Ashby, L. P., Prichard, J. R., and Porter, J. D. (1999) Vestibulo-ocular 
pathways modulate extraocular muscle myosin expression patterns. Cell Tissue Res., 295, 
477-484. 
38. Schägger, H., and von Jagow, G. (1987) Tricine-sodium dodecyl sulfatepolyacrylamide gel 
electrophoresis for the separation of proteins in the range from1 to 100 kDa. Anal. 
Biochem.,166, 368–379. 
 108 
 
39. Talmadge, R. J., and Roy, R. R. (1985) Electrophoretic separation of rat skeletal muscle 
myosin heavy chain isoforms. J. Appl. Physiol., 75, 2337-2340. 
40. Zorzato, F., Anderson, A. A., Ohlendieck, K., Froemming, G., Guerrini, R., and Treves, S. 
(2000) Identification of a novel 45 kDa protein (JP-45) from rabbit sarcoplasmic-reticulum 
junctional-face membrane. Biochem. J., 351, 537–543. 
41. Obradovic, M. M. S., Hamelin, B., Manevsk, N., Couto, J. P., Sethi, A., Coissieux, M. M., 
Münst, S., Okamoto, R., Kohler, H., Schmidt, A., and Bentires-Alj, M. (2019) 
Glucocorticoids promote breast cancer metastasis. Nature, 567, 540-544. 
42. Ahrné, E., Glatter, T., Viganò, C., von Schubert, C., Nigg, E. A., and Schmidt, A. (2016) 
Evaluation and improvement of quantification accuracy in isobaric Mass Tag-based protein 
quantification experiments. J. Proteome Res., 15, 2537-2547. 
 
  
 109 
 
Figure Legends 
Figure 1: Ex vivo isometric force measurements in mouse EOM.  A. Representative traces of the 
absolute twitch force obtained from isolated single extra ocular rectus muscles from WT, 
heterozygous Ex36, heterozygous Ex91 and DKI mice. B. Bar plot analysis of absolute twitch force. 
The bars represent the mean (±SEM). N= 10 WT, N=8 Ex36, N=4 Ex91, N= 5 HO91, N=6 DKI. 
Muscles were stimulated by electric field stimulation (EFS; 24.6V; 1 msec pulse). *P< 0.05 
Figure 2: ECC proteins are diminished in EOMs from DKI mice.  A. Representative immunoblots 
of total homogenates of EOMs from WT and DKI mice probed with the indicated antibodies. B. 
Immunoblot quantification panels show relative content of the indicated proteins as a % of the 
content of the same protein in EOMs from WT mice normalized to total MyHC content. Bar graphs 
represent the mean (± SEM) values from 2-4 separate pools of EOMs, each pool obtained from 3-
4 mice. The intensity values obtained from WT mice were considered 100%. C. Quantitative real-
time PCR (RT-qPCR) of the indicated transcripts in EOMs from DKI (filled triangles) mice relative 
to WT mice (empty circles). The latter were set as 1. Transcript levels were normalized to ACTN2 
as a muscle specific gene using the ∆∆Ct method. Each symbol represents the duplicate value 
obtained in a single mouse *p<0.05; **p<0.01; (Student’s t test). 
Figure 3: Electrically evoked Ca2+ transients are diminished in EOM fibers from DKI mice. A. 
Confocal images of a single isolated fiber under transmitted light (bottom), and fluorescence 
(Mag-Fluo-4 fluorescence, 488nm excitation and 500-550 nm emission). Scale bars=30 µm. B. 
Representative traces of Ca2+ transients in EOM fibers from WT (black) and DKI (red) mice, evoked 
by EFS with a 0.5 ms bipolar pulse. C. Peak Ca2+ (∆F/F) of the Mag-Fluo-4 fluorescence obtained 
by stimulating EOM fibers. A total of 33 fibers from 3 WT mice and 35 fibers from 2 DKI mice were 
analyzed. Box plots represents the upper and lower ∆F/F values. The central dot shows the mean 
value. D. Analysis of the kinetics of the Ca2+ transients: Half Time To Peak (HTTP), Time To Peak 
(TTP) and Half Relaxation Time (HRT) of the calcium transients are plotted White dots WT; grey 
dots DKI. A total of 33 fibers from 3 WT mice and 35 fibers from 2 DKI mice were analyzed. There 
were no significant differences in the properties of the kinetics. ****p<0.0001; Student’s t test). 
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Figure 4: Ultrastructural disruption in EOMs from DKI mice. In WT EOM (left panels) sarcomeres, 
defined by the space between two Z lines, are highly organized and ordered. The I bands (black 
arrowheads) contain the CRU which are mainly made up by triads, that are composed by two SR 
vesicles and a central t-tubule (bottom left image, white arrows). Mitochondria are abundant and 
not placed in an orderly fashion next to CRU as in EDL muscles. In fibers from the DKI mice (right 
panels) there are fewer mitochondria; additionally, muscles contain many areas characterized by 
total disruption of the myofibrillar organization (black arrowheads). Many CRUs are either missing 
or damaged (bottom right image, white arrows). Scale bars, top 1 µm; bottom 0.4 µm. 
Figure 5: EOMs from DKI mice show altered expression and content of myosin heavy chain 
isoforms. A. Quantitative real-time PCR (RT-qPCR) of the indicated transcripts in EOMs from DKI 
(filled triangles) mice relative to WT mice (empty circles). The latter were set as 1. Transcript levels 
were normalized to ACTN2 as a muscle specific gene using the ∆∆Ct method. The expression 
levels of MYH2 (encoding MyHC2A), MYH6, (encoding the  cardiac isoform), MYH7 (encoding 
MyHC slow) and MYH8 (encoding MyHC-neo) were significantly increased; transcript levels of 
MYH13 (encoding MyHC-EO) were significantly decreased. Each symbol represents the duplicate 
value obtained in EOMs from a single mouse *p<0.05; **p<0.01; ***p<0.001. B. Representative 
Coomassie Blue stained high resolution 7.5% acrylamide gel of myosin heavy chain isoforms 
present in WT and DKI EOMs. C. Western blot of a high resolution 7.5% acrylamide gel. Top panel, 
membrane stained with Ponceau Red; central panel, blots stained with a monoclonal Ab specific 
for MyHC-EOM (top lanes) and a monoclonal Ab specific for MyHC1 (bottom lanes); bottom 
panel, blot stained with a monoclonal Ab recognizing all MyHC. D. Relative expression of MyHC 
in EOMs as determined by Mass Spectrometry analysis. Results show the mean (±SEM) of 5 
experiments and asterisks indicate a significant change based on q values *q<0.05. 
Figure 6: Proteomic analysis of EOMs from DKI reveals significant differences in proteins 
involved in metabolic pathways as well as in the content of contractile proteins. A. 
Hierarchically clustered heatmaps of the relative abundance of proteins in DKI mice (green group) 
versus age and sex-matched wild type littermates (red group). Blue blocks represent proteins 
which are over-expressed, yellow blocks proteins which are decreased in DKI versus WT. Upper 
left inset, colors indicating relative protein content. Right shows overall number of increased 
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(blue) and decreased (yellow) proteins. Areas are relative to their numbers. B. Volcano plot of a 
total of 1253 quantified proteins which showed significant increased (blue) and decreased 
(yellow) content. The horizontal coordinate is the difference multiple (logarithmic transformation 
at the base of 2), and the vertical coordinate is the significant difference p value (logarithmic 
transformation at the base of 10). The proteins showing major change in content are abbreviated. 
C. Enriched GO terms analysis using Functional Enrichment Analysis from String v11.0 showing 
major pathways affected in the DKI EOMs. A q-value of equal or less than 0.05 was used to filter 
significant changes prior to the pathway analyses. Blue bars, Uniport key words; red bars, KEGG 
pathway; yellow bars, molecular function pathway; green bars, cellular component pathway. 
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Abbreviations: CCD, Central core disease; CNM, centronuclear myopathy; CFTD, congenital fiber 
type disproportion; CRU, calcium release units; DHPR, dihydropyridine receptor; DKI, double 
knock in mouse model; ECC, excitation contraction coupling; EDL, extensor digitorum longus; 
EOM, extra ocular muscles; HO91, mouse model carrying the RyR1p.A4329D mutation at the 
homozygous state; HRT, half relaxation time; HTTP, half time to peak; MmD, Multi-minicore 
disease; mtDNA, mitochondrial DNA; MyHC, myosin heavy chain; RyR1, ryanodine receptor 1; SR, 
sarcoplasmic reticulum; TTP, time to peak; WT, wild type. 
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Supplementary Table 1: Average weight and length of EOMs from WT, single and DKI 
mutant mice.  
 
    
 
Length (mm) Wet weight 
(mg) 
 
 
Cross section 
(mm2) 
 
Specific force 
(mN/mm2) 
WT EOM 
4.58 ± 0.21 
n=11 
0.95 ± 0.12  
n=11 
0.222±0.03 
n=11 
3.09±0.68 
n=10 
Ex36 EOM 
4.23± 0.19** 
n=9 
  0.71 ± 0.09** 
n=8 
0.179±0.022** 
n=8 
2.95±0.30 
n=6 
Ex91 EOM 
4.73± 0.08 
n=4 
0.90 ± 0.17  
n=4 
0.201±0.036 
n=4 
3.50±0.69 
n=4 
HO91 EOM 
4.56 ± 0.22 
n=5 
1.22 ± 0.16**  
n=5 
0.281±0.031** 
n=5 
3.23±1.02 
n=5 
DKI EOM 
4.03 ± 0.28*** 
n=7 
0.72 ± 0.11** 
n=6 
0.180±0.023* 
n=6 
0.33±0.17* 
n=5 
 
Data show mean ± SEM. N represents the number of individual muscles that were measured. 
Length was measured using a stereomicroscope (Zeiss, Stemi 508) with a micrometer scale 
incorporated into the eyepiece (Nikon CFI 10x/22). Wet weight was obtained using a Mettler 
Toledo balance (AG204 DeltaRange) after removal of the eyeballs and bones. *P<0.05; **P<0.01; 
***P<0.001 ANOVA followed by the Bonferroni post hoc test (WT as control). 
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Supplementary Table 2: Kinetic analysis of the twitch force generated in EOMs from WT, 
single mutant and DKI mutant mice. 
 
   
 
HTTP 
(ms) 
TTP  
(ms) 
HRT 
(ms) 
WT EOM 
4.36± 0.27 
n=9 
 10.29 ± 0.63 
n=10 
11.54± 0.86 
n=10 
Ex36 EOM 
4.12 ± 0.26 
n=4 
   9.53 ± 0.31 
n=8 
      11.19 ± 1.07 
n=8 
Ex91 EOM 
4.25 ± 0.14 
n=3 
9.12 ± 0.68 
n=4 
10.06 ± 1.10 
n=4 
HO91 EOM 
5.72±0.39*** 
n=5 
11.64±0.74* 
n=5 
10.04±1.44 
n=5 
DKI EOM 
3.43 ± 0.91** 
n=5 
11.06 ± 1.54 
n=6 
39.93 ± 13.12*** 
n=6 
 
Three parameters were analysed: Half Time to peak (HTTP); Time to peak (TTP) and half 
relaxation time (HRT). Data are shown as mean ± SEM. N represent individual muscles that were 
measured. *P<0.05; **P<0.01; ***P<0.001 ANOVA followed by the Bonferroni post hoc test (WT 
as control). 
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Supplementary Table 3: Analysis of Z-disc alignment and of CRU in EOMs from WT and 
DKI mice 
 
 % Z-disc 
aligned 
% Z-disc 
not 
aligned 
N° of CRU/ 
100 µm2 
% of 
Dyads 
No. of 
Mitochondria 
adjacent to 
CRU 
/100 µm2 
WT 100% 0% 70.7 ± 6.0 1.3± 0.8 30.0± 3.3 
DKI 20% 80% 40.8± 3.7*** 6.1± 2.7 16.3 ± 1.5*** 
 
Z-disk were grouped into two groups: aligned and not aligned. Data are shown as percentage of all 
analysed Z-discs. The mean (±SEM) number of Z-discs per micrograph was 2.23±0.47 for WT and 
2.33±0.53 for DKI. 13 micrographs of fibres from 3 WT mice, 15 micrographs of fibres from 3 
DKI mice were analysed. For analysis of CRU: 15 fibres from 3 WT and 3 DKI mice were 
analysed. For analysis of N° of mitochondria: 14 fibres from 3 WT and 15 fibres from 3 DKI mice 
were analysed. A total of 284 and 196 CRU were analysed in WT and DKI EOMs, respectively. 
Results are expressed as mean ± SEM (***P< 0.001, Student’s t test). 
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Supplementary Table 4: List of expressed proteins with more than 0.67-fold decreased 
content in EOM from DKI mice. 
 
UniProtKB 
protein ID 
Gene symbol Protein 
description 
(MOUSE) 
Fold change Log2 ratio q Value 
B1AR69 Myh13 
Myosin, heavy 
polypeptide 13 
0.230 -2.121 6.54E-06 
Q9DBX2 Pdcl 
Phosducin-like 
protein 
0.412 -1.280 5.54E-05 
Q5FW53 Mybphl 
Myosin-binding 
protein H-like 
0.416 -1.266 7.07E-06 
E9PZQ0 Ryr1 
Ryanodine 
receptor 1 
0.418 -1.257 9.18E-07 
A2A699 Fam171a2 
Protein 
FAM171A2 
0.452 -1.144 5.44E-06 
Q9D0B6 Pbdc1 Protein PBDC1 0.522 -0.937 5.31E-06 
Q3UV48 Lrrc30 
Leucine-rich 
repeat-containing 
protein 30 
0.539 -0.892 5.04E-06 
Q9Z0J4 Nos1 
Nitric oxide 
synthase, brain 
0.560 -0.837 7.07E-06 
Q9D164 Fxyd6 
FXYD domain-
containing ion 
transport regulator 
6 
0.568 -0.815 8.11E-05 
Q80UP3 Dgkz 
Diacylglycerol 
kinase zeta 
0.571 -0.808 1.22E-02 
Q08460 Kcnma1 
Calcium-activated 
potassium channel 
subunit alpha 
0.574 -0.801 4.05E-05 
P70663 Sparcl1 
SPARC-like 
protein 1 
0.592 -0.757 2.71E-05 
P02088 Hbb-b1 
Hemoglobin 
subunit beta-1 
0.594 -0.752 1.93E-03 
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P05366 Saa1 
Serum amyloid A-
1 protein 
0.596 -0.746 7.89E-03 
Q9QY80 Hacd1 
Very-long-chain 
(3R)-3-
hydroxyacyl-CoA 
dehydratase 1 
0.602 -0.733 4.01E-03 
O09110 Map2k3 
Dual specificity 
mitogen-activated 
protein kinase 
kinase 3 
0.607 -0.721 8.54E-05 
P16125 Ldhb 
L-lactate 
dehydrogenase B 
chain 
0.625 -0.677 8.90E-05 
Q8BK30 Ndufv3 
NADH 
dehydrogenase 
[ubiquinone] 
flavoprotein 3 
0.638 -0.649 1.50E-02 
A2VDH3 Lrrc38 
Leucine-rich 
repeat-containing 
protein 38 
0.643 -0.637 9.25E-05 
Q9CRB6 Tppp3 
Tubulin 
polymerization-
promoting protein 
family member 3 
0.660 -0.598 7.52E-04 
Q9D855 Uqcrb 
Cytochrome b-c1 
complex subunit 7 
0.660 -0.598 8.21E-03 
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Supplementary Table 5: List of preferentially expressed proteins with more than 2.0-fold 
increase in content in EOM from DKI mice.  
 
UniProtKB 
protein ID 
Gene symbol Protein description 
(MOUSE) 
Fold change Log2 ratio q Value 
P16015 Ca3 Carbonic anhydrase 3 17.577 4.136 5.44E-06 
P51667 Myl2 
Myosin regulatory light 
chain 2 ventricular/ 
cardiac muscle isoform 4.018 2.006 1.02E-04 
Q8R1H0 Hopx 
Homeodomain-only 
protein 3.584 1.842 2.71E-05 
Q9ERN0 Scamp2 
Secretory carrier-
associated membrane 
protein 2 3.139 1.650 1.27E-02 
Q91Z83 Myh7 Myosin-7 2.822 1.497 8.19E-05 
P11588 Mup1 Major urinary protein 1 2.681 1.423 1.60E-02 
P19123 Tnnc1 
Troponin C, slow 
skeletal and cardiac 
muscles 2.679 1.422 9.21E-05 
Q5NCE8 Mrs2 
Magnesium transporter 
MRS2 homolog, 
mitochondrial 2.569 1.361 5.08E-03 
Q6PHZ2 Camk2d 
Calcium/calmodulin-
dependent protein kinase 
type II subunit delta 2.332 1.221 5.44E-06 
P30275 Ckmt1 
Creatine kinase U-type, 
mitochondrial 2.327 1.219 5.44E-06 
P63044 Vamp2 
Vesicle-associated 
membrane protein 2 2.237 1.162 4.20E-02 
Q80UG2 Plxna4 Plexin-A4 2.235 1.160 1.18E-05 
Q8R4E4 Myoz3 Myozenin-3 2.215 1.147 1.35E-05 
Q7TQF7 Amph Amphiphysin 2.195 1.134 1.51E-03 
Q02566 Myh6 Myosin-6 2.127 1.089 7.07E-06 
P33267 Cyp2f2 Cytochrome P450 2F2 2.113 1.079 3.05E-03 
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P97355 Sms Spermine synthase 2.067 1.048 2.94E-05 
Q8VCT4 Ces1d Carboxylesterase 1D 2.038 1.027 2.68E-04 
Q8BFZ9 Erlin2 Erlin-2 2.014 1.010 2.84E-03 
P59108 Cpne2 Copine-2 2.004 1.003 1.35E-05 
Q9WUZ5 Tnni1 
Troponin I, slow skeletal 
muscle 2.002 1.001 2.05E-04 
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Supplementary Table 6: Sequence of primers used and target gene 
  
   
Primer Details Primer sequence 
 Forward Reverse 
Ex36 Ryr1 Genotyping GGG TGG TGC TGG CTT CAG AGT GAT CGA GGG AAG TTG AGG TTG GGG 
Ex91 Ryr1 Genotyping GAGATGTTCGTGAGTTTCTGCGAGG TGAGGGTTGTTCTTGGTGTATTTGG 
Actn2 qPCR CAT CGA GGA GGA TTT CAG GAA C CAA TCT TGT GGA ACC GCA TTT T 
Myh1 qPCR GAC CGA AGG CGG AAC TAC TG TGA CAG TGA CGC AGA ACA GG 
Myh2 qPCR ACA ACA TCA CTG GCT GGC TG CAC CAC TAC TTG CCT CTG CTT 
Myh3 qPCR TAC AAC AGA TGC GGA CGG TG CCT GGG GTC TTG GTT TCG TT 
Myh4 qPCR AAG ACC AAG GAG GAG GAG CA TCG GGA AAA CTC GCC TGA C 
Myh6 qPCR GCC AAT GAG TACCGC GTG AA CCT AGC CAA CTC CCC GTT CT 
Myh7 qPCR CGG ACA AAG GCA AAG GCA AG TCC ATC ACC CCT GGA GAC TTT 
Myh8 qPCR GCG GTC TGT AGG GGA TAC CTA A GGT TTT TCA CCT TGT TCT CCG TG 
Myh13 qPCR CTG AAT GAG ACC GTG GTG GG GAG TCA CCT GCT TCT GCT CC 
Ryr1 qPCR GCC TTT GAC GTG GGA TTA CAG CCC CAA CTC GAA CCT TCT CTC 
Ryr3 qPCR TAG AAA CCG AGG GGG AGG AG AGA GCA ACT GAA AGA GGC CC 
Dnmt1 qPCR AGG ACA AAG CAC CCA CGA AA GAC AGA CCT CAC AGA CAC CAC 
Trdmt1 qPCR TGT GGT GGC TGC TAT TGA TGT CCC CTG TAG GCC AAT TCT TGT 
Hdac1 qPCR AAC GCA TCT CCA TCT GCT CC GAC CAC CTT CTC CCT CCT CA 
Hdac4 qPCR CAC TGC ATT TCC AGC GAT CC AAG ACG GGG TGG TTG TAG GA 
Hdac5 qPCR GAC TTT CCC CTC CGT AAA ACG TGC CAT CCT TTC GAC GCA G  
Hdac7 qPCR GGC AGG CTT ACA CCA GCA A TGG GCA GGC TGT AGG GAA TA 
Hdac9 qPCR GCG GTC CAG GTT AAA ACA GAA GCC ACC TCA AAC ACT CGC TT 
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Supplementary Figure 1: Average change in content of main proteins involved in skeletal 
muscle ECC, as determined by mass spectrometry analysis.  The relative protein content in 
EOMs from WT mice (n=5) was set to 100%. Results show the mean (±SEM) fold change 
expressed as % of the indicated protein in EOMs from 5 DKI mice. Errors are calculated according 
the propagation of uncertainty. *q value <0.05. 
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Supplementary Figure 2: RYR and MyHC expression in WT, heterozygous 
RyR1p.Q1970fsX16, heterozygous RyR1p.A4329D, homozygous RyR1p.A4329D and 
compound heterozygous RyR1p.Q1970fsX16+p.A4329D EOMs. A. Quantitative real-time PCR 
(RT-qPCR) of RYR1and RYR3 transcripts in EOMs from the different mouse lines relative to WT 
mice. The latter were set as 1. Transcript levels were normalized to ACTN2 as a muscle specific 
gene using the ∆∆Ct method. Each symbol represents the duplicate value obtained in a single 
mouse. B. Quantification of RyR1 protein content mean (±SEM) in EOMs. Values were 
normalized for MyHC content, which was obtained using an antibody recognizing all MyHC 
isoforms. WT, n=6; Ex36, n=3; Ex91, n=3; HO91, n=4; DKI, n=5. where n represents the number 
of pooled muscles from the indicated number of mice. C. Quantitative real-time PCR (RT-qPCR) 
of the transcripts encoding the indicated myosin heavy chain (MYH) isoforms in EOMs from the 
different mouse lines relative to WT mice. The latter were set as 1. Transcript levels were 
normalized to ACTN2 as a muscle specific gene using the ∆∆Ct method. Each symbol represents 
the duplicate value obtained in a single mouse. D. Western blot of high-resolution gel 7.5% 
acrylamide gel. Top blot probed with anti-MyHC-EO showing its presence in WT, Ex36, Ex91and 
HO91EOMs, and its very low content in EOMs from DKI mice. Bottom, the same blot was probed 
with anti-MyHC recognizing all isoforms. *p<0.05; **p<0.01; ***p<0.001. 
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Supplementary Figure 3: Immunoreactivity of the antibodies used in the present study. Total 
muscle homogenates were prepared from WT EOMs; proteins were separated on 6% (left blot), 
7.5 % (second from left blots), 10% SDS PAGE (third from left blots) and tris-tricine gel (right 
blot), blotted onto nitrocellulose and probed with the indicated primary antibodies. Blots were then 
incubated with peroxidase conjugated anti-mouse IgG or peroxidase conjugated protein-G and the 
bands were visualized by chemiluminescence.  
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2.4 Additional Results 
2.4.1 Contribution to other Papers  
At the beginning of my thesis I was investigating the JP45-Calsequestrin complex in EDL and soleus 
muscle. For this I measured the force from three different mouse lines (JP45-CASQ1 double KO, 
JP45-CASQ2 double KO and JP45-CASQ1-CASQ2 triple KO) in different conditions: first in normal 
Krebs-Ringer solution with 1,8 mM Ca2+ then in a solution where the calcium is substituted with 
100µM La3+ and finally again in normal Krebs-Ringer solution. Our results demonstrate that the 
triple KO rely on calcium entry via La3+- and nifedipine-sensitive calcium channels. (Mosca et al., 
2016) 
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Figure 2.1: Tetanic contraction of soleus from WT/DKO1/DKO2 and TKO mice. 
(A–F) Traces of a train of tetanic contractures in wild-type and TKO carried out 
according the protocol described under “Experimental Procedures” in (Mosca et al., 
2016). Shown is a representative response of 9 muscles from 10 mice. (G) Western 
blot of 37.5 μg of total homogenate of soleus from WT and TKO stained with anti-
parvalbumin Ab. Histograms report values (mean ± S.D.) from four to six 
determinations from three different total homogenate preparations. Values are the 
mean ± S.D. *, p value of unpaired Student's t test. (H) Normalized peak indexes of 
four strains. Values are the mean ± S.D. of 4–6 muscles from 2 or 3 mice; in the 
presence of 100 μm La3+ the overall ANOVA p values are <0.0001; multicomparison 
Dunnett's ANOVA post test: WT versus DKO2, p > 0.05; WT versus DKO1, p < 0.05; WT 
versus TKO, p < 0.05. (I) Exponential curve fitting of the values of the peak indexes in 
the presence of La3+ values, which are reported in panel H. (Mosca et al., 2016) 
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Beside this I also contributed to two additional papers: (Elbaz et al., 2019b; a). 
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2.4.2 Unpublished Data 
Similar to the RyR3 KO paper (Chapter 2.2: Paper 1) (Eckhardt et al., 2019) I also analysed the 
spontaneous calcium transient of myotubes from the DKI mouse (featured in Chapter 2.3: Paper 
2). Similar to our findings in myotubes from RyR3 KO mice we found a significant reduction in the 
number of myotubes spontaneously exhibiting calcium waves. Additionally, the frequency of the 
calcium waves was also reduced in DKI EOM-derived myotubes (Figure 2.2: Spontaneous calcium 
waves in DKI EOM-derived myotubes). This data was not added in the paper because it was out 
of the scope of the paper and it would not give any new insight in the ECC machinery. 
 
 
 
Figure 2.2: Spontaneous calcium waves in DKI EOM-derived myotubes 
(Left) Analysis of the frequency of the spontaneous Ca2+ transient. Each point 
represents the number of transients per minute recorded in a single myotube. Each 
myotube was recorded for 30 s, and the frequency output is given as frequency per 
minute. Experiments were performed at room temperature. Empty circles, WT ; gray 
circles, DKI. (Right) ΔF/F of the Fluo-4 transients. The horizontal black line represents 
the mean value. 
In collaboration with Dr. Corina Kohler (FG Neutzner / Scholl; DBM Basel) we also performed the 
OKR experiments on the DKI mouse, here stated as dHT ( Figure 2.3: OKR of DKI). Interestingly, 
we could not see any differences between DKI and WT. In the RyR3 KO paper we interpreted the 
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significant difference in the accuracy as the result of impaired EOMs. And indeed, we proved the 
impairment of the EOMs in this paper by measuring the force and calcium release in isolated 
EOMs but nevertheless the interpretation of the OKR might have been wrong. Nevertheless, in 
order to really show that impaired EOMs does not affect the OKR, deeper investigation need to 
be performed. Thus, these controversial results were not included in the DKI paper. 
 
Figure 2.3: OKR of DKI 
Visual acuity of single heterozygous mouse lines (Ex36 & Ex91), double hetero mouse 
line (dHT) and wild type mouse line (WT). Each eye is represented as a single point.  
The units of visual acuity are cycles/degree (c/d 
2.4.3 Peak Analyses Program 
To analyses the calcium transients from isolated singe EOM fibers and EOM-derived myotubes I 
developed a small Vb.Net based program. The main goal was it to get a repeatable analysis which 
can also be used to analyse multiple transients in one run (batch analyses). In the following pages 
I outline the main function “PeakCalculationFiber” which analyses the individual peakparameter. 
The rest of the code is omitted in order to keep it a manageable amount of code. 
Public Function PeakCalculationFiber(ByVal FileName As String, ByVal 
OriginalFileName As String, ByRef DataArray() As DataPoint, ByVal CenterTime 
As Double, Optional OriginalData() As DataPoint = Nothing) As Boolean 
        Try 
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            Dim NewFinalPeak As FinalPeakFiber = New FinalPeakFiber 
            NewFinalPeak.FileName = FileName 
            NewFinalPeak.OriginalFileName = OriginalFileName 
            ''Dim Center As Double = Center 
 
            Dim CenterIndex As Integer = Array.FindIndex(DataArray, Function(x 
As DataPoint) Math.Abs(x.Time - CenterTime) <= 0.0000000001) 
 
 
            ''calculate Baseline 
            Dim i As Integer = 0 
            Dim BaseLine As Double = 0 
            Dim EndBaseLine As Double = 0 
            For i = 0 To BaseLineWindowCount - 1 
                BaseLine = DataArray(i).Value + BaseLine 
                EndBaseLine = EndBaseLine + DataArray(DataArray.Count - 1 - 
i).Value 
            Next 
            BaseLine = BaseLine / BaseLineWindowCount 
            EndBaseLine = EndBaseLine / BaseLineWindowCount 
 
            Dim PeakHeightOriginal As Double = Double.NaN 
            If IsNothing(OriginalData) Then 
            Else 
                PeakHeightOriginal = OriginalData.Max(Function(p) p.Value) - 
BaseLine 
            End If 
            Dim PeakHeight As Double = DataArray(CenterIndex).Value - BaseLine 
            Dim Peakfirst5Percent As Double = 0.05 * PeakHeight + BaseLine 
            Dim Peak5firstPercentIndex As Integer = 0 
            Dim Peaklast10Percent As Double = 0.1 * PeakHeight + BaseLine 
            Dim Peaklast10PercentIndex As Integer = 0 
            Dim Peaklast90Percent As Double = 0.9 * PeakHeight + BaseLine 
            Dim Peaklast90PercentIndex As Integer = 0 
            Dim PeakHalfMax As Double = 0.5 * PeakHeight + BaseLine 
            Dim HTTPIndex As Integer = 0 
            Dim HRTIndex As Integer = 0 
 
''HAP 
            Dim HeightAfterPeak As Double = DataArray(CenterIndex).Value - 
EndBaseLine  
            Dim Peakfirst5PercentHAP As Double = 0.05 * HeightAfterPeak + 
EndBaseLine 
            Dim Peakfirst5PercentHAPIndex As Integer = 0 
            Dim Peaklast10PercentHAP As Double = 0.1 * HeightAfterPeak + 
EndBaseLine 
            Dim Peaklast10PercentHAPIndex As Integer = 0 
            Dim Peaklast90PercentHAP As Double = 0.9 * HeightAfterPeak + 
EndBaseLine 
            Dim Peaklast90PercentHAPIndex As Integer = 0 
            Dim PeakHalfMaxHAP As Double = 0.5 * HeightAfterPeak + EndBaseLine 
            Dim HRTIndexHAP As Integer = 0 
            Dim HTTPIndexHAP As Integer = 0 
 
 
 
            If IsNothing(OriginalData) Then 
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            Else 
                NewFinalPeak.HeightOriginal = PeakHeightOriginal 
                NewFinalPeak.DFdivideFOriginal = PeakHeightOriginal / BaseLine 
            End If 
            NewFinalPeak.Baseline = BaseLine 
            NewFinalPeak.Height = PeakHeight 
            NewFinalPeak.DFdivideF = PeakHeight / BaseLine 
            NewFinalPeak.EndBaselineValue = EndBaseLine 
            NewFinalPeak.Height_AP = HeightAfterPeak 
            NewFinalPeak.DFdivideF_AP = HeightAfterPeak / EndBaseLine 
 
            PreCenterArray = New DataPoint(CenterIndex) {} 
            Array.Copy(DataArray, PreCenterArray, CenterIndex + 1) 
            Peak5firstPercentIndex = Array.FindLastIndex(PreCenterArray, 
Function(x As DataPoint) x.Value <= Peakfirst5Percent) 
            HTTPIndex = Array.FindLastIndex(PreCenterArray, Function(x As 
DataPoint) x.Value <= PeakHalfMax) 
            HTTPIndexHAP = Array.FindLastIndex(PreCenterArray, Function(x As 
DataPoint) x.Value <= PeakHalfMaxHAP) 
 
            NewFinalPeak.HTTP = DataArray(CenterIndex).Time - 
DataArray(HTTPIndex).Time 
            NewFinalPeak.TTP = DataArray(CenterIndex).Time - 
DataArray(Peak5firstPercentIndex).Time 
 
            ''Klassifikation 
            Select Case Math.Abs(NewFinalPeak.Baseline - 
NewFinalPeak.EndBaselineValue) 
                Case < PeakHeight * 0.1 
                    NewFinalPeak.PeakClass = PeakClassification.Equal 
 
 
 
                    PostCenterArray = New DataPoint(DataArray.Count - 
CenterIndex - 1) {} 
                    Array.Copy(DataArray, CenterIndex, PostCenterArray, 0, 
DataArray.Count - CenterIndex) 
                    Peaklast10PercentIndex = 
Array.FindLastIndex(PostCenterArray, Function(x As DataPoint) x.Value >= 
Peaklast10Percent) 
                    Peaklast90PercentIndex = 
Array.FindLastIndex(PostCenterArray, Function(x As DataPoint) x.Value >= 
Peaklast90Percent) 
                    HRTIndex = Array.FindLastIndex(PostCenterArray, Function(x 
As DataPoint) x.Value >= PeakHalfMax) 
 
                    NewFinalPeak.NinetyToTen = 
PostCenterArray(Peaklast10PercentIndex).Time - 
PostCenterArray(Peaklast90PercentIndex).Time 
                    NewFinalPeak.HRT = PostCenterArray(HRTIndex).Time - 
DataArray(CenterIndex).Time 
                    NewFinalPeak.FWHM = PostCenterArray(HRTIndex).Time - 
DataArray(HTTPIndex).Time 
 
 
                Case Else 
 138 
 
                    If (NewFinalPeak.Baseline - NewFinalPeak.EndBaselineValue) 
> 0 Then 
                        NewFinalPeak.PeakClass = 
PeakClassification.FirstHigher 
 
                        PostCenterArray = New DataPoint(DataArray.Count - 
CenterIndex - 1) {} 
                        Array.Copy(DataArray, CenterIndex, PostCenterArray, 0, 
DataArray.Count - CenterIndex) 
                        Peaklast10PercentIndex = 
Array.FindLastIndex(PostCenterArray, Function(x As DataPoint) x.Value >= 
Peaklast10Percent) 
                        Peaklast90PercentIndex = 
Array.FindLastIndex(PostCenterArray, Function(x As DataPoint) x.Value >= 
Peaklast90Percent) 
                        HRTIndex = Array.FindLastIndex(PostCenterArray, 
Function(x As DataPoint) x.Value >= PeakHalfMax) 
 
                        NewFinalPeak.NinetyToTen = 
PostCenterArray(Peaklast10PercentIndex).Time - 
PostCenterArray(Peaklast90PercentIndex).Time 
                        NewFinalPeak.HRT = PostCenterArray(HRTIndex).Time - 
DataArray(CenterIndex).Time 
                        NewFinalPeak.FWHM = PostCenterArray(HRTIndex).Time - 
DataArray(HTTPIndex).Time 
 
                    Else 
                        NewFinalPeak.PeakClass = PeakClassification.LastHigher 
                        PostCenterArray = New DataPoint(DataArray.Count - 
CenterIndex - 1) {} 
                        Array.Copy(DataArray, CenterIndex, PostCenterArray, 0, 
DataArray.Count - CenterIndex) 
                        If Math.Abs(NewFinalPeak.Baseline - 
NewFinalPeak.EndBaselineValue) < PeakHeight * 0.5 Then 
 
                            HRTIndex = Array.FindLastIndex(PostCenterArray, 
Function(x As DataPoint) x.Value >= PeakHalfMax) 
                            NewFinalPeak.HRT = PostCenterArray(HRTIndex).Time 
- DataArray(CenterIndex).Time 
                            NewFinalPeak.FWHM = PostCenterArray(HRTIndex).Time 
- DataArray(HTTPIndex).Time 
                        End If 
 
                    End If 
            End Select 
 
 
            ''Berechnung mit Bezug auf Höhe des decay(HAP) 
 
            Peaklast10PercentHAPIndex = Array.FindLastIndex(PostCenterArray, 
Function(x As DataPoint) x.Value >= Peaklast10PercentHAP) 
            Peaklast90PercentHAPIndex = Array.FindLastIndex(PostCenterArray, 
Function(x As DataPoint) x.Value >= Peaklast90PercentHAP) 
            HRTIndexHAP = Array.FindLastIndex(PostCenterArray, Function(x As 
DataPoint) x.Value >= PeakHalfMaxHAP) 
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            NewFinalPeak.NinetyToTen_AP = 
PostCenterArray(Peaklast10PercentHAPIndex).Time - 
PostCenterArray(Peaklast90PercentHAPIndex).Time 
            NewFinalPeak.HRT_AP = PostCenterArray(HRTIndexHAP).Time - 
DataArray(CenterIndex).Time 
            NewFinalPeak.FWHM_AP = PostCenterArray(HRTIndexHAP).Time - 
DataArray(HTTPIndexHAP).Time 
 
 
 
 
            FinalPeakFiberList.Add(NewFinalPeak) 
 
        Catch e As Exception 
 
            MessageBox.Show(e.Message) 
            Return False 
        End Try 
        Return True 
 
    End Function 
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3 CONCLUSION AND PERSPECTIVES 
A major goal of this PhD thesis was to establish and optimize methods to make EOMs available 
for functional measurements, specifically force measurements on individual EOMs and Ca2+ 
dynamic and homeostasis at the single fiber level as well as static measurements such as 
immunohistochemistry and structural EM imaging on whole EOMs. 
Extraocular muscles are a unique type of skeletal muscle. This is already reflected by a different 
developmental origin than the other skeletal muscles. They are known to be among the fastest 
and fatigue resistant muscles. Our previous studies showed that EOMs express a unique panel of 
transcripts and proteins. Unlike other skeletal muscle they express the cardiac DHP receptor, the 
ryanodine receptor type 3 as well as MyHC13. 
The RyR3 transcript expression in EOM’s drew our interest. The reason was that RyR3 is expressed 
widely in different tissues but no real functional role in skeletal muscles was found; there were 
reports associating RyR3 ablation with minor cognitive impairments, but its true functional role 
was still not clear. We used the new methods I established to investigate the role of RyR3 in EOMs 
by using a mouse model lacking RyR3, the RyR3-/- mouse. Our results reveal for the first time an 
important role for RyR3 in extraocular muscle function. After the first observation that RyR3-/- 
mice have an impaired visual apparatus determined by a reduced acuity (OKR and water maze) 
we decided to study the properties of isolated EOMs to reduce the complexity of the visual 
apparatus from three possible impairments, the brain, the eye and the EOM, to one. We were 
able show significant reduction of force and kinetic twitch parameter. Since proteins involved in 
ECC, as well as the MyHC composition were similar to the WT we concluded that the altered 
twitch causes the phenotype. After digging deeper in the ECC machinery and analyzing the Ca2+ 
transients we found changes in some of the kinetic parameters but not in the peak Ca2+ release. 
Interestingly the half relaxation time (during force measurements and in the Ca2+ transients) was 
consistently increased. This might sound contradictory at first view because the lack of RyR3, a 
Ca2+ releasing channel should not alter the uptake of Ca2+ into the SR. But we hypothesized that 
the different location of the RyR3 might be the reason. There are a couple of papers showing that 
the RyR3 is located parajunctional in the SR (Felder and Franzini-Armstrong, 2002; Perni et al., 
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2015) and other papers showing that RyR3 is in close proximity to the SERCA (Clark et al., 2010). 
Therefore, it is reasonable to say that the release of Ca2+ by RyR3 in WT activates the SERCA and 
speeds up the half relaxation time. This novel mechanism is unique to EOMs and may reflect their 
physiological function because EOMs require super-fast Ca2+ uptake due to their physiological 
characteristics of being both the fastest muscles and of being fatigue resistant. One fact which 
may point into the direction of a role of RyR3-SERCA and fatigue resistance is that another skeletal 
muscle, namely the diaphragm also expresses RyR3. The diaphragm is not known to be fast twitch 
muscle, but it is a muscle which needs to constantly work since it is involved in breathing. 
Even though our kinetic of force and Ca2+ release results were consistent we were unable to show 
that the reduction in force is due to the reduced Ca2+ release. There might be two reasons for 
this. The first is just the different preparation between that used for force measurements (whole 
muscle mount) and that used for Ca2+ measurements (isolated single fibers). Thus, the reduction 
in force can be due to a systematic effect which only appears at whole muscle level while we 
could only isolate functional subpopulations of fibers. Indeed, during enzymatic isolation of fibers 
it is possible that we lost exactly the fibers which have reduced Ca2+ release because they are 
damaged and are not able to survive the procedure. Another possibility of the reduced force is 
that the development of the EOM is altered because it is well known that the RyR3 is expressed 
during maturation. Compatibly, we were able to show alterations at the developmental level in 
RyR3-/- myotubes by measuring spontaneous Ca2+ oscillations.  
In conclusion, in our first paper we were able to find an EOM phenotype in the RyR3-/- mouse. 
This phenotype is caused by a reduced force and altered force kinetic which is a result of 
alterations at the developmental level as well as altered Ca2+ release kinetics. From a clinical 
perspective our study shows a new possible pathomechanism for ophthalmoplegia, strabismus, 
and ptosis with a new possible screening target, the RYR3. 
In our second paper we focused on the RYR1, since there are hundreds of mutations in this gene 
shown to cause disease, specifically myopathies. We investigated the molecular basis of the EOM 
impairment in compound heterozygous RYR1 mutant carriers. Our group created and 
characterized a compound heterozygous mouse model (DKI). The mouse model was created to 
carry RYR1 mutations identified in a patient with congenital myopathy (Klein et al., 2012; Elbaz et 
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al., 2019b; a). We performed experiments similar to those performed in the RyR3-/- mouse. We 
compared WT mice, single heterozygous RYR1 mutants as well as the DKI mice and could show 
that only the EOMs from the DKI mouse has a decreased force; the change in force was very large, 
i.e. a factor of 8-10 times compared to single heterozygous, homozygous mutant carriers or WT 
mice. Because of these results we performed the next series of experiments only on EOMs from 
DKI mice. Unlike the RyR3-/- mouse, the DKI showed significant reduction in the Ca2+ release by 
50%, which is consistent with the finding that the EOMs of the DKI only express 60% RyR1 content 
compared to WT, as determined by western blotting and mass spectrometry. Additionally, similar 
to the RyR1 DHPR content is also reduced, suggesting an overall reduction of CRU. And indeed, 
we were able to show, via EM, that the number of CRU decrease by 57% compared to WT. The 
reduced Ca2+ release clearly plays a significant part of the reduced force production. But we also 
found a tremendous reduction and almost complete absence of the EOM specific MyHC, MyHC13 
in the DKI. This was an unexpected but very interesting finding. MyHCs are directly involved in the 
force production so this reduction also plays an important role in the reduced force phenotype. 
Importantly EOMs needs to be active during development to express MyHC13 and its presence 
cannot be restored in grown-ups (Brueckner et al., 1999). In summary we showed that the DKI 
representing a congenital myopathy with compound heterozygous RYR1 mutations have EOM 
impairment. This is the first time that the molecular basis of EOM impairment linked to congenital 
myopathies has been investigated. Remarkably this dysfunction is only present in the DKI and not 
in the single heterozygous or homozygous mice. Now that the mouse model and the methods are 
available it is possible to screen which kind of treatment can increase the recovery of EOM force 
in the mouse model and this might be a potentially useful drug for patients. One should also keep 
in mind however that our results showing reduced MyHC13 content also suggest that the damage 
to the EOM is already present very early in life or during development. So, whether EOM function 
can be recovered remains an open question and must be determined experimentally in future 
studies. 
In conclusion in this work we uncovered that RyR3 plays in important role in ECC of EOMs, a fact 
that was unknow previously and might be useful for potential mutation-screening targets in the 
future. In the second part we demonstrated that our congenital mouse model has an EOM 
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dysfunction and can serve as mouse model for congenital myopathies with EOM involvement. In 
this mouse model we also showed a possible connection between EOM dysfunction and the lack 
of MyHC13. Our established methods, findings and mouse models basically open the field for in 
ex-vivo ECC studies in EOM. 
 
 
 144 
 
4 REFERENCES 
Anderson, A.A., S. Treves, D. Biral, R. Betto, D. Sandonà, M. Ronjat, and F. Zorzato. 2003. The novel 
skeletal muscle sarcoplasmic reticulum JP-45 protein. Molecular cloning, tissue distribution, 
developmental expression, and interaction with alpha 1.1 subunit of the voltage-gated 
calcium channel. J. Biol. Chem. 278:39987–92. doi:10.1074/jbc.M305016200. 
Anderson, D.M., K.M. Anderson, C.-L. Chang, C.A. Makarewich, B.R. Nelson, J.R. McAnally, P. 
Kasaragod, J.M. Shelton, J. Liou, R. Bassel-Duby, and E.N. Olson. 2015. A micropeptide 
encoded by a putative long noncoding RNA regulates muscle performance. Cell. 160:595–
606. doi:10.1016/j.cell.2015.01.009. 
Andrade, F.H., J.D. Porter, and H.J. Kaminski. 2000. Eye muscle sparing by the muscular 
dystrophies: Lessons to be learned? Microsc. Res. Tech. 48:192–203. doi:10.1002/(SICI)1097-
0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J. 
Au, Y. 2004. The muscle ultrastructure: a structural perspective of the sarcomere. Cell. Mol. Life 
Sci. 61:3016–3033. doi:10.1007/s00018-004-4282-x. 
Barone, V., F. Bertocchini, R. Bottinelli, F. Protasi, P.D. Allen, C. Franzini Armstrong, C. Reggiani, 
and V. Sorrentino. 1998. Contractile impairment and structural alterations of skeletal 
muscles from knockout mice lacking type 1 and type 3 ryanodine receptors. FEBS Lett. 
422:160–4. doi:10.1016/s0014-5793(98)00003-9. 
Barone, V., D. Randazzo, V. Del Re, V. Sorrentino, and D. Rossi. 2015. Organization of junctional 
sarcoplasmic reticulum proteins in skeletal muscle fibers. J. Muscle Res. Cell Motil. 36:501–
515. doi:10.1007/s10974-015-9421-5. 
Baylor, S.M., and S. Hollingworth. 2003. Sarcoplasmic reticulum calcium release compared in 
slow-twitch and fast-twitch fibres of mouse muscle. J. Physiol. 551:125–38. 
doi:10.1113/jphysiol.2003.041608. 
Bellinger, A.M., S. Reiken, M. Dura, P.W. Murphy, S.-X. Deng, D.W. Landry, D. Nieman, S.E. 
Lehnart, M. Samaru, A. LaCampagne, and A.R. Marks. 2008. Remodeling of ryanodine 
 145 
 
receptor complex causes “leaky” channels: a molecular mechanism for decreased exercise 
capacity. Proc. Natl. Acad. Sci. U. S. A. 105:2198–2202. doi:10.1073/pnas.0711074105. 
Berridge, M.J. 2008. Smooth muscle cell calcium activation mechanisms. J. Physiol. 586:5047–61. 
doi:10.1113/jphysiol.2008.160440. 
Bers, D.M. 2002. Cardiac excitation–contraction coupling. Nature. 415:198–205. 
doi:10.1038/415198a. 
Bicer, S., and P.J. Reiser. 2009. Myosin Isoform Expression in Dog Rectus Muscles: Patterns in 
Global and Orbital Layers and among Single Fibers. Investig. Opthalmology Vis. Sci. 50:157. 
doi:10.1167/iovs.08-2416. 
Blausen.com staff. 2014. Medical gallery of Blausen Medical 2014. WikiJournal Med. 1. 
doi:10.15347/wjm/2014.010. 
Brillantes, A.-M.B., K. Ondrias, A. Scott, E. Kobrinsky, E. Ondriašová, M.C. Moschella, T. Jayaraman, 
M. Landers, B.E. Ehrlich, and A.R. Marks. 1994. Stabilization of calcium release channel 
(ryanodine receptor) function by FK506-binding protein. Cell. 77:513–523. 
doi:10.1016/0092-8674(94)90214-3. 
Brini, M., and E. Carafoli. 2009. Calcium Pumps in Health and Disease. Physiol. Rev. 89:1341–1378. 
doi:10.1152/physrev.00032.2008. 
Brueckner, J.K., L.P. Ashby, J.R. Prichard, and J.D. Porter. 1999. Vestibulo-ocular pathways 
modulate extraocular muscle myosin expression patterns. Cell Tissue Res. 295:477–84. 
doi:10.1007/s004410051253. 
Buratti, R., G. Prestipino, P. Menegazzi, S. Treves, and F. Zorzato. 1995. Calcium-Dependent 
Activation of Skeletal-Muscle Ca2+ Release Channel (Ryanodine Receptor) by Calmodulin. 
Biochem. Biophys. Res. Commun. 213:1082–1090. doi:10.1006/BBRC.1995.2238. 
Büttner-Ennever, J. 2007. Anatomy of the oculomotor system. Dev. Ophthalmol. 40:1–14. 
doi:10.1159/000100345. 
Caiozzo, V.J., F. Haddad, M. Baker, S. McCue, and K.M. Baldwin. 2000. MHC polymorphism in 
 146 
 
rodent plantaris muscle: effects of mechanical overload and hypothyroidism. Am. J. Physiol. 
Physiol. 278:C709–C717. doi:10.1152/ajpcell.2000.278.4.C709. 
Calderón, J.C., P. Bolaños, and C. Caputo. 2014. The excitation-contraction coupling mechanism 
in skeletal muscle. Biophys. Rev. 6:133–160. doi:10.1007/s12551-013-0135-x. 
Catterall, W.A. 1995. Structure and Function of Voltage-Gated Ion Channels. Annu. Rev. Biochem. 
64:493–531. doi:10.1146/annurev.bi.64.070195.002425. 
Catterall, W.A., J. Striessnig, T.P. Snutch, and E. Perez-Reyes. 2003. International Union of 
Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. 
Pharmacol. Rev. 55:579–581. doi:10.1124/pr.55.4.8.and. 
Chang, C.-N., and C. Kioussi. 2018. Location, Location, Location: Signals in Muscle Specification. J. 
Dev. Biol. 6. doi:10.3390/jdb6020011. 
Chen, W., R. Wang, B. Chen, X. Zhong, H. Kong, Y. Bai, Q. Zhou, C. Xie, J. Zhang, A. Guo, X. Tian, 
P.P. Jones, M.L. O’Mara, Y. Liu, T. Mi, L. Zhang, J. Bolstad, L. Semeniuk, H. Cheng, J. Zhang, J. 
Chen, D.P. Tieleman, A.M. Gillis, H.J. Duff, M. Fill, L.-S. Song, and S.R.W. Chen. 2014. The 
ryanodine receptor store-sensing gate controls Ca2+ waves and Ca2+-triggered arrhythmias. 
Nat. Med. 20:184–192. doi:10.1038/nm.3440. 
Clancy, J.S., H. Takeshima, S.L. Hamilton, and M.B. Reid. 1999. Contractile function is unaltered in 
diaphragm from mice lacking calcium release channel isoform 3. Am. J. Physiol. 277:R1205-
9. 
Clark, J.H., N.P. Kinnear, S. Kalujnaia, G. Cramb, S. Fleischer, L.H. Jeyakumar, F. Wuytack, and  a 
M. Evans. 2010. Identification of functionally segregated sarcoplasmic reticulum calcium 
stores in pulmonary arterial smooth muscle. J. Biol. Chem. 285:13542–13549. 
doi:10.1074/jbc.M110.101485. 
Clarke, O.B., and W.A. Hendrickson. 2016. Structures of the colossal RyR1 calcium release channel. 
Curr. Opin. Struct. Biol. 39:144–152. doi:10.1016/j.sbi.2016.09.002. 
Close, R.I., and A.R. Luff. 1974. Dynamic properties of inferior rectus muscle of the rat. J. Physiol. 
 147 
 
236:259–70. doi:10.1113/jphysiol.1974.sp010434. 
Costello, B., C. Chadwick, A. Saito, A. Chu, A. Maurer, and S. Fleischer. 1986. Characterization of 
the junctional face membrane from terminal cisternae of sarcoplasmic reticulum. J. Cell Biol. 
103:741–53. doi:10.1083/jcb.103.3.741. 
Craig, R. 2017. Molecular structure of muscle filaments determined by electron microscopy. Appl. 
Microsc. 47:226–232. doi:10.9729/am.2017.47.4.226. 
Craig, R., and J.L. Woodhead. 2006. Structure and function of myosin filaments. Curr. Opin. Struct. 
Biol. 16:204–212. doi:10.1016/j.sbi.2006.03.006. 
Demer, J.L., S.Y. Oh, and V. Poukens. 2000. Evidence for active control of rectus extraocular 
muscle pulleys. Investig. Ophthalmol. Vis. Sci. 41:1280–1290. 
Díaz-Vegas, A., V. Eisner, and E. Jaimovich. 2019. Skeletal muscle excitation-metabolism coupling. 
Arch. Biochem. Biophys. 664:89–94. doi:10.1016/j.abb.2019.01.037. 
Dorr, M., M. Kwon, L.A. Lesmes, A. Miller, M. Kazlas, K. Chan, D.G. Hunter, Z.-L. Lu, and P.J. Bex. 
2019. Binocular Summation and Suppression of Contrast Sensitivity in Strabismus, Fusion 
and Amblyopia. Front. Hum. Neurosci. 13:234. doi:10.3389/fnhum.2019.00234. 
Drum, S.N., R. Weatherwax, and J.B. Dixon. 2016. Physiology of skeletal muscle. Muscular Inj. 
Posterior Leg Assess. Treat. 13–26. doi:10.1007/978-1-4899-7651-2_2. 
Durston, J.H. 1974. Histochemistry of primate extraocular muscles and the changes of 
denervation. Br. J. Ophthalmol. 58:193–216. doi:10.1136/bjo.58.3.193. 
Eckhardt, J., C. Bachmann, M. Sekulic-Jablanovic, V. Enzmann, K.H. Park, J. Ma, H. Takeshima, F. 
Zorzato, and S. Treves. 2019. Extraocular muscle function is impaired in ryr3-/- mice. J. Gen. 
Physiol. 151:929–943. doi:10.1085/jgp.201912333. 
Efremov, R.G., A. Leitner, R. Aebersold, and S. Raunser. 2015. Architecture and conformational 
switch mechanism of the ryanodine receptor. Nature. 517:39–43. doi:10.1038/nature13916. 
Eisner, D.A., J.L. Caldwell, K. Kistamás, and A.W. Trafford. 2017. Calcium and Excitation-
Contraction Coupling in the Heart. Circ. Res. 121:181–195. 
 148 
 
doi:10.1161/CIRCRESAHA.117.310230. 
Elbaz, M., A. Ruiz, C. Bachmann, J. Eckhardt, P. Pelczar, E. Venturi, C. Lindsay, A.D. Wilson, A. 
Alhussni, T. Humberstone, L. Pietrangelo, S. Boncompagni, R. Sitsapesan, S. Treves, and F. 
Zorzato. 2019a. Quantitative RyR1 reduction and loss of calcium sensitivity of 
RyR1Q1970fsX16+A4329D cause cores and loss of muscle strength. Hum. Mol. Genet. 
28:2987–2999. doi:10.1093/hmg/ddz092. 
Elbaz, M., A. Ruiz, J. Eckhardt, P. Pelczar, F. Muntoni, S. Boncompagni, S. Treves, and F. Zorzato. 
2019b. Quantitative reduction of RyR1 protein caused by a single-allele frameshift mutation 
in RYR1 ex36 impairs the strength of adult skeletal muscle fibres. Hum. Mol. Genet. 28:1872–
1884. doi:10.1093/hmg/ddz025. 
Elíes, J., M. Yáñez, T.M.C. Pereira, J. Gil-Longo, D.A. MacDougall, and M. Campos-Toimil. 2020. An 
Update to Calcium Binding Proteins. Springer, Cham. 183–213. 
Felder, E., and C. Franzini-Armstrong. 2002. Type 3 ryanodine receptors of skeletal muscle are 
segregated in a parajunctional position. Proc. Natl. Acad. Sci. U. S. A. 99:1695–1700. 
doi:10.1073/pnas.032657599. 
Fessenden, J.D., Y. Wang, R.A. Moore, S.R.W. Chen, P.D. Allen, and I.N. Pessah. 2000. Divergent 
Functional Properties of Ryanodine Receptor Types 1 and 3 Expressed in a Myogenic Cell 
Line. Biophys. J. 79:2509–2525. doi:10.1016/S0006-3495(00)76492-7. 
Fischer, M.D., J.R. Gorospe, E. Felder, S. Bogdanovich, F. Pedrosa-Domellöf, R.S. Ahima, N.A. 
Rubinstein, E.P. Hoffman, and T.S. Khurana. 2002. Expression profiling reveals metabolic and 
structural components of extraocular muscles. 
https://doi.org/10.1152/physiolgenomics.00115.2001. 
doi:10.1152/PHYSIOLGENOMICS.00115.2001. 
Fleischer, S., E.M. Ogunbunmi, M.C. Dixon, and E.A. Fleer. 1985. Localization of Ca2+ release 
channels with ryanodine in junctional terminal cisternae of sarcoplasmic reticulum of fast 
skeletal muscle. Proc. Natl. Acad. Sci. 82:7256–7259. doi:10.1073/pnas.82.21.7256. 
Franzini-Armstrong, C. 1987. The structure of calsequestrin in triads of vertebrate skeletal muscle: 
 149 
 
a deep-etch study. J. Cell Biol. 105:49–56. doi:10.1083/jcb.105.1.49. 
Franzini-Armstrong, C. 2018. The relationship between form and function throughout the history 
of excitation–contraction coupling. J. Gen. Physiol. 150:189–210. 
doi:10.1085/jgp.201711889. 
Franzini-Armstrong, C., and G. Nunzi. 1983. Junctional feet and particles in the triads of a fast-
twitch muscle fibre. J. Muscle Res. Cell Motil. 4:233–252. doi:10.1007/BF00712033. 
Franzini-Armstrong, C., and L.D. Peachey. 1981. Striated muscle-contractile and control 
mechanisms. J. Cell Biol. 91:166s-186s. doi:10.1083/jcb.91.3.166s. 
Frontera, W.R., and J. Ochala. 2015. Skeletal Muscle: A Brief Review of Structure and Function. 
Calcif. Tissue Int. 96:183–195. doi:10.1007/s00223-014-9915-y. 
Fuentes, O., C. Valdivia, D. Vaughan, R. Coronado, and H.H. Valdivia. 1994. Calcium-dependent 
block of ryanodine receptor channel of swine skeletal muscle by direct binding of calmodulin. 
Cell Calcium. 15:305–316. doi:10.1016/0143-4160(94)90070-1. 
Furuichi, T., D. Furutama, Y. Hakamata, J. Nakai, H. Takeshima, and K. Mikoshiba. 1994. Multiple 
types of ryanodine receptor/Ca2+ release channels are differentially expressed in rabbit 
brain. J. Neurosci. 14:4794–805. 
Galfré, E., S.J. Pitt, E. Venturi, M. Sitsapesan, N.R. Zaccai, K. Tsaneva-Atanasova, S. O’Neill, and R. 
Sitsapesan. 2012. FKBP12 Activates the Cardiac Ryanodine Receptor Ca2+-Release Channel 
and Is Antagonised by FKBP12.6. PLoS One. 7:e31956. doi:10.1371/journal.pone.0031956. 
Gambardella, J., B. Trimarco, G. Iaccarino, and G. Santulli. 2017. New Insights in Cardiac Calcium 
Handling and Excitation-Contraction Coupling. In Advances in experimental medicine and 
biology. 373–385. 
des Georges, A., O.B. Clarke, R. Zalk, Q. Yuan, K.J. Condon, R.A. Grassucci, W.A. Hendrickson, A.R. 
Marks, and J. Frank. 2016. Structural Basis for Gating and Activation of RyR1. Cell. 167:145-
157.e17. doi:10.1016/j.cell.2016.08.075. 
Giannini, G., E. Clementi, R. Ceci, G. Marziali, and V. Sorrentino. 1992. Expression of a ryanodine 
 150 
 
receptor-Ca2+ channel that is regulated by TGF-beta. Science. 257:91–4. 
doi:10.1126/SCIENCE.1320290. 
Giannini, G., A. Conti, S. Mammarella, M. Scrobogna, and V. Sorrentino. 1995. The ryanodine 
receptor/calcium channel genes are widely and differentially expressed in murine brain and 
peripheral tissues. J. Cell Biol. 128:893–904. doi:10.1083/JCB.128.5.893. 
Greenstein, J.L., and R.L. Winslow. 2011. Integrative systems models of cardiac excitation-
contraction coupling. Circ. Res. 108:70–84. doi:10.1161/CIRCRESAHA.110.223578. 
Guerrini, R., P. Menegazzi, R. Anacardio, M. Marastoni, R. Tomatis, F. Zorzato, and S. Treves. 1995. 
Calmodulin Binding Sites of the Skeletal, Cardiac, and Brain Ryanodine Receptor Ca2+ 
Channels: Modulation by the Catalytic Subunit of cAMP-Dependent Protein Kinase? 
Biochemistry. 34:5120–5129. doi:10.1021/bi00015a024. 
Hakamata, Y., J. Nakai, H. Takeshima, and K. Imoto. 1992. Primary structure and distribution of a 
novel ryanodine receptor/calcium release channel from rabbit brain. FEBS Lett. 312:229–
235. doi:10.1016/0014-5793(92)80941-9. 
Hall, J.E. (John E. 2016. Guyton and Hall textbook of medical physiology. Saunders. 1168 pp. 
Hamilton, S., and D. Terentyev. 2019. Altered Intracellular Calcium Homeostasis and 
Arrhythmogenesis in the Aged Heart. Int. J. Mol. Sci. 20:2386. doi:10.3390/ijms20102386. 
Harrison, A.R., B.C. Anderson, L. V Thompson, and L.K. McLoon. 2007. Myofiber length and three-
dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular 
muscles. Invest. Ophthalmol. Vis. Sci. 48:3594–601. doi:10.1167/iovs.06-1239. 
Helveston, E.M. 2010. Understanding, detecting, and managing strabismus. Community eye Heal. 
23:12–4. 
Hernández-Ochoa, E.O., and M.F. Schneider. 2018. Voltage sensing mechanism in skeletal muscle 
excitation-contraction coupling: coming of age or midlife crisis? Skelet. Muscle. 8:22. 
doi:10.1186/s13395-018-0167-9. 
Hill, J.A., E.N. Olson, and K.K. Griendling. 2012. Muscle : fundamental biology and mechanisms of 
 151 
 
disease. Academic Press. 
Horstick, E.J., J.W. Linsley, J.J. Dowling, M.A. Hauser, K.K. McDonald, A. Ashley-Koch, L. Saint-
Amant, A. Satish, W.W. Cui, W. Zhou, S.M. Sprague, D.S. Stamm, C.M. Powell, M.C. Speer, C. 
Franzini-Armstrong, H. Hirata, and J.Y. Kuwada. 2013. Stac3 is a component of the 
excitation–contraction coupling machinery and mutated in Native American myopathy. Nat. 
Commun. 4:1952. doi:10.1038/ncomms2952. 
Huang, X., B. Fruen, D.T. Farrington, T. Wagenknecht, and Z. Liu. 2012. Calmodulin-binding 
Locations on the Skeletal and Cardiac Ryanodine Receptors. J. Biol. Chem. 287:30328–30335. 
doi:10.1074/jbc.M112.383109. 
Hwang, J.H., F. Zorzato, N.F. Clarke, and S. Treves. 2012. Mapping domains and mutations on the 
skeletal muscle ryanodine receptor channel. Trends Mol. Med. 18:644–657. 
doi:10.1016/j.molmed.2012.09.006. 
Ikemoto, T., M. Iino, and M. Endo. 1995. Enhancing effect of calmodulin on Ca(2+)-induced Ca2+ 
release in the sarcoplasmic reticulum of rabbit skeletal muscle fibres. J. Physiol. 487:573–
582. doi:10.1113/jphysiol.1995.sp020901. 
Jayaraman, T., A.M. Brillantes, A.P. Timerman, S. Fleischer, H. Erdjument-Bromage, P. Tempst, 
and A.R. Marks. 1992. FK506 binding protein associated with the calcium release channel 
(ryanodine receptor). J. Biol. Chem. 267:9474–7. 
Jungbluth, H. 2007a. Multi-minicore Disease. Orphanet J. Rare Dis. 2:31. doi:10.1186/1750-1172-
2-31. 
Jungbluth, H. 2007b. Central core disease. Orphanet J. Rare Dis. 2:25. doi:10.1186/1750-1172-2-
25. 
Jungbluth, H., C.A. Sewry, and F. Muntoni. 2011. Core myopathies. Semin. Pediatr. Neurol. 
18:239–249. doi:10.1016/j.spen.2011.10.005. 
Jungbluth, H., S. Treves, F. Zorzato, A. Sarkozy, J. Ochala, C. Sewry, R. Phadke, M. Gautel, and F. 
Muntoni. 2018. Congenital myopathies: disorders of excitation–contraction coupling and 
 152 
 
muscle contraction. Nat. Rev. Neurol. 14:151–167. doi:10.1038/nrneurol.2017.191. 
Al Kahtani, E.S., R. Khandekar, K. Al-Rubeaan, A.M. Youssef, H.M. Ibrahim, and A.H. Al-Sharqawi. 
2016. Assessment of the prevalence and risk factors of ophthalmoplegia among diabetic 
patients in a large national diabetes registry cohort. BMC Ophthalmol. 16:118. 
doi:10.1186/s12886-016-0272-7. 
Kallestad, K.M., S.L. Hebert, A.A. McDonald, M.L. Daniel, S.R. Cu, and L.K. McLoon. 2011. Sparing 
of extraocular muscle in aging and muscular dystrophies: A myogenic precursor cell 
hypothesis. Exp. Cell Res. 317:873–885. doi:10.1016/j.yexcr.2011.01.018. 
Khanna, S., C.R. Richmonds, H.J. Kaminski, and J.D. Porter. 2003. Molecular Organization of the 
Extraocular Muscle Neuromuscular Junction: Partial Conservation of and Divergence from 
the Skeletal Muscle Prototype. Investig. Opthalmology Vis. Sci. 44:1918. 
doi:10.1167/iovs.02-0890. 
Khurana, T.S., R.A. Prendergast, H.S. Alameddine, F.M. Tomé, M. Fardeau, K. Arahata, H. Sugita, 
and L.M. Kunkel. 1995. Absence of extraocular muscle pathology in Duchenne’s muscular 
dystrophy: role for calcium homeostasis in extraocular muscle sparing. J. Exp. Med. 182:467–
75. doi:10.1084/jem.182.2.467. 
Kimlicka, L., and F. Van Petegem. 2011. The structural biology of ryanodine receptors. Sci. China 
Life Sci. 54:712–724. doi:10.1007/s11427-011-4198-2. 
King, W.M. 2011. Binocular coordination of eye movements--Hering’s Law of equal innervation or 
uniocular control? Eur. J. Neurosci. 33:2139–46. doi:10.1111/j.1460-9568.2011.07695.x. 
Kjellgren, D., L.-E. Thornell, J. Andersen, and F. Pedrosa-Domello¨f. 2003. Myosin Heavy Chain 
Isoforms in Human Extraocular Muscles. Investig. Opthalmology Vis. Sci. 44:1419. 
doi:10.1167/iovs.02-0638. 
Klein, A., S. Lillis, I. Munteanu, M. Scoto, H. Zhou, R. Quinlivan, V. Straub, A.Y. Manzur, H. Roper, 
P.-Y. Jeannet, W. Rakowicz, D.H. Jones, U.B. Jensen, E. Wraige, N. Trump, U. Schara, H. 
Lochmuller, A. Sarkozy, H. Kingston, F. Norwood, M. Damian, J. Kirschner, C. Longman, M. 
Roberts, M. Auer-Grumbach, I. Hughes, K. Bushby, C. Sewry, S. Robb, S. Abbs, H. Jungbluth, 
 153 
 
and F. Muntoni. 2012. Clinical and genetic findings in a large cohort of patients with 
ryanodine receptor 1 gene-associated myopathies. Hum. Mutat. 33:981–8. 
doi:10.1002/humu.22056. 
Kranjc, B.S., J. Sketelj, A. D’Albis, M. Ambrož, and I. Eržen. 2000. Fibre types and Myosin heavy 
chain expression in the Ocular Medial Rectus Muscle of the Adult Rat. J. Muscle Res. Cell 
Motil. 21:753–761. doi:10.1023/A:1010362926221. 
Kushnir, A., and A.R. Marks. 2010. The ryanodine receptor in cardiac physiology and disease. Adv. 
Pharmacol. 59:1–30. doi:10.1016/S1054-3589(10)59001-X. 
Kuwajima, G., A. Futatsugi, M. Niinobe, S. Nakanishi, and K. Mikoshiba. 1992. Two types of 
ryanodine receptors in mouse brain: skeletal muscle type exclusively in Purkinje cells and 
cardiac muscle type in various neurons. Neuron. 9:1133–42. doi:10.1016/0896-
6273(92)90071-k. 
Lai, F.A., M. Dent, C. Wickenden, L. Xu, G. Kumari, M. Misra, H.B. Lee, M. Sar, and G. Meissner. 
1992. Expression of a cardiac Ca(2+)-release channel isoform in mammalian brain. Biochem. 
J. 288 ( Pt 2):553–64. doi:10.1042/bj2880553. 
Laitinen, P.J., K.M. Brown, K. Piippo, H. Swan, J.M. Devaney, B. Brahmbhatt, E.A. Donarum, M. 
Marino, N. Tiso, M. Viitasalo, L. Toivonen, D.A. Stephan, and K. Kontula. 2001. Mutations of 
the Cardiac Ryanodine Receptor (RyR2) Gene in Familial Polymorphic Ventricular 
Tachycardia. Circulation. 103:485–490. doi:10.1161/01.CIR.103.4.485. 
Laitinen, P.J., H. Swan, and K. Kontula. 2003. Molecular genetics of exercise-induced polymorphic 
ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations 
and two common calsequestrin 2 amino-acid polymorphisms. Eur. J. Hum. Genet. 11:888–
91. doi:10.1038/sj.ejhg.5201061. 
Lamb, G. 2000. Excitation-Contraction Coupling In Skeletal Muscle: Comparisons With Cardiac 
Muscle. Clin. Exp. Pharmacol. Physiol. 27:216–224. doi:10.1046/j.1440-1681.2000.03224.x. 
Lanner, J.T., D.K. Georgiou, A.D. Joshi, and S.L. Hamilton. 2010. Ryanodine Receptors: Structure, 
Expression, Molecular Details, and Function in Calcium Release. Cold Spring Harb. Perspect. 
 154 
 
Biol. 2:a003996. doi:10.1101/CSHPERSPECT.A003996. 
Lasa-Elgarresta, J., L. Mosqueira-Martín, N. Naldaiz-Gastesi, A. Sáenz, A. López de Munain, and A. 
Vallejo-Illarramendi. 2019. Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with 
CAPN3 Mutations. Int. J. Mol. Sci. 20:4548. doi:10.3390/ijms20184548. 
Lattanzio, F.A., R.G. Schlatterer, M. Nicar, K.P. Campbell, and J.L. Sutko. 1987. The effects of 
ryanodine on passive calcium fluxes across sarcoplasmic reticulum membranes. J. Biol. 
Chem. 262:2711–8. 
Lee, L.A., A. Karabina, L.J. Broadwell, and L.A. Leinwand. 2019. The ancient sarcomeric myosins 
found in specialized muscles. Skelet. Muscle. 9:7. doi:10.1186/s13395-019-0192-3. 
Liao, M., E. Cao, D. Julius, and Y. Cheng. 2013. Structure of the TRPV1 ion channel determined by 
electron cryo-microscopy. Nature. 504:107–112. doi:10.1038/nature12822. 
Liu, X., M.J. Betzenhauser, S. Reiken, A.C. Meli, W. Xie, B.-X. Chen, O. Arancio, and A.R. Marks. 
2012. Role of Leaky Neuronal Ryanodine Receptors in Stress- Induced Cognitive Dysfunction. 
Cell. 150:1055–1067. doi:10.1016/j.cell.2012.06.052. 
Liu, Z., J. Zhang, M.R. Sharma, P. Li, S.R.W. Chen, and T. Wagenknecht. 2001. Three-dimensional 
reconstruction of the recombinant type 3 ryanodine receptor and localization of its amino 
terminus. Proc. Natl. Acad. Sci. 98:6104–6109. doi:10.1073/pnas.111382798. 
Lopez, R.J., S. Byrne, M. Vukcevic, M. Sekulic-Jablanovic, L. Xu, M. Brink, J. Alamelu, N. Voermans, 
M. Snoeck, E. Clement, F. Muntoni, H. Zhou, A. Radunovic, S. Mohammed, E. Wraige, F. 
Zorzato, S. Treves, and H. Jungbluth. 2016. An RYR1 mutation associated with malignant 
hyperthermia is also associated with bleeding abnormalities. Sci. Signal. 9:ra68. 
doi:10.1126/scisignal.aad9813. 
MacIntosh, B.R., P.F. Gardiner, and A.J. McComas. 2006. Skeletal muscle : form and function. 
Human Kinetics. 423 pp. 
MacLennan, D.H., and E.G. Kranias. 2003. Phospholamban: a crucial regulator of cardiac 
contractility. Nat. Rev. Mol. Cell Biol. 4:566–577. doi:10.1038/nrm1151. 
 155 
 
Marieb, E.N., P.B. Wilhelm, and J. Mallatt. Human anatomy. 895 pp. 
Marks, A.R., P. Tempst, K.S. Hwang, M.B. Taubman, M. Inui, C. Chadwick, S. Fleischer, and B. 
Nadal-Ginard. 1989. Molecular cloning and characterization of the ryanodine 
receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum. 
Proc. Natl. Acad. Sci. U. S. A. 86:8683–7. doi:10.1073/pnas.86.22.8683. 
Matsuo, N., K. Tanda, K. Nakanishi, N. Yamasaki, K. Toyama, K. Takao, H. Takeshima, and T. 
Miyakawa. 2009. Comprehensive behavioral phenotyping of ryanodine receptor type 3 
(RyR3) knockout mice: decreased social contact duration in two social interaction tests. 
Front. Behav. Neurosci. 3:3. doi:10.3389/neuro.08.003.2009. 
Mayr, R. 1971. Structure and distribution of fibre types in the external eye muscles of the rat. 
Tissue Cell. 3:433–462. doi:10.1016/S0040-8166(71)80045-9. 
McLoon, L.K., and F. Andrade. 2012. Craniofacial Muscles: A New Framework for Understanding 
the Effector Side of Craniofacial Muscle Control. L.K. McLoon and F. Andrade, editors. 
Springer New York, New York, NY. 
McLoon, L.K., V.M. Harandi, T. Brännström, P.M. Andersen, and J.-X. Liu. 2014. Wnt and 
extraocular muscle sparing in amyotrophic lateral sclerosis. Invest. Ophthalmol. Vis. Sci. 
55:5482–96. doi:10.1167/iovs.14-14886. 
McLoon, L.K., H. n. Park, J.-H. Kim, F. Pedrosa-Domellof, and L. V. Thompson. 2011. A continuum 
of myofibers in adult rabbit extraocular muscle: force, shortening velocity, and patterns of 
myosin heavy chain colocalization. J. Appl. Physiol. 111:1178–1189. 
doi:10.1152/japplphysiol.00368.2011. 
Meissner, G. 1975. Isolation and characterization of two types of sarcoplasmic reticulum vesicles. 
Biochim. Biophys. Acta - Biomembr. 389:51–68. doi:10.1016/0005-2736(75)90385-5. 
Meissner, G. 1986. Ryanodine activation and inhibition of the Ca2+ release channel of 
sarcoplasmic reticulum. J. Biol. Chem. 261:6300–6. 
Meissner, G. 2002. Regulation of mammalian ryanodine receptors. Front. Biosci. 7:d2072-80. 
 156 
 
Meissner, G., E. Darling, and J. Eveleth. 1986. Kinetics of rapid calcium release by sarcoplasmic 
reticulum. Effects of calcium, magnesium, and adenine nucleotides. Biochemistry. 25:236–
244. doi:10.1021/bi00349a033. 
Meissner, G., E. Rios, A. Tripathy, and D.A. Pasek. 1997. Regulation of Skeletal Muscle Ca 2+ Release 
Channel (Ryanodine Receptor) by Ca 2+ and Monovalent Cations and Anions. J. Biol. Chem. 
272:1628–1638. doi:10.1074/jbc.272.3.1628. 
Menegazzi, P., F. Larini, S. Treves, R. Guerrini, M. Quadroni, and F. Zorzato. 1994. Identification 
and Characterization of Three Calmodulin Binding Sites of the Skeletal Muscle Ryanodine 
Receptor. Biochemistry. 33:9078–9084. doi:10.1021/bi00197a008. 
Michailovici, I., T. Eigler, and E. Tzahor. 2015. Craniofacial Muscle Development. Curr. Top. Dev. 
Biol. 115:3–30. doi:10.1016/BS.CTDB.2015.07.022. 
Miller, J.M. 2007. Understanding and misunderstanding extraocular muscle pulleys. J. Vis. 7:10. 
doi:10.1167/7.11.10. 
MOLLER, J., P. NISSEN, T. SORENSEN, and M. MAIRE. 2005. Transport mechanism of the 
sarcoplasmic reticulum Ca-ATPase pump. Curr. Opin. Struct. Biol. 15:387–393. 
doi:10.1016/j.sbi.2005.06.005. 
Moncman, C.L., and F.H. Andrade. 2010. Nonmuscle myosin IIB, a sarcomeric component in the 
extraocular muscles. Exp. Cell Res. 316:1958–65. doi:10.1016/j.yexcr.2010.03.018. 
Morgan, D.L., and U. Proske. 1984. Vertebrate slow muscle: its structure, pattern of innervation, 
and mechanical properties. Physiol. Rev. 64:103–169. doi:10.1152/physrev.1984.64.1.103. 
Mosca, B., O. Delbono, M. Laura Messi, L. Bergamelli, Z.-M. Wang, M. Vukcevic, R. Lopez, S. 
Treves, M. Nishi, H. Takeshima, C. Paolini, M. Martini, G. Rispoli, F. Protasi, and F. Zorzato. 
2013. Enhanced dihydropyridine receptor calcium channel activity restores muscle strength 
in JP45/CASQ1 double knockout mice. Nat. Commun. 4:1541. doi:10.1038/ncomms2496. 
Mosca, B., J. Eckhardt, L. Bergamelli, S. Treves, R. Bongianino, M. De Negri, S.G. Priori, F. Protasi, 
and F. Zorzato. 2016. Role of the JP45-calsequestrin complex on calcium entry in slow twitch 
 157 
 
skeletal muscles. J. Biol. Chem. 291:14555–14565. doi:10.1074/jbc.M115.709071. 
Mühlendyck, H. 1978. Die Größe der motorischen Einheiten der unterschiedlich innervierten 
Augenmuskelfasern. J.F. Bergmann-Verlag. 17–26. 
Nakai, J., T. Imagawa, Y. Hakamata, M. Shigekawa, H. Takeshima, and S. Numa. 1990a. Primary 
structure and functional expression from cDN A of the cardiac ryanodine receptor/calcium 
release channel. FEBS Lett. 271:169–177. doi:10.1016/0014-5793(90)80399-4. 
Nakai, J., T. Imagawa, Y. Hakamata, M. Shigekawa, H. Takeshima, and S. Numa. 1990b. Primary 
structure and functional expression from cDN A of the cardiac ryanodine receptor/calcium 
release channel. FEBS Lett. 271:169–177. doi:10.1016/0014-5793(90)80399-4. 
Nakashima, Y., S. Nishimura, A. Maeda, E.L. Barsoumian, Y. Hakamata, J. Nakai, P.D. Allen, K. 
Imoto, and T. Kita. 1997. Molecular cloning and characterization of a human brain ryanodine 
receptor. FEBS Lett. 417:157–62. doi:10.1016/s0014-5793(97)01275-1. 
Nathan, E., A. Monovich, L. Tirosh-Finkel, Z. Harrelson, T. Rousso, A. Rinon, I. Harel, S.M. Evans, 
and E. Tzahor. 2008. The contribution of Islet1-expressing splanchnic mesoderm cells to 
distinct branchiomeric muscles reveals significant heterogeneity in head muscle 
development. Development. 135:647–57. doi:10.1242/dev.007989. 
Nelson, B.R., F. Wu, Y. Liu, D.M. Anderson, J. McAnally, W. Lin, S.C. Cannon, R. Bassel-Duby, and 
E.N. Olson. 2013. Skeletal muscle-specific T-tubule protein STAC3 mediates voltage-induced 
Ca2+ release and contractility. Proc. Natl. Acad. Sci. 110:11881–11886. 
doi:10.1073/pnas.1310571110. 
Neylon, C.B., S.M. Richards, M.A. Larsen, A. Agrotis, and A. Bobik. 1995. Multiple types of 
ryanodine receptor/Ca2+ release channels are expressed in vascular smooth muscle. 
Biochem. Biophys. Res. Commun. 215:814–21. doi:10.1006/bbrc.1995.2536. 
Noden, D.M., and P. Francis-West. 2006. The differentiation and morphogenesis of craniofacial 
muscles. Dev. Dyn. 235:1194–1218. doi:10.1002/dvdy.20697. 
Von Noorden, G.K., and E.C. (Emilio C.. Campos. 2002. Binocular vision and ocular motility : theory 
 158 
 
and management of strabismus. Mosby. 653 pp. 
Odermatt, A., S. Becker, V.K. Khanna, K. Kurzydlowski, E. Leisner, D. Pette, and D.H. MacLennan. 
1998. Sarcolipin regulates the activity of SERCA1, the fast-twitch skeletal muscle 
sarcoplasmic reticulum Ca2+-ATPase. J. Biol. Chem. 273:12360–9. 
doi:10.1074/jbc.273.20.12360. 
Ogawa, Y., N. Kurebayashi, and T. Murayama. 2000. Putative Roles of Type 3 Ryanodine Receptor 
Isoforms (RyR3). Trends Cardiovasc. Med. 10:65–70. doi:10.1016/S1050-1738(00)00050-5. 
Otsu, K., H.F. Willard, V.K. Khanna, F. Zorzato, N.M. Green, and D.H. MacLennan. 1990. Molecular 
cloning of cDNA encoding the Ca2+ release channel (ryanodine receptor) of rabbit cardiac 
muscle sarcoplasmic reticulum. J. Biol. Chem. 265:13472–83. 
OTTINI, L., G. MARZIALI, A. CONTI, A. CHARLESWORTH, and V. SORRENTINO. 1996. α and β 
isoforms of ryanodine receptor from chicken skeletal muscle are the homologues of 
mammalian RyR1 and RyR3. Biochem. J. 315:207–216. doi:10.1042/bj3150207. 
Pachter, B.R., J. Davidowitz, and G.M. Breinin. 1976. Light and electron microscopic serial analysis 
of mouse extraocular muscle: morphology, innervation and topographical organization of 
component fiber populations. Tissue Cell. 8:547–60. 
Park, K.A., J. Lim, S. Sohn, and S.Y. Oh. 2012. Myosin heavy chain isoform expression in human 
extraocular muscles: Longitudinal variation and patterns of expression in global and orbital 
layers. Muscle and Nerve. 45:713–720. doi:10.1002/mus.23240. 
Peng, W., H. Shen, J. Wu, W. Guo, X. Pan, R. Wang, S.R.W. Chen, and N. Yan. 2016. Structural basis 
for the gating mechanism of the type 2 ryanodine receptor RyR2. Science. 354. 
doi:10.1126/science.aah5324. 
Periasamy, M., and A. Kalyanasundaram. 2007. SERCA pump isoforms: Their role in calcium 
transport and disease. Muscle Nerve. 35:430–442. doi:10.1002/mus.20745. 
Perni, S., K.C. Marsden, M. Escobar, S. Hollingworth, S.M. Baylor, and C. Franzini-Armstrong. 2015. 
Structural and functional properties of ryanodine receptor type 3 in zebrafish tail muscle. J. 
 159 
 
Gen. Physiol. 145:253. doi:10.1085/jgp.20141130302112015c. 
Van Petegem, F. 2015. Ryanodine Receptors: Allosteric Ion Channel Giants. J. Mol. Biol. 427:31–
53. doi:10.1016/J.JMB.2014.08.004. 
Pineles, S.L., M.Y. Chang, E.L. Oltra, M.S. Pihlblad, J.P. Davila-Gonzalez, T.C. Sauer, and F.G. Velez. 
2018. Anterior segment ischemia: etiology, assessment, and management. Eye. 32:173–178. 
doi:10.1038/eye.2017.248. 
Polster, A., S. Perni, H. Bichraoui, and K.G. Beam. 2015. Stac adaptor proteins regulate trafficking 
and function of muscle and neuronal L-type Ca2+channels. Proc. Natl. Acad. Sci. U. S. A. 
112:602–606. doi:10.1073/pnas.1423113112. 
Porter, J.D., S. Khanna, H.J. Kaminski, J.S. Rao, A.P. Merriam, C.R. Richmonds, P. Leahy, J. Li, and 
F.H. Andrade. 2001. Extraocular muscle is defined by a fundamentally distinct gene 
expression profile. Proc. Natl. Acad. Sci. U. S. A. 98:12062–7. doi:10.1073/pnas.211257298. 
Pouvreau, S., L. Royer, J. Yi, G. Brum, G. Meissner, E. Ríos, and J. Zhou. 2007. Ca(2+) sparks 
operated by membrane depolarization require isoform 3 ryanodine receptor channels in 
skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 104:5235–5240. 
doi:10.1073/pnas.0700748104. 
Powers, S.K. (Scott K., and E.T. Howley. 2018. Exercise physiology : theory and application to 
fitness and performance. 10th ed. McGraw-Hill Education. 594 pp. 
Priori, S.G., C. Napolitano, N. Tiso, M. Memmi, G. Vignati, R. Bloise, V. Sorrentino, and G.A. Danieli. 
2001. Mutations in the Cardiac Ryanodine Receptor Gene ( hRyR2 ) Underlie 
Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 103:196–200. 
doi:10.1161/01.CIR.103.2.196. 
Protasi, F., H. Takekura, Y. Wang, S.R.W. Chen, G. Meissner, P.D. Allen, and C. Franzini-Armstrong. 
2000. RYR1 and RYR3 Have Different Roles in the Assembly of Calcium Release Units of 
Skeletal Muscle. Biophys. J. 79:2494–2508. doi:10.1016/S0006-3495(00)76491-5. 
Rashed, R.M., and S.H. El-Alfy. 2012. Ultrastructural organization of muscle fiber types and their 
 160 
 
distribution in the rat superior rectus extraocular muscle. Acta Histochem. 114:217–225. 
doi:10.1016/J.ACTHIS.2011.04.007. 
Rashed, R.M., S.H. El-Alfy, and I.K. Mohamed. 2010. Histochemical analysis of muscle fiber types 
of rat superior rectus extraocular muscle. Acta Histochem. 112:536–545. 
doi:10.1016/j.acthis.2009.05.009. 
Rebbeck, R.T., Y. Karunasekara, P.G. Board, N.A. Beard, M.G. Casarotto, and A.F. Dulhunty. 2014. 
Skeletal muscle excitation-contraction coupling: Who are the dancing partners? Int. J. 
Biochem. Cell Biol. 48:28–38. doi:10.1016/j.biocel.2013.12.001. 
Ríos, E. 2018. Calcium-induced release of calcium in muscle: 50 years of work and the emerging 
consensus. J. Gen. Physiol. 150:521–537. doi:10.1085/jgp.201711959. 
Ríos, E., D. Gillespie, and C. Franzini-Armstrong. 2019. The binding interactions that maintain 
excitation–contraction coupling junctions in skeletal muscle. J. Gen. Physiol. 151:593–605. 
doi:10.1085/jgp.201812268. 
Rosenberg, H., N. Pollock, A. Schiemann, T. Bulger, and K. Stowell. 2015. Malignant hyperthermia: 
a review. Orphanet J. Rare Dis. 10:93. doi:10.1186/s13023-015-0310-1. 
Rossi, A.C., C. Mammucari, C. Argentini, C. Reggiani, and S. Schiaffino. 2010. Two novel/ancient 
myosins in mammalian skeletal muscles: MYH14/7b and MYH15 are expressed in extraocular 
muscles and muscle spindles. J. Physiol. 588:353–364. doi:10.1113/jphysiol.2009.181008. 
Rubinstein, N.A., and J.F. Hoh. 2000. The distribution of myosin heavy chain isoforms among rat 
extraocular muscle fiber types. Invest. Ophthalmol. Vis. Sci. 41:3391–3398. 
Rushbrook, J.I., C. Weiss, K. Ko, M.H. Feuerman, S. Carleton, A. Ing, and J. Jacoby. 1994. 
Identification of alpha-cardiac myosin heavy chain mRNA and protein in extraocular muscle 
of the adult rabbit. J. Muscle Res. Cell Motil. 15:505–15. 
Ruskell, G.L., I.-B. Kjellevold Haugen, J.R. Bruenech, and F. van der Werf. 2005. Double insertions 
of extraocular rectus muscles in humans and the pulley theory. J. Anat. 206:295–306. 
doi:10.1111/j.1469-7580.2005.00383.x. 
 161 
 
Saito, A., S. Seiler, A. Chu, and S. Fleischer. 1984. Preparation and morphology of sarcoplasmic 
reticulum terminal cisternae from rabbit skeletal muscle. J. Cell Biol. 99:875–885. 
doi:10.1083/jcb.99.3.875. 
Sambasivan, R., S. Kuratani, and S. Tajbakhsh. 2011. An eye on the head: the development and 
evolution of craniofacial muscles. Development. 138:2401–15. doi:10.1242/dev.040972. 
Samsó, M., and T. Wagenknecht. 2002. Apocalmodulin and Ca2+-calmodulin bind to neighboring 
locations on the ryanodine receptor. J. Biol. Chem. 277:1349–1353. 
doi:10.1074/jbc.M109196200. 
Samsó, M., T. Wagenknecht, and P.D. Allen. 2005. Internal structure and visualization of 
transmembrane domains of the RyR1 calcium release channel by cryo-EM. Nat. Struct. Mol. 
Biol. 12:539–544. doi:10.1038/nsmb938. 
Santulli, G., D. Lewis, A. des Georges, A.R. Marks, and J. Frank. 2018. Ryanodine Receptor 
Structure and Function in Health and Disease. In Sub-cellular biochemistry. 329–352. 
Santulli, G., D.R. Lewis, and A.R. Marks. 2017a. Physiology and pathophysiology of excitation-
contraction coupling: the functional role of ryanodine receptor. J. Muscle Res. Cell Motil. 
38:37–45. doi:10.1007/s10974-017-9470-z. 
Santulli, G., R. Nakashima, Q. Yuan, and A.R. Marks. 2017b. Intracellular calcium release channels: 
an update. J. Physiol. 595:3041–3051. doi:10.1113/JP272781. 
Santulli, G., G. Pagano, C. Sardu, W. Xie, S. Reiken, S.L. D’Ascia, M. Cannone, N. Marziliano, B. 
Trimarco, T.A. Guise, A. Lacampagne, and A.R. Marks. 2015. Calcium release channel RyR2 
regulates insulin release and glucose homeostasis. J. Clin. Invest. 125:1968–1978. 
doi:10.1172/JCI79273. 
Schiaffino, S., and C. Reggiani. 2011. Fiber types in mammalian skeletal muscles. Physiol. Rev. 
91:1447–531. doi:10.1152/physrev.00031.2010. 
Schindelin, J., I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. 
Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D.J. White, V. Hartenstein, K. Eliceiri, P. 
 162 
 
Tomancak, and A. Cardona. 2012. Fiji: an open-source platform for biological-image analysis. 
Nat. Methods. 9:676–682. doi:10.1038/nmeth.2019. 
Sekulic-Jablanovic, M., A. Palmowski-Wolfe, F. Zorzato, and S. Treves. 2015. Characterization of 
excitation–contraction coupling components in human extraocular muscles. Biochem. J. 
466:29–36. doi:10.1042/BJ20140970. 
Sekulic-Jablanovic, M., N.D. Ullrich, D. Goldblum, A. Palmowski-Wolfe, F. Zorzato, and S. Treves. 
2016a. Functional characterization of orbicularis oculi and extraocular muscles. J. Gen. 
Physiol. 147:395–406. doi:10.1085/jgp.201511542. 
Sekulic-Jablanovic, M., N.D. Ullrich, D. Goldblum, A. Palmowski-Wolfe, F. Zorzato, and S. Treves. 
2016b. Functional characterization of orbicularis oculi and extraocular muscles. J. Gen. 
Physiol. 147:395–406. doi:10.1085/jgp.201511542. 
Sharma, M.R., L.H. Jeyakumar, S. Fleischer, and T. Wagenknecht. 2000. Three-dimensional 
Structure of Ryanodine Receptor Isoform Three in Two Conformational States as Visualized 
by Cryo-electron Microscopy. J. Biol. Chem. 275:9485–9491. doi:10.1074/jbc.275.13.9485. 
Shy, G.M., and K.R. Magee. 1956. A NEW CONGENITAL NON-PROGRESSIVE MYOPATHY. Brain. 
79:610–621. doi:10.1093/brain/79.4.610. 
Siebeck, R., and P. Kruger. 1955. Die histologische Struktur der äuβeren Augenmuskeln als 
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